

Supporting Information

Organocatalytic Enantioselective oxa-Piancatelli Rearrangement

Rahul Sarkar, Alexander Korell, and Christoph Schneider*

Institut für Organische Chemie, Universität Leipzig, 04103 Leipzig, Germany

schneider@chemie.uni-leipzig.de

Table of Contents


I.	General information	S-2
II.	Representative examples of natural products containing γ -hydroxy cyclopentenone core structures	S-3
III.	Challenges associated with the asymmetric oxa-Piancatelli rearrangement	S-3
IV.	Procedure for the synthesis of 2-furyl carbinols	S-4
V.	Catalyst and reaction conditions optimization for the enantioselective oxa-Piancatelli rearrangement	S-30
VI.	General procedure for the preparation of racemic products (<i>rac</i> - 4/5)	S-33
VII.	Typical procedure for the catalytic enantioselective oxa-Piancatelli rearrangement	S-33
VIII.	Unsuccessful substrates for enantioselective oxa-Piancatelli rearrangement	S-60
IX.	Large scale synthesis of 4a	S-61
X.	Procedure for the γ -hydroxy protection of 4a	S-61
XI.	Procedure for selective reduction of the carbonyl group of 8	S-62
XII.	Procedure for vinyl Grignard addition on the carbonyl group of 8	S-63
XIII.	Procedure for the γ -hydroxy protection of 5a	S-64
XIV.	Procedure for selective reduction of the conjugated double bond of 11	S-65
XV.	Control experiments	S-66
XVI.	NMR-Spectra and HPLC-Chromatograms	S-67
XVII.	Single crystal X-ray diffraction analysis of 4j	S-293

I. General information:

Infrared (FT-IR) spectra were recorded on a FTIR spectrometer (JASCO FT/IR-4100), ν_{max} in cm^{-1} and the bands are characterized as broad (br), strong (s), medium (m), and weak (w). NMR spectra were recorded on Brucker Avance III HD (400 MHz), a Varian MERCURYplus 400 (400 MHz) or a Varian MERCURYplus 300 (300 MHz). Chemical shifts are reported in ppm from tetramethylsilane with the solvent resonance as internal standard [CDCl_3 : δ 7.26, CD_2Cl_2 : δ 5.32, CD_3OD : δ 3.31 for $^1\text{H-NMR}$ and CDCl_3 : δ 77.16, CD_2Cl_2 : δ 53.84, CD_3OD : δ 49.00 for $^{13}\text{C-NMR}$]. For $^1\text{H-NMR}$, data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, dd = double doublet, ddd = doublet of doublet of doublets, t = triplet, q = quartet, br = broad, m = multiplet), coupling constants (Hz) and integration. High resolution mass spectrometry ESI-HRMS was performed on a Brucker ESI-TOF microTOF, and EI-HRMS was performed on MAT 8230 Finnigan (Thermo Scientific) instrument. Optical rotations were measured using a Polarotronic polarimeter (Schmidt & Haensch). Melting points are uncorrected and were determined on a Büchi melting point apparatus. Enantiomeric ratios were determined by Jasco MD-4015 using stationary phase chiral columns (25 cm \times 0.46 cm) in comparison with authentic racemic compounds.

THF, CH_2Cl_2 , and toluene for reactions were purified and dried by a Solvent Purification System MB SPS-800 (Braun). The solvents for column chromatography and TLC were distilled from indicated drying agents: hexane (KOH), ethyl acetate (KOH), *tert*-butyl methyl ether (KOH), dichloromethane (CaH_2). Thin-layer chromatography was performed using ALUGRAM[®] Xtra SIL G/UV₂₅₄ pre-coated plates (0.20 mm). Spots were visualized by UV ($\lambda = 254$ nm) and were treated with a vanillin solution in methanol (technical grade). Flash column chromatography was performed by using Merck silica gel 60 230-400 mesh (0.040-0.063 mm). All reactions that required heating were heated using an oil bath. NMR yields were determined by using 1,3,5-trimethoxybenzene as an internal standard. Unless otherwise noted, all reported yields of the chiral phosphoric acid catalyzed oxa-Piancatelli Rearrangements are isolated yields.

II. Representative examples of natural products containing γ -hydroxy cyclopentenone core structures:




III. Challenges associated with the asymmetric oxa-Piancatelli rearrangement:

A) Poor nucleophilicity of H_2O compare to aryl amines:




B) Intrinsic instability of furanoxonium ion leads to the undesired side reactions in the presence of poor nucleophile such as H_2O :



C) Inefficient ring-opening step compare to aza-Piancatelli rearrangement:




D) Isomerization of product under acidic conditions:



IV. Procedure for the synthesis of 2-furyl carbinols:

3-Substituted furan-2-carbaldehydes (**S1**) were prepared according to the literature procedure.¹

General procedure A: Preparation of secondary 2-furyl carbinols




Condition I: In an oven and vacuum-dried round-bottom flask, **S1** (1.5 equiv.) was taken, degassed, purged with nitrogen, and dissolved in dry THF (5.0 mL/mmol of **S1**). Then, the solution was cooled to 0 °C and commercially available Grignard reagent R^2MgBr (1.1 equiv.) was added dropwise. The resulting solution was first stirred at 0 °C for 1 h, then warmed to 25 °C and stirred for another 1 h. The reaction was quenched with pH 6.0 buffer (10 mL) and the organic layer was separated from the aqueous layer. The aqueous layer was extracted with EtOAc (3×10.0 mL). Combined organic layer was washed with brine (10.0 mL), dried over anh. Na_2SO_4 and concentrated under reduced pressure to obtain crude product. The crude product was purified by silica-gel column chromatography (7-10% EtOAc in hexane) to obtain **1**.

Condition II: In an oven and vacuum-dried two-necked round-bottom flask, equipped with reflux condenser, magnesium turnings (2.6 equiv.) were taken and heated to 150 °C for 30 min under vacuum. The flask was cooled to 25 °C, purged with nitrogen and one crystal of iodine was added along with dry THF (1.7 mL/mmol of **S1**). To this mixture, corresponding aryl/alkyl bromide ($\text{R}^2\text{-Br}$, 2.5 equiv.) was added and the resulting solution was refluxed at 70 °C for 1 h. The reaction mixture was cooled to 0 °C and diluted with dry THF (1.7 mL/mmol of **S**). Next, a solution of **S1** (1.0 equiv.) in dry THF (1.7 mL/mmol of **S1**) was added, and the resulting solution was first stirred at 0 °C for 1 h, then warmed to 25 °C and stirred for another 1 h. The reaction was quenched with pH 6.0 buffer (10 mL) and the organic layer was separated from the aqueous layer. The aqueous layer was extracted with EtOAc (3×10.0 mL). Combined organic layer was washed with brine (10.0 mL), dried over anh. Na_2SO_4 and concentrated under reduced pressure to obtain crude product. The crude product was purified by silica-gel column chromatography (6-10% EtOAc in hexane) to obtain **1/6**.


¹ A. Hiscox, K. Ribeiro, R. A. Batey, *Org. Lett.* **2018**, *20*, 6668.

General procedure B: Preparation of secondary 2-furyl carbinols



In an oven and vacuum-dried round-bottom flask, aryl/heteroaryl bromide ($R^2\text{-Br}$, 2.5 equiv.) was taken, degassed, purged with nitrogen, and dissolved in dry THF (2.5 mL/mmol of **S1**). To this solution, $i\text{-PrMgCl}\cdot\text{LiCl}$ (1.3 M in THF, 2.6 equiv.) was added and the resulting solution was stirred at 25 °C for 1 h. Then, the reaction mixture was cooled to 0 °C and a solution of **S1** (1.0 equiv.) in dry THF (2.5 mL/mmol of **S1**) was added dropwise. The resulting solution was first stirred at 0 °C for 1 h, then warmed to 25 °C and stirred for another 1 h. The reaction was quenched with pH 6.0 buffer (10 mL) and the organic layer was separated from the aqueous layer. The aqueous layer was extracted with EtOAc (3×10.0 mL). Combined organic layer was washed with brine (10.0 mL), dried over anh. Na_2SO_4 and concentrated under reduced pressure to obtain crude product. The crude product was purified by silica-gel column chromatography (6-10% EtOAc in hexane) to obtain **1**.


General procedure C: Preparation of secondary 2-furyl carbinols



In an oven and vacuum-dried round-bottom flask, aryl bromide ($R^2\text{-Br}$, 2.0 equiv.) was taken under nitrogen atmosphere, dissolved in dry THF (2.5 mL/mmol of **S1**) and cooled to -78 °C. To this solution, $n\text{-BuLi}$ (2.5 M in hexane, 2.4 equiv.) was added and the resulting solution was stirred at -78 °C for 2 h. Next, a solution of **S1** (1.0 equiv.) in dry THF (2.5 mL/mmol of **S1**) was added at -78 °C. The resulting solution was warmed to 0 °C, stirred at for 1 h, then warmed to 25 °C and stirred for another 1 h. The reaction was quenched with sat. NH_4Cl solution (10 mL) and the organic layer was separated from the aqueous layer. The aqueous layer was extracted with EtOAc (3×10.0 mL). Combined organic layer was washed with brine (10.0 mL), dried over anh. Na_2SO_4 and concentrated under reduced pressure to obtain crude product. The crude product was purified by silica-gel column chromatography (7-10% EtOAc in hexane) to obtain **1/6**.

General procedure D: Preparation of tertiary 2-furyl carbinols

Selected secondary 2-furyl carbinols (**1**) were oxidized to the corresponding ketones (**S2**), which were then converted to the tertiary 2-furyl carbinols (**2**) by using the following scheme:



In an oven and vacuum-dried round-bottom flask, equipped with reflux condenser, secondary 2-furyl carbinol **1** (1.0 equiv.) was taken and dissolved in EtOAc (10.0 mL/mmol of **1**). To this solution, 2-iodoxybenzoic acid (IBX) (2.0 equiv.) was added and the resulting solution was stirred at 70 °C for 21 h. Solid was removed by filtering through a cotton plug and washed with EtOAc. The filtrate was concentrated under reduced pressure and the residue was passed through a small bed of silica-gel to obtain **S2**. The ketone **S2** was subjected to the next step without further purification.

Condition I: In an oven and vacuum-dried round-bottom flask, **S2** was taken, degassed, purged with nitrogen, and dissolved in dry THF (10.0 mL/mmol of **1**). Then, the solution was cooled to 0 °C and commercially available Grignard reagent *R*³MgBr (1.5 equiv.) was added dropwise. The resulting solution was first stirred at 0 °C for 1 h, then warmed to 25 °C and stirred for another 1 h. The reaction was quenched with pH 6.0 buffer (10 mL) and the organic layer was separated from the aqueous layer. The aqueous layer was extracted with EtOAc (3 × 10.0 mL). Combined organic layer was washed with brine (10.0 mL), dried over anh. Na₂SO₄ and concentrated under reduced pressure to obtain crude product. The crude product was purified by silica-gel column chromatography (5-10% EtOAc in hexane) to obtain **2**.

Condition II: In an oven and vacuum-dried two-necked round-bottom flask, equipped with reflux condenser, magnesium turnings (2.6 equiv.) were taken and heated to 150 °C for 30 min under vacuum. The flask was cooled to 25 °C, purged with nitrogen and one crystal of iodine was added along with dry THF (3.4 mL/mmol of **1**). To this mixture, corresponding aryl bromide (*R*³-Br, 2.5 equiv.) was added and the resulting solution was refluxed at 70 °C for 1 h. The reaction mixture was cooled to 0 °C and diluted with dry THF (3.4 mL/mmol of **1**). Next, a solution of **S2** in dry THF (3.4 mL/mmol of **1**) was added, and the resulting solution was first stirred at 0 °C for 1 h, then warmed to 25 °C and stirred for another 1 h. The reaction was quenched with pH 6.0 buffer (10 mL) and the organic layer was separated from the aqueous layer. The aqueous layer was extracted with EtOAc (3 × 10.0 mL). Combined organic layer was washed with brine (10.0 mL), dried over anh. Na₂SO₄ and concentrated under reduced pressure to obtain crude product. The

crude product was purified by silica-gel column chromatography (7-10% EtOAc in hexane) to obtain **2**.

Condition III: In an oven and vacuum-dried round-bottom flask, aryl bromide (R^3-Br , 2.5 equiv.) was taken, degassed, purged with nitrogen, and dissolved in dry THF (5.0 mL/mmol of **1**). To this solution, *i*-PrMgCl·LiCl (1.3 M in THF, 2.6 equiv.) was added and the resulting solution was stirred at 25 °C for 1 h. Then, the reaction mixture was cooled to 0 °C and a solution of **S2** in dry THF (5.0 mL/mmol of **1**) was added dropwise. The resulting solution was first stirred at 0 °C for 1 h, then warmed to 25 °C and stirred for another 1 h. The reaction was quenched with pH 6.0 buffer (10 mL) and the organic layer was separated from the aqueous layer. The aqueous layer was extracted with EtOAc (3 × 10.0 mL). Combined organic layer was washed with brine (10.0 mL), dried over anh. Na₂SO₄ and concentrated under reduced pressure to obtain crude product. The crude product was purified by silica-gel column chromatography (7-10% EtOAc in hexane) to obtain **2**.

[*Note:* These secondary and tertiary 2-furyl carbinols (**1/6** and **2**) are sensitive to temperature, pH, and rotary evaporation at 25 °C is necessary.]




Compound 1a: Prepared according to General Procedure A, Condition I; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (1.30 g, 6.280 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (10% EtOAc in hexane); Yellow thick oil (1.68 g, 5.993 mmol, 95% yield); **FT-IR (Thin film):** 3421 (br), 1519 (s), 1452 (w), 1247 (s), 1182 (m), 1032 (m), 833 (s), 763 (w); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.44-7.34 (m, 7H), 7.32-7.27 (m, 1H), 6.96 (d, *J* = 8.7 Hz, 2H), 6.55 (d, *J* = 1.9 Hz, 1H), 5.95 (d, *J* = 5.7 Hz, 1H), 3.83 (s, 3H), 2.53 (d, *J* = 5.7 Hz, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 159.5, 149.9, 142.5, 141.9, 129.7, 128.8, 128.1, 126.8, 125.7, 124.2, 114.5, 112.1, 68.4, 55.7; **HRMS (ESI+):** Calcd. for C₁₈H₁₆O₃ ([M+Na]⁺): 303.0992, Found: 303.0993.

Compound 1b: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (600.0 mg, 2.970 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); Yellow thick oil (700.0 mg, 2.378 mmol, 80% yield); **FT-IR (Thin film):** 3434 (br), 2921 (w), 1604 (m), 1518 (s), 1248 (s), 1179 (s), 1032 (s), 894 (w); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.41 (d, *J* = 1.9 Hz, 1H), 7.38 (d, *J* = 8.7 Hz, 2H), 7.31 (d, *J* = 8.0 Hz, 2H), 7.18 (d, *J* = 7.7 Hz, 2H), 6.96 (d, *J* = 8.7 Hz, 2H), 6.54 (d, *J* = 1.9 Hz, 1H), 5.91 (d, *J* = 5.1 Hz, 1H), 3.83 (s, 3H), 2.48 (d, *J* = 5.6 Hz, 1H), 2.34 (s, 3H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 159.4, 150.1, 142.4, 138.9, 138.0, 129.7, 129.5, 126.8, 125.8, 123.9, 114.5, 112.0, 68.3, 55.7, 21.2; **HRMS (ESI+):** Calcd. for C₁₉H₁₈O₃ ([M+Na]⁺): 317.1148, Found: 317.1151.

Compound 1c: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (600.0 mg, 2.970 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Colorless oil (843.0 mg, 2.860 mmol, 96% yield); **FT-IR (Thin film):** 3409 (br), 2934 (w), 1604 (m), 1518 (s), 1462 (m), 1248 (s), 1179 (m), 1032 (m), 835 (m), 744 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.65 (dd, *J* = 7.7, 1.5 Hz, 1H), 7.41-7.38 (m, 3H), 7.25 (td, *J* = 7.5, 1.6 Hz, 1H), 7.19 (td, *J* = 7.4, 1.6 Hz, 1H), 7.12 – 7.09 (m, 1H), 6.96 (d, *J* = 8.7 Hz, 2H), 6.54 (d, *J* = 1.9 Hz, 1H), 6.02 (d, *J* = 5.2 Hz, 1H), 3.83 (s, 3H), 2.43 (d, *J* = 5.3 Hz, 1H), 2.00 (s, 3H); **¹³C-NMR (75 MHz, CD₂Cl₂):** δ 159.5, 149.3, 142.4, 139.8, 135.7, 130.7, 129.6, 128.0, 126.3, 126.3, 125.8, 124.2, 114.5, 111.9, 66.2, 55.7, 19.0; **HRMS (ESI+):** Calcd. for C₁₉H₁₈O₃ ([M+Na]⁺): 317.1148, Found: 317.1141.

Compound 1d: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (300.0 mg, 1.480 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (6% EtOAc in hexane); Yellow oil (439.0 mg, 1.420 mmol, 96% yield); **FT-IR (Thin film):** 3213 (br), 3039 (w), 2915 (s), 1606 (s), 1516 (s), 1250 (s), 1180 (s), 1036 (s), 834 (s), 754 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.42 (d, *J* = 1.9 Hz, 1H), 7.39 (d, *J* = 8.8 Hz, 2H), 7.04-7.03 (m, 2H), 6.98-6.94 (m, 3H), 6.54 (d, *J* = 1.9 Hz, 1H), 5.87 (d, *J* = 5.5 Hz, 1H), 3.83 (s, 3H), 2.48 (d, *J* = 5.6 Hz, 1H), 2.31 (s, 6H); **¹³C-NMR (100 MHz, CD₂Cl₂):** 159.4, 150.1, 142.4, 141.7, 138.5, 129.8, 129.7, 125.8, 124.5, 123.9, 114.5, 112.0, 68.4, 55.7, 21.5; **HRMS (ESI+):** Calcd. for C₂₀H₂₀O₃ ([M+Na]⁺): 331.1305, Found: 331.1296.



Compound 1e: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (600.0 mg, 2.970 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); Yellow thick oil (887.0 mg, 2.858 mmol, 96% yield); **FT-IR (Thin film):** 3444 (br), 2835 (w), 1602 (m), 1518 (s), 1249 (s), 1033 (s), 962 (m), 835 (m); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.42 (d, *J* = 1.9 Hz, 1H), 7.39 (d, *J* = 8.7 Hz, 2H), 7.26 (t, *J* = 7.9 Hz, 1H), 7.01-7.00 (m, 1H), 6.98-6.94 (m, 1H), 6.96 (d, *J* = 8.7 Hz, 2H), 6.83 (dd, *J* = 8.3, 2.7 Hz, 1H), 6.54 (d, *J* = 1.9 Hz, 1H), 5.92 (d, *J* = 5.7 Hz, 1H), 3.83 (s, 3H), 3.79 (s, 3H), 2.53 (d, *J* = 5.7 Hz, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 160.2, 159.5, 149.8, 143.5, 142.4, 129.8, 129.7, 125.7, 124.2, 119.0, 114.5, 113.4, 112.5, 112.1, 68.3, 55.7, 55.6; **HRMS (ESI+):** Calcd. for C₁₉H₁₈O₄ ([M+Na]⁺): 333.1097, Found: 333.1100.



Compound 1f: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (600.0 mg, 2.970 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Orange solid (814.0 mg, 2.490 mmol, 84% yield); **m.p.** 80-82 °C; **FT-IR (Thin film):** 3412 (br), 3366 (s), 3002 (w), 1610 (m), 1519 (s), 1248 (s), 1180 (s), 1036 (m), 836 (s), 775 (m); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.42 (d, *J* = 1.9 Hz, 1H), 7.37 (d, *J* = 8.8 Hz, 2H), 7.34 (d, *J* = 8.4 Hz, 2H), 7.24 (d, *J* = 8.4 Hz, 2H), 6.95 (d, *J* = 8.7 Hz, 2H), 6.54 (d, *J* = 1.9 Hz, 1H), 5.91 (d, *J* = 5.5 Hz, 1H), 3.82 (s, 3H), 2.50 (d, *J* = 5.7 Hz, 1H), 2.47 (s, 3H); **¹³C-NMR (100 MHz, CD₂Cl₂):** 159.5, 149.7, 142.5, 138.6, 138.5, 129.7, 127.4, 126.7, 125.7, 124.1, 114.5, 112.1, 68.1, 15.9; **HRMS (ESI+):** Calcd. for C₁₉H₁₈O₃S ([M+Na]⁺): 349.0869, Found: 349.0864.

Compound 1g: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (600.0 mg, 2.970 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Pale-yellow solid (910.0 mg, 2.550 mmol, 86% yield); **m.p.** 100-102 °C; **FT-IR (Thin film):** 3398 (br), 3031 (w), 2934 (w), 1615 (m), 1521 (s), 1248 (s), 1183 (s), 989 (s), 833 (s), 699 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.61 (d, *J* = 8.4 Hz, 4H), 7.50 (d, *J* = 8.3 Hz, 2H), 7.46-7.40 (m, 5H), 7.37-7.33 (m, 1H), 6.97 (d, *J* = 8.7 Hz, 2H), 6.56 (d, *J* = 1.9 Hz, 1H), 6.00 (d, *J* = 5.6 Hz, 1H), 3.83 (s, 3H), 2.55 (d, *J* = 5.7 Hz, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** 159.5, 149.8, 142.5, 141.1, 140.9, 129.8, 129.2, 127.8, 127.5, 127.4, 127.3, 125.7, 124.2, 114.6, 112.1, 68.2, 55.7; **HRMS (ESI+):** Calcd. for C₂₄H₂₀O₃ ([M+Na]⁺): 379.1305, Found: 379.1302.

Compound 1h: Prepared according to General Procedure B; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (600.0 mg, 2.970 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); Yellow thick oil (649.0 mg, 2.176 mmol, 73% yield); **FT-IR (Thin film):** 3435 (br), 1591 (m), 1518 (s), 1487 (w), 1465 (s), 1247 (s), 1179 (m), 834 (m); **¹H-NMR (300 MHz, CD₂Cl₂):** δ 7.42 (d, *J* = 1.9 Hz, 1H), 7.38 (d, *J* = 8.9 Hz, 2H), 7.34-7.29 (m, 1H), 7.20-7.15 (m, 2H), 7.03-6.98 (m, 1H), 6.96 (d, *J* = 8.9 Hz, 2H), 6.55 (d, *J* = 1.8 Hz, 1H), 5.95 (d, *J* = 5.2 Hz, 1H), 3.83 (s, 3H), 2.58 (d, *J* = 5.6 Hz, 1H); **¹³C-NMR (75 MHz, CD₂Cl₂):** δ 163.3 (d, *J* = 245.0 Hz), 159.6, 149.2, 144.5 (d, *J* = 6.9 Hz), 142.7, 130.3 (d, *J* = 8.1 Hz), 129.7, 125.5, 124.6, 122.5 (d, *J* = 2.6 Hz), 114.8 (d, *J* = 21.3 Hz), 114.6, 113.8 (d, *J* = 22.7 Hz), 112.2, 67.8 (d, *J* = 2.0 Hz), 55.7; **HRMS (ESI+):** Calcd. for C₁₈H₁₅FO₃ ([M+Na]⁺): 321.0897, Found: 321.0895.







Compound 1i: Prepared according to General Procedure A, Condition I; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (702.0 mg, 3.470 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (6% EtOAc in hexane); Yellow thick oil (814.0 mg, 2.586 mmol, 75% yield); **FT-IR (Thin film):** 3408 (br), 1518 (s), 1491 (m), 1249 (s), 1179 (s), 1091 (m), 960 (m), 833 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.41 (d, *J* = 1.9 Hz, 1H), 7.38-7.32 (m, 6H), 6.95 (d, *J* = 8.9 Hz, 2H), 6.54 (d, *J* = 1.8 Hz, 1H), 5.93 (d, *J* = 2.8 Hz, 1H), 3.83 (s, 3H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 159.5, 149.4, 142.6, 140.4, 133.7, 129.7, 128.8, 128.4, 125.5, 124.5, 114.6, 112.1, 67.8, 55.7; **HRMS (ESI+):** Calcd. for C₁₈H₁₅ClO₃ ([M+Na]⁺): 337.0602, Found: 337.0596.

Compound 1j: Prepared according to General Procedure B; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (400.0 mg, 1.976 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); Yellow thick oil (649.0 mg, 1.807 mmol, 91% yield); **FT-IR (Thin film):** 3407 (br), 1518 (s), 1486 (m), 1249 (s), 1179 (m), 1146 (m), 1070 (w), 834 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.48 (d, *J* = 8.5 Hz, 2H), 7.41 (d, *J* = 1.9 Hz, 1H), 7.36 (d, *J* = 8.8 Hz, 2H), 7.32-7.28 (m, 2H), 6.95 (d, *J* = 8.7 Hz, 2H), 6.54 (d, *J* = 1.9 Hz, 1H), 5.91 (d, *J* = 5.3 Hz, 1H), 3.83 (s, 3H), 2.54 (d, *J* = 5.5 Hz, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 159.5, 149.3, 142.6, 140.9, 131.8, 129.7, 128.7, 125.5, 124.5, 121.8, 114.6, 112.2, 67.9, 55.7; **HRMS (ESI+):** Calcd. for C₁₈H₁₅BrO₃ ([M+Na]⁺): 381.0097, Found: 381.0090.

Compound 1k: Prepared according to General Procedure B; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (600.0 mg, 2.970 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Orange oil (924.0 mg, 2.570 mmol, 86% yield); **FT-IR (Thin film):** 3417 (br), 2836 (m), 1597 (s), 1571 (s), 1518 (s), 1298 (m), 1247 (s), 1179 (s), 1032 (s), 961 (s), 896 (m), 834 (s), 755 (s), 604 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.61-7.60 (m, 1H), 7.44-7.41 (m, 2H), 7.37 (d, *J* = 8.8 Hz, 2H), 7.33 (dt, *J* = 7.7, 1.8 Hz, 1H), 7.23 (t, *J* = 7.8 Hz, 1H), 6.96 (d, *J* = 8.8 Hz, 2H), 6.55 (d, *J* = 1.9 Hz, 1H), 5.92 (d, *J* = 5.6 Hz, 1H), 3.83 (s, 3H), 2.53 (d, *J* = 5.6 Hz, 1H); **¹³C-NMR (75 MHz, CD₂Cl₂):** δ 159.6, 149.1, 144.1, 142.7, 131.1, 130.4, 129.9, 129.7, 125.6, 125.5, 124.7, 122.8, 114.6, 112.2, 67.8, 55.7; **HRMS (ESI+):** Calcd. for C₁₈H₁₅BrO₃ ([M+Na]⁺): 381.0097, Found: 381.0090.

Compound 1l: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (600.0 mg, 2.970 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Yellow oil (995.0 mg, 2.860 mmol, 96% yield); **FT-IR (Thin film):** 3388 (br), 3154 (w), 2839 (w), 1619 (m), 1519 (s), 1326 (s), 1249 (s), 1178 (s), 1122 (s), 1067 (s), 834 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.62 (d, *J* = 8.1 Hz, 2H),






7.55 (d, $J = 8.9$ Hz, 2H), 7.41 (d, $J = 1.9$ Hz, 1H), 7.38 (d, $J = 8.8$ Hz, 2H), 6.96 (d, $J = 8.7$ Hz, 2H), 6.55 (d, $J = 1.9$ Hz, 1H), 6.01 (d, $J = 5.3$ Hz, 1H), 3.83 (s, 3H), 2.66 (d, $J = 5.5$ Hz, 1H); **^{13}C -NMR (100 MHz, CD₂Cl₂)**: 159.6, 149.0, 145.8, 142.8, 129.9 (q, $J = 32.3$ Hz), 129.8, 127.2, 125.7 (q, $J = 3.8$ Hz), 125.2 (q, $J = 54.7$ Hz), 124.7 (q, $J = 272.0$ Hz), 115.7 (q, $J = 118.0$ Hz), 114.6, 112.2, 67.9, 55.7; **HRMS (ESI+)**: Calcd. for C₁₉H₁₅F₃O₃ ([M+H]⁺): 349.1046, Found: 349.1048.

Compound 1m: Prepared according to General Procedure B; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (600.0 mg, 2.970 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (14% EtOAc in hexane); Yellow thick oil (742.0 mg, 2.430 mmol, 82% yield); **FT-IR (Thin film)**: 3397 (br), 2240 (s), 1516 (s), 1245 (s), 1027 (m), 962 (m), 832 (m), 771 (m); **$^1\text{H-NMR}$ (400 MHz, CDCl₃)**: δ 7.62 (d, $J = 8.5$ Hz, 2H), 7.51 (d, $J = 8.0$ Hz, 2H), 7.38 (d, $J = 1.9$ Hz, 1H), 7.35 (d, $J = 8.7$ Hz, 2H), 6.95 (d, $J = 8.7$ Hz, 2H), 6.52 (d, $J = 1.9$ Hz, 1H), 5.98 (s, 1H), 3.84 (s, 3H), 2.58 (br s, 1H); **$^{13}\text{C-NMR}$ (100 MHz, CDCl₃)**: δ 159.3, 148.2, 146.4, 142.7, 132.4, 129.5, 127.3, 125.0, 118.9, 114.5, 112.1, 111.6, 67.7, 55.5; **HRMS (ESI+)**: Calcd. for C₁₉H₁₅NO₃ ([M+Na]⁺): 328.0944, Found: 328.0943.

Compound 1n: Prepared according to General Procedure B; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (600.0 mg, 2.970 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (12% EtOAc in hexane); Pale-yellow thick oil (848.0 mg, 2.510 mmol, 85% yield); **FT-IR (Thin film)**: 3447 (br), 3006 (w), 2952 (w), 1720 (s), 1610 (m), 1519 (s), 1284 (s), 1115 (m), 835 (m), 734 (m); **$^1\text{H-NMR}$ (300 MHz, CD₂Cl₂)**: δ 7.99 (d, $J = 8.6$ Hz, 2H), 7.50-7.47 (m, 2H), 7.41-7.36 (m, 3H), 6.96 (d, $J = 8.8$ Hz, 2H), 6.55 (d, $J = 1.9$ Hz, 1H), 6.00 (d, $J = 5.2$ Hz, 1H), 3.88 (s, 3H), 3.82 (s, 3H), 2.67 (d, $J = 5.5$ Hz, 1H); **$^{13}\text{C-NMR}$ (75 MHz, CD₂Cl₂)**: 167.1, 159.6, 149.2, 146.7, 142.7, 130.0, 129.9, 129.7, 126.8, 125.5, 124.7, 114.6, 112.2, 68.1, 55.7, 52.4; **HRMS (ESI+)**: Calcd. for C₂₀H₁₈O₅ ([M+Na]⁺): 361.1046, Found: 361.1048.

Compound 1o: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (600.0 mg, 2.970 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Blueish solid (885.0 mg, 2.680 mmol, 90% yield); **m.p.** 102-104 °C; **FT-IR (Thin film)**: 3437 (br), 3051 (w), 1600 (w), 1518 (s), 1248 (s), 1033 (m), 834 (m), 785 (s); **$^1\text{H-NMR}$ (300 MHz, CD₂Cl₂)**: δ 7.88-7.81 (m, 2H), 7.77-7.74 (m, 1H), 7.73-7.69 (m, 1H), 7.54-7.49 (m, 1H), 7.47-7.42 (m, 3H), 7.38-7.32 (m, 2H), 6.97 (d, $J = 8.8$ Hz, 2H), 6.60-6.57 (m, 2H), 3.83 (s, 3H), 2.65 (d, $J = 5.6$ Hz, 1H); **$^{13}\text{C-NMR}$ (75 MHz, CD₂Cl₂)**: δ 159.5, 149.7, 142.5, 137.2, 134.2, 130.9, 129.7, 129.1, 128.9, 126.6, 126.0, 125.7, 125.7, 124.3,






124.1, 123.7, 114.6, 112.0, 66.3, 55.7; **HRMS (ESI+)**: Calcd. for $C_{22}H_{18}O_3$ ($[M+Na]^+$): 353.1148, Found: 353.1152.

Compound 1p: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (600.0 mg, 2.970 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); Yellow thick oil (835.0 mg, 2.527 mmol, 85% yield); **FT-IR (Thin film)**: 3434 (br), 1518 (s), 1248 (s), 1179 (m), 1145 (w), 1031 (s), 834 (s), 760 (s); **¹H-NMR (300 MHz, CD₂Cl₂)**: δ 7.91-7.90 (m, 1H), 7.88-7.82 (m, 3H), 7.53-48 (m, 3H), 7.46-7.41 (m, 3H), 6.97 (d, $J = 8.8$ Hz, 2H), 6.57 (d, $J = 1.9$ Hz, 1H), 6.12 (d, $J = 4.7$ Hz, 1H), 3.83 (s, 3H), 2.65 (d, $J = 5.2$ Hz, 1H); **¹³C-NMR (75 MHz, CD₂Cl₂)**: δ 159.5, 149.8, 142.6, 139.3, 133.7, 133.3, 129.8, 128.5, 128.4, 128.0, 126.6, 126.5, 125.7, 125.3, 125.1, 124.4, 114.6, 112.1, 68.6, 55.7; **HRMS (ESI+)**: Calcd. for $C_{22}H_{18}O_3$ ($[M+Na]^+$): 353.1148, Found: 353.1150.

Compound 1q: Prepared according to General Procedure B; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (500.0 mg, 2.470 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Orange solid (648.0 mg, 1.630 mmol, 66% yield); **m.p.** 46-48 °C; **FT-IR (Thin film)**: 3434 (br), 2959 (m), 1615 (m), 1519 (m), 1448 (m), 1247 (m), 1034 (m), 832 (m), 739 (s); **¹H-NMR (400 MHz, CD₂Cl₂)**: δ 7.74-7.72 (m, 1H), 7.70 (d, $J = 7.9$ Hz, 1H), 7.58 (m, 1H), 7.47-7.45 (m, 2H), 7.44-7.40 (m, 2H), 7.37-7.32 (m, 3H), 6.97 (d, $J = 8.8$ Hz, 2H), 6.57 (d, $J = 1.8$ Hz, 1H), 6.03 (d, $J = 5.4$ Hz, 1H), 3.83 (s, 3H), 2.59 (d, $J = 5.6$ Hz, 1H), 1.48 (d, $J = 4.7$ Hz, 6H); **¹³C-NMR (100 MHz, CD₂Cl₂)**: 159.5, 154.4, 150.0, 142.4, 141.1, 139.2, 139.2, 129.8, 127.7, 127.4, 125.9, 125.8, 124.1, 123.0, 121.3, 120.4, 120.2, 114.5, 112.2, 68.7, 55.7, 47.3, 27.3, 27.3; **HRMS (ESI+)**: Calcd. for $C_{27}H_{24}O_3$ ($[M+Na]^+$): 419.1618, Found: 419.1617.

Compound 1r: Prepared according to General Procedure B; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (600.0 mg, 2.970 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (8% EtOAc in hexane); Yellow thick oil (359.0 mg, 1.254 mmol, 42% yield); **FT-IR (Thin film)**: 3444 (br), 2931 (w), 1604 (m), 1517 (s), 1249 (s), 1179 (m), 1032 (m), 834 (s); **¹H-NMR (400 MHz, CD₂Cl₂)**: δ 7.44 (d, $J = 1.8$ Hz, 1H), 7.36 (d, $J = 8.8$ Hz, 2H), 7.34-7.31 (m, 1H), 7.28-7.27 (m, 1H), 7.11 (dd, $J = 5.0, 1.4$ Hz, 1H), 6.95 (d, $J = 8.8$ Hz, 2H), 6.55 (d, $J = 1.9$ Hz, 1H), 5.98 (s, 1H), 3.82 (s, 3H), 2.54 (br s, 1H); **¹³C-NMR (75 MHz, CD₂Cl₂)**: δ 159.4, 149.6, 143.2, 142.4, 129.7, 127.0, 126.5, 125.7, 123.8, 122.4, 114.5, 112.0, 65.2, 55.7; **HRMS (ESI+)**: Calcd. for $C_{16}H_{14}O_3S$ ($[M+Na]^+$): 309.0556, Found: 309.0562. [Note: This compound is very unstable, sensitive to silica-gel, temperature, and rotary evaporation at 20 °C is necessary.]




Compound 1s: Prepared according to General Procedure C (thiophene was used instead of 2-bromothiophene to generate corresponding 2-thienyllithium); Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (500.0 mg, 2.470 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (4% EtOAc in hexane); Orange oil (589.0 mg, 2.060 mmol, 83% yield); **FT-IR (Thin film):** 3434 (br), 3109 (w), 2836 (w), 1604 (m), 1518 (s), 1249 (s), 1179 (m), 1031 (m), 958 (m), 835 (m), 704 (m); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.48 (d, *J* = 1.8 Hz, 1H), 7.35 (d, *J* = 8.8 Hz, 2H), 7.32 (dd, *J* = 4.9, 1.4 Hz, 1H), 6.99-6.94 (m, 4H), 6.56 (d, *J* = 1.9 Hz, 1H), 6.14 (dd, *J* = 6.3, 1.0 Hz, 1H), 3.82 (s, 3H), 2.73 (d, *J* = 6.3 Hz, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** 159.5, 148.9, 145.6, 142.6, 129.7, 127.1, 126.0, 125.5, 125.5, 123.9, 114.6, 112.1, 65.0, 55.7; **HRMS (ESI+):** Calcd. for C₁₆H₁₄O₃S ([M+Na]⁺): 309.0556, Found: 309.0554.

Compound 1t: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (600.0 mg, 2.970 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (11% EtOAc in hexane); Yellow thick oil (814.0 mg, 2.510 mmol, 85% yield); **FT-IR (Thin film):** 3444 (br), 2902 (m), 1604 (m), 1234 (m), 1442 (m), 1180 (s), 1034 (s), 835 (s), 769 (m); **¹H-NMR (300 MHz, CD₂Cl₂):** δ 7.42 (d, *J* = 1.9 Hz, 1H), 7.35 (d, *J* = 8.8 Hz, 2H), 6.96-6.93 (m, 3H), 6.85 (ddd, *J* = 8.0, 1.7, 0.7 Hz, 1H), 6.77 (d, *J* = 8.0 Hz, 1H), 6.53 (d, *J* = 1.9 Hz, 1H), 5.95 (s, 2H), 5.85 (d, *J* = 5.4 Hz, 1H), 3.82 (s, 3H), 2.46 (d, *J* = 5.5 Hz, 1H); **¹³C-NMR (75 MHz, CD₂Cl₂):** 159.5, 149.8, 148.3, 147.6, 142.4, 135.9, 129.7, 125.7, 123.9, 120.2, 114.5, 112.1, 108.3, 107.6, 101.7, 68.3, 55.7; **HRMS (ESI+):** Calcd. for C₁₉H₁₆O₅ ([M+Na]⁺): 347.0890, Found: 347.0881.


Compound 1u: Prepared according to General Procedure A, Condition I; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (600.0 mg, 2.970 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (10% EtOAc in hexane); White thick oil (608.0 mg, 2.618 mmol, 88% yield); **FT-IR (Thin film):** 3303 (br), 2967 (m), 1614 (m), 1519 (s), 1275 (m), 1250 (s), 885 (s), 731 (m); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.41 (d, *J* = 1.8 Hz, 1H), 7.36 (d, *J* = 8.7 Hz, 2H), 6.94 (d, *J* = 8.7 Hz, 2H), 6.51 (d, *J* = 1.8 Hz, 1H), 4.70-4.65 (m, 1H), 3.82 (s, 3H), 1.99-1.93 (m, 2H), 1.92-1.88 (m, 1H), 0.89 (t, *J* = 7.4 Hz, 3H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 159.3, 151.1, 141.8, 129.7, 126.1, 123.6, 114.4, 111.9, 68.0, 55.7, 29.1, 10.4; **HRMS (ESI+):** Calcd. for C₁₄H₁₆O₃ ([M+Na]⁺): 255.0992, Found: 255.0998.

Compound 1v: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (300.0 mg, 1.483 mmol, 1.0 equiv.);




Purified by silica-gel flash column chromatography (10% EtOAc in hexane); White thick oil (241.0 mg, 0.797 mmol, 54% yield); **FT-IR (Thin film):** 3443 (br), 2927 (s), 1519 (s), 1465 (w), 1248 (s), 1037 (m), 890 (m), 834 (s); **¹H-NMR (300 MHz, CD₂Cl₂):** δ 7.41 (d, *J* = 1.9 Hz, 1H), 7.35 (d, *J* = 8.8 Hz, 2H), 6.94 (d, *J* = 8.8 Hz, 2H), 6.50 (d, *J* = 1.9 Hz, 1H), 4.78-4.72 (m, 1H), 3.82 (s, 3H), 1.95-1.87 (m, 3H), 1.37-1.26 (m, 6H), 1.24-1.17 (m, 3H), 0.89-0.84 (m, 3H); **¹³C-NMR (75 MHz, CD₂Cl₂):** δ 159.3, 151.3, 141.7, 129.7, 126.1, 123.4, 114.4, 111.9, 66.6, 55.7, 36.1, 32.2, 29.7, 29.6, 26.2, 23.0, 14.3; **HRMS (ESI+):** Calcd. for C₁₉H₂₆O₃ ([M+Na]⁺): 325.1774, Found: 325.1768.

Compound 1w: Prepared according to General Procedure A, Condition I; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (300.0 mg, 1.483 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); White thick oil (215.0 mg, 0.873 mmol, 59% yield); **FT-IR (Thin film):** 3419 (br), 2959 (m), 1518 (s), 1247 (s), 1179 (m), 1032 (m), 834 (m), 751 (w); **¹H-NMR (400 MHz, CD₂Cl₂):**




δ 7.41 (d, *J* = 1.8 Hz, 1H), 7.35 (d, *J* = 8.9 Hz, 2H), 6.94 (d, *J* = 8.9 Hz, 2H), 6.49 (d, *J* = 1.8 Hz, 1H), 4.36 (dd, *J* = 8.9, 5.6 Hz, 1H), 3.82 (s, 3H), 2.26-2.17 (m, 1H), 1.94 (d, *J* = 6.0 Hz, 1H), 1.07 (d, *J* = 6.7 Hz, 3H), 0.74 (d, *J* = 6.8 Hz, 3H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 159.3, 151.0, 141.7, 129.8, 126.1, 124.0, 114.4, 112.0, 72.3, 55.7, 33.9, 19.4, 19.2; **HRMS (ESI+):** Calcd. for C₁₅H₁₈O₃ ([M+Na]⁺): 269.1148, Found: 269.1141.

Compound 1x: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (300.0 mg, 1.483 mmol, 1.0 equiv.);



Purified by silica-gel flash column chromatography (7% EtOAc in hexane); White thick oil (233.0 mg, 0.895 mmol, 60% yield); **FT-IR (Thin film):** 3389 (br), 2956 (m), 1604 (w), 1519 (s), 1466 (m), 1248 (s), 1179 (m), 834 (m); **¹H-NMR (300 MHz, CD₂Cl₂):** δ 7.41 (d, *J* = 1.9 Hz, 1H), 7.36 (d, *J* = 8.8 Hz, 2H), 6.95 (d, *J* = 8.8 Hz, 2H), 6.50 (d, *J* = 1.9 Hz, 1H), 4.86-4.81 (m, 1H), 3.82 (s, 3H), 1.92-1.82 (m, 2H), 1.78-1.69 (m, 1H), 1.67-1.58 (m, 1H), 0.87 (d, *J* = 6.6 Hz, 3H), 0.85 (d, *J* = 6.6 Hz, 3H); **¹³C-NMR (75 MHz, CD₂Cl₂):** δ 159.3, 151.4, 141.7, 129.7, 126.1, 123.2, 114.5, 112.0, 64.9, 55.7, 44.9, 25.3, 23.1, 22.3; **HRMS (ESI+):** Calcd. for C₁₆H₂₀O₃ ([M+Na]⁺): 283.1305, Found: 283.1304.

Compound 1y: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (300.0 mg, 1.483 mmol, 1.0 equiv.);






Purified by silica-gel flash column chromatography (8% EtOAc in hexane); White thick oil (345.0 mg, 1.336 mmol, 90% yield); **FT-IR (Thin film):** 3397 (br), 2934 (m), 1603 (w), 1519 (s), 1293 (m), 1248 (s), 957 (w), 834 (s); **¹H-**

NMR (300 MHz, CD₂Cl₂): δ 7.42 (d, *J* = 1.9 Hz, 1H), 7.35 (d, *J* = 8.9 Hz, 2H), 6.94 (d, *J* = 8.9 Hz, 2H), 6.51 (d, *J* = 1.9 Hz, 1H), 5.85-5.73 (m, 1H), 5.01-4.91 (m, 2H), 4.81-4.75 (m, 1H), 3.82 (s, 3H), 2.12-2.00 (m, 4H), 1.97-1.95 (m, 1H); **¹³C-NMR (75 MHz, CD₂Cl₂):** δ 159.3, 150.9, 141.9, 138.4, 129.7, 126.0, 123.5, 115.2, 114.5, 112.0, 66.1, 55.7, 35.2, 30.4; **HRMS (ESI+):** Calcd. for C₁₆H₁₈O₃ ([M+Na]⁺): 281.1148, Found: 281.1139.

Compound 1z: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (300.0 mg, 1.483 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (8% EtOAc in hexane); White thick oil (369.0 mg, 1.197 mmol, 81% yield); **FT-IR (Thin film):** 3397 (br), 2951 (w), 1604 (m), 1519 (s), 1291 (m), 1248 (s), 955 (m), 834 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.43 (d, *J* = 1.9 Hz, 1H), 7.28 (d, *J* = 8.7 Hz, 2H), 7.26-7.21 (m, 2H), 7.19-7.12 (m, 3H), 6.91 (d, *J* = 8.7 Hz, 2H), 6.52 (d, *J* = 1.9 Hz, 1H), 4.77 (q, *J* = 6.5 Hz, 1H), 3.82 (s, 3H), 2.71-2.56 (m, 2H), 2.31-2.15 (m, 2H), 1.99 (d, *J* = 5.4 Hz, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 159.3, 150.9, 142.0, 142.0, 129.7, 128.8, 128.7, 126.2, 125.9, 123.5, 114.5, 111.9, 65.8, 55.7, 37.7, 32.4; **HRMS (ESI+):** Calcd. for C₂₀H₂₀O₃ ([M+Na]⁺): 331.1305, Found: 331.1307.

Compound 1aa: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (300.0 mg, 1.483 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); Colorless oil (128.0 mg, 0.470 mmol, 32% yield); **FT-IR (Thin film):** 3436 (br), 2953 (m), 1604 (w), 1518 (s), 1248 (s), 1179 (m), 957 (m), 834 (m); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.40 (d, *J* = 1.9 Hz, 1H), 7.37 (d, *J* = 8.7 Hz, 2H), 6.94 (d, *J* = 8.8 Hz, 2H), 6.49 (d, *J* = 1.8 Hz, 1H), 4.46 (d, *J* = 9.5 Hz, 1H), 3.82 (s, 3H), 2.58-2.48 (m, 1H), 1.97 (br s, 1H), 1.94-1.89 (m, 1H), 1.63-1.56 (m, 2H), 1.53-1.44 (m, 4H), 1.02-0.95 (m, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 159.3, 151.4, 141.7, 129.8, 126.2, 123.6, 114.4, 111.9, 70.9, 55.7, 45.3, 30.4, 29.4, 26.0, 25.8; **HRMS (ESI+):** Calcd. for C₁₇H₂₀O₃ ([M+Na]⁺): 295.1305, Found: 295.1309.

Compound 1ab: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (300.0 mg, 1.483 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); Colorless oil (256.0 mg, 0.894 mmol, 60% yield); **FT-IR (Thin film):** 3435 (br), 2926 (s), 1518 (s), 1247 (s), 1178 (m), 1034 (m), 891 (m), 756 (m); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.41 (d, *J* = 1.8 Hz, 1H), 7.34 (d, *J* = 8.8 Hz, 2H), 6.94 (d, *J* = 8.7 Hz, 2H), 6.48 (d, *J* = 1.9 Hz, 1H), 4.40 (dd, *J* = 9.1, 5.9 Hz, 1H), 3.82 (s, 3H), 2.15-2.09 (m, 1H), 1.96-1.87 (m, 2H), 1.80-1.74 (m, 1H), 1.67-1.60 (m, 2H), 1.30-1.23 (m, 2H), 1.20-1.08 (m, 3H), 1.06-0.97 (m, 1H), 0.78-0.78 (m, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 159.3, 150.9, 141.7, 129.8,







126.2, 124.1, 114.4, 111.9, 71.2, 55.7, 43.2, 30.2, 29.7, 26.8, 26.4, 26.3; **HRMS (ESI+)**: Calcd. for C₁₈H₂₂O₃ ([M+Na]⁺): 309.1461, Found: 309.1454.

Compound 1ac: Prepared according to General Procedure A, Condition I; Starting from 3-phenylfuran-2-carbaldehyde (238.0 mg, 1.380 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); Yellow solid (209.0 mg, 0.835 mmol, 61% yield); **m.p.** 75-77 °C; **FT-IR (Thin film)**: 3541 (s), 1509 (m), 1492 (m), 1450 (m), 1249 (w), 1143 (s), 962 (m), 837 (m); **¹H-NMR (400 MHz, CDCl₃)**: δ 7.46-7.41 (m, 6H), 7.40-7.36 (m, 3H), 7.35-7.29 (m, 2H), 6.56 (d, *J* = 1.9 Hz, 1H), 5.99 (d, *J* = 5.8 Hz, 1H), 2.43 (d, *J* = 6.0 Hz, 1H); **¹³C-NMR (100 MHz, CDCl₃)**: δ 149.9, 142.4, 141.3, 133.2, 128.9, 128.6, 128.4, 128.0, 127.4, 126.7, 124.4, 111.8, 68.3; **HRMS (ESI+)**: Calcd. for C₁₇H₁₄O₂ ([M+Na]⁺): 273.0886, Found: 273.0886.

Compound 1ad: Prepared according to General Procedure A, Condition I; Starting from 3-(p-tolyl)furan-2-carbaldehyde (528.0 mg, 2.836 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); Yellow thick oil (643.0 mg, 2.433 mmol, 86% yield); **FT-IR (Thin film)**: 3409 (br), 1519 (s), 1450 (m), 1185 (w), 1146 (s), 960 (s), 821 (m), 788 (w); **¹H-NMR (300 MHz, CD₂Cl₂)**: δ 7.44-7.40 (m, 3H), 7.39-7.34 (m, 4H), 7.32-7.28 (m, 1H), 7.27-7.23 (m, 2H), 6.57 (d, *J* = 1.9 Hz, 1H), 5.97 (d, *J* = 5.5 Hz, 1H), 2.50 (d, *J* = 5.7 Hz, 1H), 2.39 (s, 3H); **¹³C-NMR (75 MHz, CD₂Cl₂)**: δ 150.1, 142.5, 141.9, 137.6, 130.4, 129.8, 128.8, 128.5, 128.1, 126.8, 124.5, 112.0, 68.4, 21.3; **HRMS (ESI+)**: Calcd. for C₁₈H₁₆O₂ ([M+Na]⁺): 287.1043, Found: 287.1049.

Compound 1ae: Prepared according to General Procedure A, Condition I; Starting from 3-(2-methylphenyl)furan-2-carbaldehyde (600.0 mg, 3.220 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Yellow solid (840.0 mg, 3.180 mmol, 99% yield); **m.p.** 60-62 °C; **FT-IR (Thin film)**: 3333 (br), 3321 (s), 3029 (m), 2922 (w), 1604 (m), 1493 (s), 1319 (m), 1237 (s), 1013 (s), 752 (s); **¹H-NMR (400 MHz, CD₂Cl₂)**: δ 7.45 (d, *J* = 1.9 Hz, 1H), 7.38-7.31 (m, 4H), 7.30-7.25 (m, 3H), 7.24-7.21 (m, 2H), 6.44 (d, *J* = 1.8 Hz, 1H), 5.66 (d, *J* = 5.5 Hz, 1H), 2.42 (d, *J* = 5.5 Hz, 1H), 2.26 (s, 3H); **¹³C-NMR (100 MHz, CD₂Cl₂)**: 151.0, 142.2, 141.9, 137.5, 132.9, 130.8, 130.6, 128.7, 128.2, 128.0, 126.7, 126.1, 123.6, 113.2, 68.3, 20.6; **HRMS (ESI+)**: Calcd. for C₁₈H₁₆O₂ ([M+Na]⁺): 287.1043, Found: 287.1034.

Compound 1af: Prepared according to General Procedure A, Condition I; Starting from 3-(4-fluorophenyl)furan-2-carbaldehyde (647.0 mg, 3.402 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); Off-white solid (872.0 mg, 3.250 mmol, 96% yield); **m.p.** 60-62 °C; **FT-IR (Thin film)**: 3290 (br), 1602 (m), 1517 (s), 1492 (m), 1336 (w), 1222 (s), 962 (s), 835 (s), 720 (m); **¹H-NMR (400 MHz, CD₂Cl₂)**: δ 7.46-7.40 (m, 5H), 7.38-7.34 (m, 2H), 7.32-7.28 (m,






1H), 7.15-7.09 (m, 2H), 6.55 (d, J = 1.8 Hz, 1H), 5.93 (d, J = 5.6 Hz, 1H), 2.53 (d, J = 5.7 Hz, 1H); **$^{13}\text{C-NMR}$ (100 MHz, CD_2Cl_2)**: δ 162.6 (d, J = 245.8 Hz), 150.4, 142.6, 141.6, 130.4 (d, J = 8.0 Hz), 129.6 (d, J = 3.3 Hz), 128.8, 128.2, 126.8, 123.6, 115.9 (d, J = 21.6 Hz), 112.1, 68.4; **HRMS (ESI+)**: Calcd. for $\text{C}_{17}\text{H}_{13}\text{FO}_2$ ([M+Na] $^+$): 291.0792, Found: 291.0794.

Compound 1ag: Prepared according to General Procedure A, Condition I; Starting from 3-(2-fluorophenyl)furan-2-carbaldehyde (160.0 mg, 0.840 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Yellow oil (218.0 mg, 0.810 mmol, 96% yield); **FT-IR (Thin film)**: 3398 (br), 3031 (w), 2924 (w), 1514 (m), 1492 (m), 1454 (m), 1145 (m), 1012 (m), 965 (m), 756 (s), 699 (m); **$^1\text{H-NMR}$ (400 MHz, CD_2Cl_2)**: δ 7.48 (d, J = 1.9 Hz, 1H), 7.42-7.39 (m, 3H), 7.38-7.33 (m, 3H), 7.31-7.28 (m, 1H), 7.24-7.15 (m, 2H), 6.57 (t, J = 1.8 Hz, 1H), 5.86 (d, J = 5.0 Hz, 1H), 2.55 (d, J = 5.3 Hz, 1H); **$^{13}\text{C-NMR}$ (100 MHz, CD_2Cl_2)**: 160.3 (d, J = 246.1 Hz), 159.0, 151.7, 142.7, 141.4, 131.7 (d, J = 3.3 Hz), 129.8 (d, J = 8.1 Hz), 128.7, 128.1, 126.8, 124.8 (d, J = 3.7 Hz), 118.1, 116.2 (d, J = 22.4 Hz), 112.8 (d, J = 2.3 Hz), 68.4 (d, J = 2.4 Hz); **HRMS (ESI+)**: Calcd. for $\text{C}_{17}\text{H}_{13}\text{FO}_2$ ([M+Na] $^+$): 291.0792, Found: 291.0790. [Note: This compound is very unstable, sensitive to silica-gel, temperature, and rotary evaporation at 20 °C is necessary.]

Compound 1ah: Prepared according to General Procedure A, Condition I; Starting from 3-(1-naphthalen-1-yl)furan-2-carbaldehyde (600.0 mg, 2.700 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Brown oil (608.0 mg, 2.020 mmol, 75% yield); **FT-IR (Thin film)**: 3365 (br), 3045 (w), 1508 (m), 1451 (m), 1145 (m), 1014 (m), 938 (m), 779 (s), 698 (m); **$^1\text{H-NMR}$ (300 MHz, CD_2Cl_2)**: δ 7.95-7.88 (m, 3H), 7.56-7.44 (m, 5H), 7.38-7.25 (m, 5H), 6.60 (d, J = 1.8 Hz, 1H), 5.69 (d, J = 5.4 Hz, 1H), 2.43 (d, J = 5.5 Hz, 1H); **$^{13}\text{C-NMR}$ (75 MHz, CD_2Cl_2)**: 151.9, 142.5, 141.7, 134.2, 132.8, 131.0, 128.7, 128.5, 128.2, 128.0, 126.8, 126.7, 126.4, 126.2, 125.8, 122.4, 114.0, 68.3; **HRMS (ESI+)**: Calcd. for $\text{C}_{21}\text{H}_{16}\text{O}_2$ ([M+Na] $^+$): 323.1043, Found: 323.1045.

Compound 1ai: Prepared according to General Procedure A, Condition I; Starting from 3-(thiophen-3-yl)furan-2-carbaldehyde (600.0 mg, 3.370 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Red oil (775.0 mg, 3.020 mmol, 90% yield); **FT-IR (Thin film)**: 3377 (br), 3105 (w), 2920 (w), 1493 (m), 1450 (m), 1166 (m), 1186 (m), 1144 (s), 1016 (s), 898 (s), 855 (s), 786 (s), 751 (s), 701 (s) 651 (m); **$^1\text{H-NMR}$ (400 MHz, CD_2Cl_2)**: δ 7.44-7.41 (m, 4H), 7.39-7.37 (m, 2H), 7.34 (dd, J = 3.0, 1.3 Hz, 1H), 7.33-7.30 (m, 1H), 7.26 (dd, J = 5.0, 1.3 Hz, 1H), 6.58 (d, J = 1.9 Hz, 1H), 6.04 (br s, 1H), 2.56 (br s, 1H); **$^{13}\text{C-NMR}$ (100 MHz, CD_2Cl_2)**: 150.4, 142.5, 141.6, 133.6, 128.8, 128.2, 128.0, 126.8, 126.5, 122.2, 119.4, 111.9, 68.6; **HRMS (ESI+)**: Calcd. for $\text{C}_{15}\text{H}_{12}\text{O}_2\text{S}$ ([M+Na] $^+$): 279.0450, Found: 279.0455.







Compound 2a: Prepared according to General Procedure D, Condition I; Starting from **1a** (900.0 mg, 3.210 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); Yellow thick oil (961.0 mg, 2.696 mmol, 84% yield, over two steps); **FT-IR (Thin film):** 3442 (br), 1519 (s), 1447 (m), 1245 (s), 1179 (m), 1028 (s), 974 (w), 754 (s); **¹H-NMR (400 MHz, CDCl₃):** δ 7.38 (d, *J* = 1.9 Hz, 1H), 7.29-7.28 (m, 2H), 7.27-7.26 (m, 6H), 7.26-7.25 (m, 2H), 7.02 (d, *J* = 8.6 Hz, 2H), 6.70 (d, *J* = 8.8 Hz, 2H), 6.43 (d, *J* = 1.8 Hz, 1H), 3.76 (s, 3H), 3.07 (br s, 1H); **¹³C-NMR (100 MHz, CDCl₃):** δ 158.7, 151.7, 145.4, 140.8, 130.3, 128.0, 127.7, 126.3, 123.3, 114.1, 113.7, 79.7, 55.4; **HRMS (ESI+):** Calcd. for C₂₄H₂₀O₃ ([M+Na]⁺): 379.1305, Found: 379.1301.

Compound 2b: Prepared according to General Procedure D, Condition II; Starting from **1b** (400.0 mg, 1.359 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); Yellow thick oil (144.0 mg, 0.375 mmol, 28% yield, over two steps); **FT-IR (Thin film):** 3476 (br), 2921 (w), 1518 (s), 1246 (s), 1178 (m), 1034 (m), 877 (w), 786 (m); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.38 (d, *J* = 1.8 Hz, 1H), 7.12-7.08 (m, 7H), 7.06-7.02 (m, 3H), 6.70 (d, *J* = 8.7 Hz, 2H), 6.45 (d, *J* = 1.8 Hz, 1H), 3.75 (s, 3H), 2.98 (s, 1H), 2.32 (s, 6H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 159.0, 152.4, 143.1, 140.9, 137.6, 130.6, 128.9, 127.7, 126.7, 123.4, 114.4, 113.8, 79.6, 55.6, 21.1; **HRMS (ESI+):** Calcd. for C₂₆H₂₄O₃ ([M+Na]⁺): 407.1618, Found: 407.1616.

Compound 2c: Prepared according to General Procedure D, Condition II; Starting from **1d** (400.0 mg, 1.300 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Colorless oil (383.0 mg, 0.930 mmol, 72% yield, over two steps); **FT-IR (Thin film):** 3481 (br), 3007 (w), 2917 (m), 1599 (m), 1519 (s), 1246 (s), 1178 (m), 1037 (s), 833 (m), 758 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.40 (d, *J* = 1.8 Hz, 1H), 7.01 (d, *J* = 8.8 Hz, 2H), 6.88-6.85 (m, 6H), 6.70 (d, *J* = 8.8 Hz, 2H), 6.44 (d, *J* = 1.8 Hz, 1H), 3.75 (s, 3H), 2.97 (s, 1H), 2.23 (s, 12H); **¹³C-NMR (100 MHz, CD₂Cl₂):** 158.9, 152.4, 145.7, 140.8, 137.7, 130.5, 129.4, 126.9, 125.6, 123.6, 114.4, 113.6, 79.6, 55.6, 21.6; **HRMS (ESI+):** Calcd. for C₂₈H₂₈O₃ ([M+Na]⁺): 435.1931, Found: 435.1927.

Compound 2d: Prepared according to General Procedure D, Condition II; Starting from **1e** (326.0 mg, 1.050 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (10% EtOAc in hexane); Colorless thick oil (155.0 mg, 0.372 mmol, 35% yield, over two steps); **FT-IR (Thin film):** 3474 (br), 2835 (w), 1599 (s), 1247 (w), 1036 (s), 833 (m), 777 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.40 (d, *J* = 1.8 Hz, 1H), 7.19-7.15 (m, 2H), 7.03 (d, *J* = 8.7 Hz, 2H), 6.84-6.82 (m, 4H), 6.79-6.76 (m, 2H), 6.70 (d, *J* = 8.7 Hz, 2H), 6.45 (d, *J* = 1.8 Hz,



1H), 3.75 (s, 3H), 3.71 (s, 6H), 3.09 (s, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂)**: δ 159.8, 159.0, 151.8, 147.1, 141.0, 130.5, 129.2, 126.5, 123.8, 120.2, 114.4, 113.9, 113.8, 113.1, 79.6, 55.6, 55.5; **HRMS (ESI+)**: Calcd. for C₂₆H₂₄O₅ ([M+Na]⁺): 439.1516, Found: 439.1521.

Compound 2e: Prepared according to General Procedure D, Condition II; Starting from **1f** (450.0 mg, 1.380 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (6% EtOAc in hexane); Yellow oil (351.0 mg, 0.780 mmol, 57% yield, over two steps); **FT-IR (Thin film)**: 3458 (br), 3004 (w), 2921 (m), 2834 (w), 1596 (m), 1519 (s), 1493 (s), 1246 (s), 1093 (m), 1034 (m), 813 (s), 756 (s); **¹H-NMR (300 MHz, CD₂Cl₂)**: δ 7.40 (d, *J* = 1.8 Hz, 1H), 7.16-7.13 (m, 4H), 7.12-7.09 (m, 4H), 6.98 (d, *J* = 8.7 Hz, 2H), 6.68 (d, *J* = 8.7 Hz, 2H), 6.44 (d, *J* = 1.8 Hz, 1H), 3.75 (s, 3H), 3.09 (s, 1H), 2.45 (s, 6H); **¹³C-NMR (75 MHz, CD₂Cl₂)**: 159.0, 151.7, 142.3, 141.1, 138.4, 130.5, 128.3, 126.4, 126.0, 124.0, 114.5, 113.8, 79.2, 55.6, 15.8; **HRMS (ESI+)**: Calcd. for C₂₆H₂₄O₃S₂ ([M+Na]⁺): 471.1059, Found: 471.1065.




Compound 2f: Prepared according to General Procedure D, Condition II; Starting from **1g** (600.0 mg, 1.680 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Pale-yellow solid (598.0 mg, 1.180 mmol, 70% yield, over two steps); **m.p.** 141-143 °C; **FT-IR (Thin film)**: 3420 (br), 3030 (w), 1616 (m), 1518 (s), 1486 (s), 1246 (s), 1178 (m), 1034 (m), 832 (s), 768 (s), 755 (s), 699 (s); **¹H-NMR (400 MHz, CD₂Cl₂)**: δ 7.61-7.58 (m, 4H), 7.52-7.49 (m, 4H), 7.47-7.43 (m, 5H), 7.39-7.33 (m, 6H), 7.04 (d, *J* = 8.7 Hz, 2H), 6.67 (d, *J* = 8.7 Hz, 2H), 6.49 (d, *J* = 1.8 Hz, 1H), 3.66 (s, 3H), 3.23 (s, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂)**: 159.0, 151.8, 144.6, 141.2, 141.1, 140.7, 130.6, 129.2, 128.3, 127.8, 127.4, 126.9, 126.5, 124.2, 114.6, 113.7, 79.4, 55.5; **HRMS (ESI+)**: Calcd. for C₃₆H₂₈O₃ ([M+Na]⁺): 531.1931, Found: 531.1924.

Compound 2g: Prepared according to General Procedure D, Condition III; Starting from **1j** (500.0 mg, 1.392 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (10% EtOAc in hexane); White solid (291.0 mg, 0.566 mmol, 41% yield, over two steps); **m.p.** 55-57 °C; **FT-IR (Thin film)**: 3457 (br), 2929 (w), 1518 (s), 1396 (s), 1247 (s), 974 (m), 754 (m); **¹H-NMR (400 MHz, CD₂Cl₂)**: δ 7.41 (d, *J* = 1.8 Hz, 1H), 7.36 (d, *J* = 8.7 Hz, 4H), 7.11 (d, *J* = 8.6 Hz, 4H), 6.94 (d, *J* = 8.7 Hz, 2H), 6.69 (d, *J* = 8.7 Hz, 2H), 6.45 (d, *J* = 1.8 Hz, 1H), 3.76 (s, 3H), 3.19 (s, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂)**: δ 159.2, 150.7, 144.3, 141.4, 131.4, 130.5, 129.7, 125.9, 124.5, 122.1, 114.6, 113.9, 78.9, 55.7; **HRMS (ESI+)**: Calcd. for C₂₄H₁₈Br₂O₃ ([M+Na]⁺): 534.9515, Found: 534.9496.

Compound 2h: Prepared according to General Procedure D, Condition III; Starting from **1k** (400.0 mg, 1.110 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Yellow oil (241 mg, 0.47 mmol, 42% yield, over two steps); **FT-IR (Thin film):** 3465 (br), 2929 (w), 1568 (m), 1519 (s), 1247 (s), 1178 (m), 1034 (m), 787 (m), 756 (s); **¹H-NMR (300 MHz, CD₂Cl₂):** δ 7.42 (t, *J* = 1.8 Hz, 3H), 7.39 (t, *J* = 1.9 Hz, 1H), 7.36 (t, *J* = 1.8 Hz, 1H), 7.20-7.15 (m, 3H), 7.12 (d, *J* = 7.8 Hz, 1H), 6.98 (d, *J* = 8.7 Hz, 2H), 6.71 (d, *J* = 8.7 Hz, 2H), 6.46 (d, *J* = 1.8 Hz, 1H), 3.76 (s, 3H), 3.21 (s, 1H); **¹³C-NMR (75 MHz, CD₂Cl₂):** 159.2, 150.4, 147.3, 141.6, 131.2, 130.8, 130.5, 129.9, 126.6, 125.9, 124.7, 122.6, 114.6, 113.9, 78.7, 55.6; **HRMS (ESI+):** Calcd. for C₂₄H₁₈Br₂O₃ ([M+Na]⁺): 534.9515, Found: 534.9515.

Compound 2i: Prepared according to General Procedure D, Condition I; Starting from **1i** (400.0 mg, 1.270 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Yellow thick oil (253.0 mg, 0.595 mmol, 47% yield, over two steps); **FT-IR (Thin film):** 3464 (br), 2835 (w), 1614 (w), 1519 (s), 1490 (s), 1401 (m), 1247 (s), 879 (m), 728 (m); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.38 (d, *J* = 1.8 Hz, 1H), 7.22-7.19 (m, 4H), 7.17-7.14 (m, 4H), 6.93 (d, *J* = 8.8 Hz, 2H), 6.70 (d, *J* = 8.8 Hz, 2H), 6.42 (d, *J* = 1.8 Hz, 1H), 3.77 (s, 3H), 3.13 (s, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 158.9, 150.7, 143.4, 141.1, 133.8, 130.2, 129.0, 128.2, 125.7, 124.0, 114.3, 113.8, 78.7, 55.5; **HRMS (ESI+):** Calcd. for C₂₄H₁₈Cl₂O₃ ([M+Na]⁺): 447.0525, Found: 447.0516.




Compound 2j: Prepared according to General Procedure D, Condition III; Starting from **1h** (400.0 mg, 1.341 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); Yellow thick oil (143.0 mg, 0.364 mmol, 27% yield, over two steps); **FT-IR (Thin film):** 3465 (br), 1612 (m), 1590 (s), 1519 (s), 1442 (m), 1246 (s), 1179 (w), 1034 (m), 834 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.42 (d, *J* = 1.8 Hz, 1H), 7.26-7.21 (m, 2H), 7.06-6.99 (m, 6H), 6.97-6.92 (m, 2H), 6.71 (d, *J* = 8.7 Hz, 2H), 6.47 (d, *J* = 1.9 Hz, 1H), 3.75 (s, 3H), 3.21 (s, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 163.0 (d, *J* = 244.9 Hz), 159.2, 150.7, 147.8 (d, *J* = 6.8 Hz), 141.5, 130.5, 129.9 (d, *J* = 8.3 Hz), 126.0, 124.4, 123.5 (d, *J* = 2.9 Hz), 115.0 (d, *J* = 2.6 Hz), 114.8, 114.6, 113.9, 78.9, 55.6; **HRMS (ESI+):** Calcd. for C₂₄H₁₈F₂O₃ ([M+Na]⁺): 415.1116, Found: 415.1122.



Compound 2k: Prepared according to General Procedure D, Condition II; Starting from **1l** (600.0 mg, 1.720 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (8% EtOAc in hexane); Red solid (520.0 mg, 1.060 mmol, 62% yield, over two steps); **m.p.** 94-96 °C; **FT-IR (Thin film):** 3456 (br), 2997 (w), 2844 (w), 1617 (m), 1517 (s), 1417 (s), 1322 (s), 1166 (s), 1111 (s), 1068 (s), 1017 (s), 835 (s), 759 (s), 608 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.50 (d, *J* = 8.2 Hz, 4H), 7.44 (d, *J* = 1.8 Hz, 1H), 7.40 (d, *J* = 8.0 Hz, 4H), 6.91 (d, *J* = 8.7 Hz, 2H), 6.64 (d, *J* = 8.7 Hz, 2H), 6.47 (d, *J* = 1.8 Hz, 1H), 3.72 (s, 3H), 3.36 (s, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** 159.2, 150.1, 148.7, 141.7, 130.5, 129.9 (q, *J* = 32.3 Hz), 128.3, 125.7, 125.3 (q, *J* = 3.8 Hz), 125.2, 124.6 (q, *J* = 272 Hz), 114.7, 113.8, 78.9, 55.5; **HRMS (ESI+):** Calcd. for C₂₆H₁₈F₆O₃ ([M+Na]⁺): 515.1052, Found: 515.1060.

Compound 2l: Prepared according to General Procedure D, Condition II; Starting from **1o** (500.0 mg, 1.513 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (6% EtOAc in hexane); White solid (251.0 mg, 0.550 mmol, 36% yield, over two steps); **m.p.** 56-58 °C; **FT-IR (Thin film):** 3454 (br), 1519 (m), 1385 (w), 1247 (m), 1034 (w), 811 (m), 748 (w); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.83-7.81 (m, 2H), 7.76-7.73 (m, 4H), 7.70-7.69 (m, 2H), 7.51-7.44 (m, 7H), 7.03 (d, *J* = 8.7 Hz, 2H), 6.53 (d, *J* = 8.8 Hz, 2H), 6.52 (d, *J* = 1.9 Hz, 1H), 3.60 (s, 3H), 3.37 (s, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 159.0, 151.8, 143.0, 141.3, 133.2, 130.5, 128.8, 128.0, 127.8, 126.7, 126.6, 126.4, 126.3, 126.3, 124.2, 114.5, 113.7, 80.1, 55.5; **HRMS (ESI+):** Calcd. for C₃₂H₂₄O₃ ([M+Na]⁺): 479.1618, Found: 479.1602.

Compound 2m: Prepared according to General Procedure D, Condition III; Starting from **1q** (400.0 mg, 1.010 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Yellow solid (507.0 mg, 0.860 mmol, 85% yield, over two steps); **m.p.** 67-69 °C; **FT-IR (Thin film):** 3426 (br), 3061 (w), 2959 (m), 1604 (m), 1518 (s), 1448 (m), 1295 (m), 1247 (s), 1178 (m), 1032 (m), 962 (m), 834 (s), 759 (s), 739 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.72-7.69 (m, 2H), 7.59 (d, *J* = 8.0 Hz, 2H), 7.46 (d, *J* = 1.8 Hz, 1H), 7.44-7.41 (m, 4H), 7.34-7.30 (m, 4H), 7.21 (dd, *J* = 8.0, 1.8 Hz, 2H), 7.03 (d, *J* = 8.7 Hz, 2H), 6.58 (d, *J* = 8.8 Hz, 2H), 6.50 (d, *J* = 1.8 Hz, 1H), 3.57 (s, 3H), 3.25 (s, 1H), 1.40 (s, 6H), 1.39 (s, 6H); **¹³C-NMR (75 MHz, CD₂Cl₂):** 158.9, 154.5, 153.8, 152.3, 145.0, 141.0, 139.2, 139.0, 130.6, 127.7, 127.4, 127.2, 126.5, 124.0, 123.0, 122.3, 120.4, 119.5, 114.6, 113.7, 80.3, 55.5, 47.2, 27.3, 27.2; **HRMS (ESI+):** Calcd. for C₄₂H₃₆O₃ ([M+Na]⁺): 611.2557, Found: 611.2555.



Compound 2n: Followed General Procedure D to obtain the corresponding ketone (**S2**), then




followed General Procedure C (thiophene was used instead of 2-bromothiophene to generate corresponding 2-thienyllithium); Starting from **1s** (400.0 mg, 1.400 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Brown solid (195.0 mg, 0.530 mmol, 38% yield, over two steps); **m.p.** 103-105 °C; **FT-IR (Thin film):** 3509 (br), 3114 (w), 2966 (w), 2839 (w), 1611 (m), 1516 (s), 1296 (m), 1237 (s), 1183 (s), 1029 (m), 996 (s), 833 (s), 713 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.42 (d, *J* = 1.8 Hz, 1H), 7.28 (dd, *J* = 5.0, 1.3 Hz, 2H), 7.15 (d, *J* = 8.7 Hz, 2H), 6.90 (dd, *J* = 5.0, 3.6 Hz, 2H), 6.87 (dd, *J* = 3.6, 1.3 Hz, 2H), 6.77 (d, *J* = 8.7 Hz, 2H), 6.45 (d, *J* = 1.8 Hz, 1H), 3.77 (s, 3H), 3.49 (s, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** 159.2, 150.4, 149.9, 141.2, 130.6, 126.8, 126.8, 126.2, 126.1, 123.2, 114.7, 113.9, 75.9, 55.6; **HRMS (ESI+):** Calcd. for C₂₀H₁₆O₃S₂ ([M+Na]⁺): 391.0433, Found: 391.0434.

Compound 2o: Prepared according to General Procedure D, Condition II; Starting from **1t** (500.0

mg, 1.540 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (12% EtOAc in hexane); Light-blue solid (438.0 mg, 0.990 mmol, 64% yield, over two steps); **m.p.** 52-54 °C; **FT-IR (Thin film):** 3445 (br), 2896 (w), 1614 (m), 1519 (s), 1485 (s), 1438 (m), 1244 (s), 1178 (m), 1038 (s), 934 (m), 805 (m); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.39 (d, *J* = 1.8 Hz, 1H), 7.00 (d, *J* = 8.8 Hz, 2H), 6.73-6.72 (m, 1H), 6.71-6.67 (m, 7H), 6.43 (d, *J* = 1.8 Hz, 1H), 5.91-5.90 (m, 4H), 3.76 (s, 3H), 3.06 (s, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** 159.0, 152.0, 147.8, 147.4, 141.0, 139.7, 130.5, 126.6, 123.8, 121.3, 114.5, 113.7, 108.9, 107.6, 101.7, 79.4, 55.6; **HRMS (ESI+):** Calcd. for C₂₆H₂₀O₇ ([M+Na]⁺): 467.1101, Found: 467.1109.

Compound 2p: Prepared according to General Procedure D, Condition I; Starting from **1c** (270.0




mg, 0.920 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); White solid (199.0 mg, 0.540 mmol, 59% yield, over two steps); **m.p.** 132-134 °C; **FT-IR (Thin film):** 3419 (br), 2999 (w), 2919 (w), 2837 (w), 1600 (m), 1572 (m), 1519 (s), 1248 (s), 1147 (s), 1038 (s), 840 (s), 748 (s), 709 (s), 617 (m), 558 (m); **¹H-NMR (300 MHz, CD₂Cl₂):** δ 7.40 (d, *J* = 1.8 Hz, 1H), 7.31-7.29 (m, 5H), 7.18 (td, *J* = 7.3, 1.4 Hz, 1H), 7.13-7.09 (m, 1H), 7.07-7.01 (m, 3H), 6.74-6.69 (m, 3H), 6.47 (d, *J* = 1.8 Hz, 1H), 3.75 (s, 3H), 3.08 (s, 1H), 2.06 (s, 3H); **¹³C-NMR (75 MHz, CD₂Cl₂):** 159.2, 152.3, 145.4, 143.5, 140.8, 138.7, 132.6, 130.4, 129.1, 128.4, 128.3, 127.8, 127.8, 126.5, 125.4, 123.1, 114.5, 114.0, 80.9, 55.6, 21.1; **HRMS (ESI+):** Calcd. for C₂₅H₂₂O₃ ([M+Na]⁺): 393.1461, Found: 393.1466.



Compound 2q: Prepared according to General Procedure D, Condition II; Starting from **1a** (230.0 mg, 0.820 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (6% EtOAc in hexane); White solid (227.0 mg, 0.590 mmol, 72% yield, over two steps); **m.p.** 119-121 °C; **FT-IR (Thin film):** 3520 (br), 3065 (w), 2942 (m), 2841 (m), 1599 (s), 1520 (s), 1488 (s), 1241 (s), 1188 (s), 1024 (s), 876 (s), 829 (s), 755 (s), 702 (s), 672 (m); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.34-7.30 (m, 6H), 7.26 (ddd, *J* = 8.2, 7.4, 1.7 Hz, 1H), 7.11 (d, *J* = 8.9 Hz, 2H), 6.88 (dd, *J* = 8.3, 1.1 Hz, 1H), 6.81 (td, *J* = 7.6, 1.2 Hz, 1H), 6.68 (d, *J* = 8.8 Hz, 2H), 6.56 (dd, *J* = 7.7, 1.7 Hz, 1H), 6.51 (d, *J* = 1.8 Hz, 1H), 4.92 (s, 1H), 3.74 (s, 3H), 3.66 (s, 3H); **¹³C-NMR (100 MHz, CD₂Cl₂):** 158.6, 157.7, 151.9, 145.2, 140.6, 134.2, 130.6, 129.7, 129.6, 128.2, 127.8, 127.7, 126.9, 123.1, 120.9, 114.1, 113.2, 112.1, 79.7, 56.1, 55.5; **HRMS (ESI+):** Calcd. for C₂₅H₂₂O₄ ([M+Na]+): 409.1410, Found: 409.1405.

Compound 2r: Prepared according to General Procedure D, Condition II; Starting from **1a** (214 mg, 0.763 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (4% EtOAc in hexane); White solid (215.0 mg, 0.540 mmol, 71% yield, over two steps); **m.p.** 51-53 °C; **FT-IR (Thin film):** 3456 (br), 3060 (w), 2957 (m), 1599 (m), 1519 (s), 1446 (s), 1247 (s), 1034 (s), 833 (s), 759 (s), 700 (s), 633 (m); **¹H-NMR (300 MHz, CD₂Cl₂):** δ 7.38 (td, *J* = 3.8, 1.6 Hz, 2H), 7.32 (dd, *J* = 7.2, 1.4 Hz, 1H), 7.27-7.25 (m, 5H), 7.08-7.02 (m, 3H), 6.74 (d, *J* = 8.8 Hz, 2H), 6.67 (dd, *J* = 7.9, 1.4 Hz, 1H), 6.47 (d, *J* = 1.8 Hz, 1H), 3.75 (s, 3H), 3.24 (hept, *J* = 6.8 Hz, 1H), 3.16 (s, 1H), 1.01 (d, *J* = 6.8 Hz, 3H), 0.83 (d, *J* = 6.8 Hz, 3H); **¹³C-NMR (75 MHz, CD₂Cl₂):** 159.2, 152.8, 150.0, 145.8, 142.7, 140.8, 130.4, 128.8, 128.8, 128.3, 128.1, 127.8, 127.7, 126.6, 125.1, 122.8, 114.6, 114.1, 81.1, 55.6, 30.0, 24.7, 23.8; **HRMS (ESI+):** Calcd. for C₂₇H₂₆O₃ ([M+Na]+): 421.1774, Found: 421.1782.

Compound 2s: Prepared according to General Procedure D, Condition II; Starting from **1a** (214 mg, 0.763 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (4% EtOAc in hexane); White solid (146.0 mg, 0.360 mmol, 47% yield, over two steps); **m.p.** 65-67 °C; **FT-IR (Thin film):** 3435 (br), 1619 (m), 1519 (m), 1247 (m), 1033 (m), 802 (m), 778 (m), 701 (m); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 8.11-8.08 (m, 1H), 7.82-7.78 (m, 2H), 7.40-7.35 (m, 3H), 7.35-7.28 (m, 5H), 7.27-7.23 (m, 1H), 7.00 (d, *J* = 8.8 Hz, 2H), 6.89 (dd, *J* = 7.3, 1.2 Hz, 1H), 6.66 (d, *J* = 8.8 Hz, 2H), 6.48 (d, *J* = 1.8 Hz, 1H), 3.72 (s, 3H), 3.39 (s, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** 159.1, 152.4, 145.6, 141.0, 135.2, 131.9, 130.3, 129.9, 128.9, 128.3, 127.9, 127.9, 127.7, 126.4, 125.7, 125.7, 124.7, 123.3, 114.6, 113.9, 81.3, 55.6; **HRMS (ESI+):** Calcd. for C₂₈H₂₂O₃ ([M+Na]+): 429.1461, Found: 429.1463.







Compound 2t: Prepared according to General Procedure D, Condition I; Starting from **1ac** (444.0 mg, 1.775 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (6% EtOAc in hexane); Colorless oil (414.0 mg, 1.268 mmol, 71% yield, over two steps); **FT-IR (Thin film):** 3443 (w), 1491 (w), 1447 (m), 1144 (m), 1025 (m), 1279 (s), 868 (w), 752 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.43 (d, *J* = 1.8 Hz, 1H), 7.28-7.27 (m, 2H), 7.27-7.26 (m, 6H), 7.25-7.23 (m, 2H), 7.18-7.11 (m, 5H), 6.50 (d, *J* = 1.8 Hz, 1H), 3.06 (s, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 152.2, 145.7, 141.2, 134.4, 129.5, 128.3, 128.2, 127.9, 127.8, 127.2, 124.3, 114.4, 79.8; **HRMS (ESI+):** Calcd. for C₂₃H₁₈O₂ ([M+Na]⁺): 349.1199, Found: 349.1201.

Compound 2u: Prepared according to General Procedure D, Condition I; Starting from **1ad** (400.0 mg, 1.513 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); White solid (219.0 mg, 0.643 mmol, 43% yield, over two steps); **m.p.** 108-110 °C; **FT-IR (Thin film):** 3417 (br), 2519 (m), 1447 (s), 1343 (w), 1146 (m), 1028 (m), 867 (m), 824 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.40 (d, *J* = 1.8 Hz, 1H), 7.30-7.27 (m, 5H), 7.27-7.23 (m, 5H), 7.04-6.99 (m, 4H), 6.48 (d, *J* = 1.9 Hz, 1H), 3.05 (s, 1H), 2.29 (s, 3H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 152.2, 145.9, 141.1, 137.1, 131.3, 129.3, 129.1, 128.2, 127.9, 127.8, 123.9, 114.4, 79.9, 21.2; **HRMS (ESI+):** Calcd. for C₂₄H₂₀O₂ ([M+Na]⁺): 363.1356, Found: 363.1360.

Compound 2v: Prepared according to General Procedure D, Condition I; Starting from **1af** (500.0 mg, 1.864 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (3% EtOAc in hexane); Yellow thick oil (344.0 mg, 0.999 mmol, 54% yield, over two steps); **FT-IR (Thin film):** 3465 (br), 2924 (w), 1519 (s), 1491 (s), 1446 (s), 1337 (s), 1162 (s), 812 (m), 723 (w); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.43 (d, *J* = 1.8 Hz, 1H), 7.26-7.25 (m, 4H), 7.25-7.22 (m, 6H), 7.07-7.03 (m, 2H), 6.85-6.79 (m, 2H), 6.46 (d, *J* = 1.8 Hz, 1H), 3.05 (s, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 162.1 (d, *J* = 245.2 Hz), 152.2, 145.4, 141.3, 131.2 (d, *J* = 8.1 Hz), 130.4 (d, *J* = 3.5 Hz), 128.3, 128.0, 127.8, 123.6, 114.9 (d, *J* = 21.5 Hz), 114.4, 79.6; **HRMS (ESI+):** Calcd. for C₂₃H₁₇FO₂ ([M+Na]⁺): 367.1105, Found: 367.1091.

Compound 2w: Prepared according to General Procedure D, Condition I; Starting from **1ae** (500.0 mg, 1.890 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (2% EtOAc in hexane); Colorless oil (533.0 mg, 1.570 mmol, 83% yield, over two steps); **FT-IR (Thin film):** 3560 (br), 3025 (w), 2921 (w), 1491 (m), 1448 (m), 1338 (m), 1145 (m), 868 (m), 762 (s), 699 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.46 (d, *J* = 1.8 Hz, 1H), 7.24-7.23 (m, 2H), 7.23-7.22 (m, 8H), 7.10-7.09 (m, 2H), 6.98-6.93 (m, 1H), 6.92-6.89 (m, 1H), 6.34 (d, *J* = 1.8 Hz, 1H), 2.84 (s, 1H), 2.13 (s, 3H); **¹³C-NMR (100 MHz, CD₂Cl₂):** 152.0, 145.6, 141.2, 137.3, 133.9, 130.6, 130.1, 128.1, 127.9, 127.9,






127.8, 125.6, 123.0, 114.5, 79.7, 20.6; **HRMS (ESI+)**: Calcd. for C₂₄H₂₀O₃ ([M+Na]+): 363.1356, Found: 363.1352.

Compound 2x: Prepared according to General Procedure D, Condition I; Starting from **1ag** (150.0 mg, 0.560 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Yellow oil (144.0 mg, 0.420 mmol, 75% yield, over two steps); **FT-IR (Thin film)**: 3464 (br), 3060 (m), 3029 (w), 1599 (m), 1514 (m), 1490 (s), 1448 (s), 1337 (m), 1215 (m), 1145 (m), 1032 (m), 814 (m), 754 (s), 700 (s); **¹H-NMR (400 MHz, CD₂Cl₂)**: δ 7.49 (d, *J* = 1.8 Hz, 1H), 7.34-7.32 (m, 1H), 7.28-7.26 (m, 4H), 7.21-7.18 (m, 5H), 7.13-7.09 (m, 1H), 6.98 (td, *J* = 7.6, 1.9 Hz, 1H), 6.91-6.87 (m, 1H), 6.86-6.83 (m, 1H), 6.44 (dd, *J* = 1.9, 0.9 Hz, 1H), 3.08 (d, *J* = 2.0 Hz, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂)**: 159.9 (d, *J* = 244.7 Hz), 153.2, 145.0, 141.5, 132.1 (d, *J* = 3.0 Hz), 129.3 (d, *J* = 8.1 Hz), 128.4, 128.1, 127.9, 127.8, 127.5, 123.9 (d, *J* = 3.6 Hz), 115.4 (d, *J* = 22.5 Hz), 114.5 (d, *J* = 1.4 Hz), 79.4; **HRMS (ESI+)**: Calcd. for C₂₃H₁₇FO₃ ([M+Na]+): 367.1105, Found: 367.1099. [Note: This compound is very unstable, sensitive to silica-gel, temperature, and rotary evaporation at 20 °C is necessary.]

Compound 2y: Prepared according to General Procedure D, Condition I; Starting from **1ai** (400.0 mg, 1.560 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Pale-yellow solid (427.0 mg, 1.280 mmol, 82% yield, over two steps); **m.p.** 78-80 °C; **FT-IR (Thin film)**: 3377 (br), 3105 (w), 3028 (w), 1493 (m), 1450 (m), 1186 (m), 1144 (s), 1016 (s), 898 (s), 855 (s), 786 (s), 751 (s), 701 (s), 651 (m); **¹H-NMR (300 MHz, CD₂Cl₂)**: δ 7.39 (d, *J* = 1.9 Hz, 1H), 7.31-7.28 (m, 10H), 7.18 (dd, *J* = 4.9, 3.0 Hz, 1H), 6.95 (dd, *J* = 3.0, 1.3 Hz, 1H), 6.92 (dd, *J* = 4.9, 1.3 Hz, 1H), 6.55 (d, *J* = 1.8 Hz, 1H), 3.23 (s, 1H); **¹³C-NMR (75 MHz, CD₂Cl₂)**: 152.6, 145.6, 141.2, 134.1, 129.0, 128.3, 128.0, 127.7, 125.5, 123.2, 119.0, 114.0, 79.6; **HRMS (ESI+)**: Calcd. for C₂₁H₁₆O₂S ([M+Na]+): 355.0763, Found: 355.0761.




Compound 2z: Prepared according to General Procedure D, Condition I; Starting from [2,3'-bifuran]-2'-yl(phenyl)methanol (130.0 mg, 0.540 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (8% EtOAc in hexane); Pink solid (136.0 mg, 0.430 mmol, 80% yield, over two steps); **m.p.** 115-117 °C; **FT-IR (Thin film)**: 3445 (br), 3145 (w), 3026 (w), 1492 (m), 1447 (m), 1216 (m), 1018 (m), 857 (m), 753 (s), 701 (s), 636 (m); **¹H-NMR (400 MHz, CD₂Cl₂)**: δ 7.33 (d, *J* = 1.9 Hz, 1H), 7.32-7.28 (m, 10H), 7.27 (dd, *J* = 1.9, 0.7 Hz, 1H), 6.69 (d, *J* = 1.9 Hz, 1H), 6.35 (dd, *J* = 3.4, 1.9 Hz, 1H), 6.28 (dd, *J* = 3.4, 0.8 Hz, 1H), 4.38 (s, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂)**: 153.7, 148.0, 145.5, 142.1, 141.5, 128.2, 127.9, 127.7, 114.0, 111.8, 111.4, 108.0, 79.1; **HRMS (ESI+)**: Calcd. for C₂₁H₁₆O₃ ([M+Na]+): 339.0992, Found: 339.0989.



Compound 2aa: Prepared according to General Procedure D, Condition I; Starting from (3-bromofuran-2-yl)(phenyl)methanol (400.0 mg, 1.590 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (5% EtOAc in hexane); Off-white solid (423.0 mg, 1.285 mmol, 81% yield, over two steps); **m.p.** 55-57 °C; **FT-IR (Thin film):** 3435 (br), 1492 (w), 1492 (m), 1447 (s), 1184 (m), 1141 (m), 987 (s), 755 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.36 (d, *J* = 2.0 Hz, 1H), 7.35-7.32 (m, 6H), 7.31-7.27 (m, 4H), 6.50 (d, *J* = 2.0 Hz, 1H), 3.40 (s, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 153.3, 144.3, 142.3, 128.4, 128.3, 127.9, 115.9, 9 8.0, 79.2; **HRMS (ESI+):** Calcd. for C₁₇H₁₃BrO₂ ([M+Na]⁺): 350.9991, Found: 350.9989.

Compound 6a: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (300.0 mg, 1.483 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); Yellow thick oil (542.0 mg, 1.208 mmol, 82% yield); **FT-IR (Thin film):** 3406 (br), 2953 (s), 1518 (s), 1248 (s), 1179 (s), 960 (m), 833 (s), 756 (m); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.41 (d, *J* = 1.9 Hz, 1H), 7.39-7.37 (m, 4H), 7.34-7.32 (m, 2H), 6.96 (d, *J* = 8.7 Hz, 2H), 6.54 (d, *J* = 1.8 Hz, 1H), 5.94 (d, *J* = 5.7 Hz, 1H), 4.64 (d, *J* = 11.5 Hz, 1H), 4.37 (d, *J* = 11.5 Hz, 1H), 3.83 (s, 3H), 3.18 (td, *J* = 10.5, 4.1 Hz, 1H), 2.52 (d, *J* = 5.7 Hz, 1H), 2.30-2.18 (m, 2H), 1.74-1.66 (m, 1H), 1.65-1.61 (m, 2H), 1.42-1.33 (m, 1H), 1.30-1.25 (m, 1H), 1.05-0.98 (m, 1H), 0.94 (d, *J* = 6.5 Hz, 3H), 0.90 (d, *J* = 7.1 Hz, 3H), 0.88-0.85 (m, 1H), 0.73 (dd, *J* = 7.0, 1.6 Hz, 3H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 159.5, 149.9, 142.4, 140.9, 139.5, 129.7, 128.2, 126.7, 125.8, 124.1, 114.5, 112.0, 79.3, 70.3, 68.3, 55.7, 48.9, 40.8, 35.0, 32.0, 26.1, 23.8, 22.6, 21.2, 16.4; **HRMS (ESI+):** Calcd. for C₂₉H₃₆O₄ ([M+Na]⁺): 471.2506, Found: 471.2506.




Compound 6b: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (202.0 mg, 1.000 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); Yellow thick oil (318.0 mg, 0.709 mmol, 71% yield); **FT-IR (Thin film):** 3409 (br), 2924 (s), 1604 (w), 1518 (s), 1248 (s), 1178 (s), 1034 (m), 894 (w), 833 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.41 (d, *J* = 1.9 Hz, 1H), 7.40-7.36 (m, 4H), 7.33-7.31 (m, 2H), 6.96 (d, *J* = 8.7 Hz, 2H), 6.54 (d, *J* = 1.8 Hz, 1H), 5.94 (d, *J* = 5.6 Hz, 1H), 5.13-5.09 (m, 1H), 4.47 (s, 2H), 3.83 (s, 3H), 3.54-3.46 (m, 2H), 2.53 (d, *J* = 5.7 Hz, 1H), 2.06-1.91 (m, 2H), 1.68 (s, 3H), 1.66-1.63 (m, 1H), 1.60 (s, 3H), 1.60-1.57 (m, 1H), 1.45-1.30 (m, 2H), 1.21-1.12 (m, 1H), 0.89 (d, *J* = 6.6 Hz, 3H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 159.5, 149.9, 142.4, 141.0, 139.0, 131.4, 129.7, 128.0, 126.8, 125.8, 125.2, 124.1, 114.5, 112.1, 72.8, 69.2, 68.3, 55.7, 37.6, 37.1, 30.0, 25.9, 25.8, 19.7, 17.7; **HRMS (ESI+):** Calcd. for C₂₉H₃₆O₄ ([M+Na]⁺): 471.2506, Found: 471.2504.



Compound 6c: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (202.0 mg, 1.000 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (9% EtOAc in hexane); Yellow thick oil (366.0 mg, 0.820 mmol, 82% yield); **FT-IR (Thin film):** 3408 (br), 2916 (m), 1518 (s), 1292 (w), 1248 (s), 1179 (m), 894 (w), 834 (m), 727 (w); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.41 (d, *J* = 1.9 Hz, 1H), 7.40-7.36 (m, 4H), 7.33-7.31 (m, 2H), 6.95 (d, *J* = 8.7 Hz, 2H), 6.54 (d, *J* = 1.9 Hz, 1H), 5.94 (d, *J* = 5.6 Hz, 1H), 5.39-5.35 (m, 1H), 5.14-5.10 (m, 1H), 4.46 (s, 2H), 4.02 (d, *J* = 6.6 Hz, 2H), 3.83 (s, 3H), 2.53 (d, *J* = 5.7 Hz, 1H), 2.15-2.09 (m, 2H), 2.07-2.03 (m, 2H), 1.68 (s, 3H), 1.65 (s, 3H), 1.61 (s, 3H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 159.5, 149.9, 142.4, 141.0, 140.5, 138.9, 132.0, 129.7, 128.2, 126.8, 125.8, 124.4, 124.1, 121.4, 114.5, 112.1, 71.8, 68.3, 67.1, 55.7, 40.0, 26.8, 25.8, 17.8, 16.6; **HRMS (ESI+):** Calcd. for C₂₉H₃₄O₄ ([M+Na]⁺): 469.2349, Found: 469.2354.

Compound 6d: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (202.0 mg, 1.000 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in petroleum eth er); Yellow thick oil (369.0 mg, 0.826 mmol, 83% yield); **FT-IR (Thin film):** 3435 (br), 2951 (s), 1518 (s), 1248 (s), 1178 (m), 1119 (s), 833 (m), 758 (s); **¹H-NMR (300 MHz, CD₂Cl₂):** δ 7.42 (d, *J* = 1.9 Hz, 1H), 7.40-7.32 (m, 6H), 6.96 (d, *J* = 8.7 Hz, 2H), 6.54 (d, *J* = 1.9 Hz, 1H), 5.94 (s, 1H), 4.55 (d, *J* = 12.0 Hz, 1H), 4.42 (d, *J* = 12.0 Hz, 1H), 3.83 (s, 3H), 3.75-3.70 (m, 1H), 2.50 (s, 1H), 2.21-2.11 (m, 1H), 2.09-2.00 (m, 1H), 1.79-1.73 (m, 1H), 1.67-1.64 (m, 1H), 1.30-1.27 (m, 1H), 1.24-1.19 (m, 1H), 1.10 (dd, *J* = 13.0, 3.4 Hz, 1H), 0.91 (s, 3H), 0.86 (d, *J* = 3.4 Hz, 6H); **¹³C-NMR (75 MHz, CD₂Cl₂):** δ 159.5, 149.9, 142.4, 140.8, 139.7, 129.7, 127.8, 126.7, 125.8, 124.1, 114.5, 112.0, 85.0, 71.7, 68.3, 55.7, 49.7, 48.2, 45.6, 36.5, 28.6, 27.2, 19.9, 19.0, 14.2; **HRMS (ESI+):** Calcd. for C₂₉H₃₄O₄ ([M+Na]⁺): 469.2349, Found: 469.2346.



Compound 6e: Prepared according to General Procedure A, Condition II; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (148.0 mg, 0.732 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in petroleum eth er); Yellow thick oil (168.0 mg, 0.376 mmol, 51% yield); **FT-IR (Thin film):** 3426 (br), 2952 (s), 1518 (s), 1463 (m), 1248 (s), 1178 (m), 1034 (s), 833 (s), 727 (w); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.42 (d, *J* = 1.8 Hz, 1H), 7.40-7.34 (m, 6H), 6.96 (d, *J* = 8.8 Hz, 2H), 6.54 (d, *J* = 1.9 Hz, 1H), 5.95 (s, 1H), 4.58 (d, *J* = 11.9 Hz, 1H), 4.43 (d, *J* = 11.7 Hz, 1H), 3.83 (s, 3H), 3.05 (d, *J* = 1.9 Hz, 1H), 2.52 (br s, 1H), 1.81-1.67 (m, 2H), 1.65-1.64 (m, 1H), 1.50-1.46 (m, 1H), 1.45-1.36 (m, 1H), 1.11 (s, 3H), 1.10-1.07 (m, 1H), 1.05 (s, 3H), 1.03-0.99 (m, 1H), 0.98 (s, 3H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 159.5, 149.9, 142.4, 140.9, 139.6, 129.7, 127.9, 126.7, 125.8, 124.1, 114.5,




112.1, 93.1, 73.7, 68.3, 55.7, 49.6, 49.3, 41.7, 39.9, 31.8, 26.5, 26.4, 20.9, 20.3; **HRMS (ESI+):** Calcd. for $C_{29}H_{34}O_4$ ($[M+Na]^+$): 469.2349, Found: 469.2346.

Compound 6f: Prepared according to General Procedure C; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (101.0 mg, 0.500 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (7% EtOAc in hexane); Yellow thick oil (210.0 mg, 0.380 mmol, 76% yield); **FT-IR (Thin film):** 3443 (br), 2932 (m), 1519 (s), 1383 (m), 1251 (s), 1176 (m), 1069 (s), 960 (w); **1H -NMR (400 MHz, CD₂Cl₂):** δ 7.42 (d, $J = 1.9$ Hz, 1H), 7.41-7.36 (m, 4H), 7.35-7.33 (m, 2H), 6.96 (d, $J = 8.7$ Hz, 2H), 6.54 (d, $J = 1.9$ Hz, 1H), 5.94 (d, $J = 5.5$ Hz, 1H), 5.49 (d, $J = 5.0$ Hz, 1H), 4.60-4.58 (m, 1H), 4.57-4.50 (m, 2H), 4.30 (dd, $J = 5.0, 2.4$ Hz, 1H), 4.23 (dd, $J = 7.9, 1.9$ Hz, 1H), 4.00-3.96 (m, 1H), 3.83 (s, 3H), 3.64 (dd, $J = 10.1, 5.4$ Hz, 1H), 3.58 (dd, $J = 10.1, 7.0$ Hz, 1H), 2.55 (d, $J = 5.7$ Hz, 1H), 1.51 (s, 3H), 1.41 (s, 3H), 1.32 (s, 6H); **^{13}C -NMR (100 MHz, CD₂Cl₂):** δ 159.5, 149.9, 142.5, 141.2, 138.5, 129.7, 128.2, 126.9, 125.8, 124.1, 114.6, 112.0, 109.5, 108.9, 96.8, 73.3, 71.7, 71.2, 71.1, 69.7, 68.3, 67.4, 55.7, 26.3, 26.2, 25.1, 24.6; **HRMS (ESI+):** Calcd. for $C_{31}H_{36}O_9$ ($[M+Na]^+$): 575.2252, Found: 575.2255.

Compound 6g: Prepared according to General Procedure C; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (101.0 mg, 0.500 mmol, 1.0 equiv.); Purified by silica-gel flash column chromatography (12% EtOAc in petroleum ether); Yellow thick oil (183.0 mg, 0.316 mmol, 63% yield); **FT-IR (Thin film):** 3444 (br), 2926 (m), 1609 (m), 1518 (s), 1250 (s), 1035 (m), 960 (m), 834 (s); **1H -NMR (400 MHz, CD₂Cl₂):** δ 7.42 (d, $J = 1.9$ Hz, 1H), 7.41-7.37 (m, 4H), 7.35-7.33 (m, 2H), 7.18 (d, $J = 8.5$ Hz, 1H), 6.96 (d, $J = 8.8$ Hz, 2H), 6.68-6.65 (m, 1H), 6.61-6.60 (m, 1H), 6.55 (d, $J = 1.9$ Hz, 1H), 5.95 (d, $J = 5.5$ Hz, 1H), 4.54 (s, 2H), 3.83 (s, 3H), 3.74 (s, 3H), 3.54-3.49 (m, 1H), 2.89-2.78 (m, 2H), 2.51 (d, $J = 5.7$ Hz, 1H), 2.32-2.26 (m, 1H), 2.21-2.14 (m, 1H), 2.12-2.02 (m, 2H), 1.90-1.85 (m, 1H), 1.74-1.66 (m, 1H), 1.63-1.57 (m, 1H), 1.54-1.47 (m, 1H), 1.45-1.33 (m, 4H), 1.26-1.20 (m, 1H), 0.85 (s, 3H); **^{13}C -NMR (100 MHz, CD₂Cl₂):** δ 159.5, 157.9, 149.9, 142.4, 140.9, 139.5, 138.5, 133.2, 129.7, 127.8, 126.7, 126.6, 125.8, 124.1, 114.5, 114.0, 112.1, 111.7, 89.1, 71.7, 68.3, 55.7, 55.5, 50.6, 44.4, 43.8, 39.1, 38.4, 30.2, 28.4, 27.7, 26.9, 23.5, 12.0; **HRMS (ESI+):** Calcd. for $C_{38}H_{42}O_5$ ($[M+Na]^+$): 601.2924, Found: 601.2931.




Compound 6h: Prepared according to General Procedure C; Starting from 3-(4-methoxyphenyl)furan-2-carbaldehyde (101.0 mg, 0.500 mmol, 1.0 equiv.); Purified by silica-gel



flash column chromatography (12% EtOAc in petroleum ether); Yellow thick oil (170.0 mg, 0.250 mmol, 50% yield); **FT-IR (Thin film):** 3420 (br), 2933 (s), 1519 (s), 1465 (m), 1248 (m), 1180 (w), 960 (w), 894 (s); **¹H-NMR (300 MHz, CD₂Cl₂):** δ 7.41 (d, *J* = 1.9 Hz, 1H), 7.39-7.36 (m, 4H), 7.33-7.31 (m, 2H), 6.95 (d, *J* = 8.9 Hz, 2H), 6.54 (d, *J* = 1.9 Hz, 1H), 5.94 (s, 1H), 5.36-5.34 (m, 1H), 4.53 (s, 2H), 3.83 (s, 3H), 3.30-3.20 (m, 1H), 2.44-2.37 (m, 1H), 2.28-2.19 (m, 1H), 2.12 (s, 1H), 2.05-1.78 (m, 6H), 1.63-1.57 (m, 2H), 1.55-1.44 (m, 7H), 1.42-1.30 (m, 5H), 1.21-1.07 (m, 7H), 1.02 (s, 3H), 0.93 (d, *J* = 6.5 Hz, 3H), 0.87 (dd, *J* = 6.6, 1.2 Hz, 6H), 0.69 (s, 3H); **¹³C-NMR (75 MHz, CD₂Cl₂):** δ 159.5, 149.9, 142.4, 141.4, 140.9, 139.4, 129.7, 128.0, 126.8, 125.7, 124.1, 121.9, 114.5, 112.0, 79.1, 69.8, 68.3, 57.2, 56.6, 55.7, 50.7, 42.7, 40.3, 39.9, 39.6, 37.7, 37.3, 36.6, 36.2, 32.4, 32.3, 28.9, 28.6, 28.4, 24.8, 24.2, 23.0, 22.7, 21.5, 19.6, 18.9, 12.0; **HRMS (ESI+):** Calcd. for C₄₆H₆₂O₄ ([M+Na]⁺): 701.4540, Found: 701.4542.

Compound 2' was known and prepared by following representative literature procedures.²

Compound 1a': Prepared according to General Procedure A, Condition I; Starting from 4-(4-methoxyphenyl)furan-2-carbaldehyde (600.0 mg, 2.970 mmol, 1.0 equiv.);




Purified by silica-gel flash column chromatography (10% EtOAc in hexane); Yellow solid (739.0 mg, 2.636 mmol, 89% yield); **m.p.** 87-89 °C; **FT-IR (Thin film):** 3444 (br), 1556 (m), 1505 (s), 1181 (m), 1024 (s), 928 (m), 701 (s); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 7.63 (d, *J* = 1.0 Hz, 1H), 7.49-7.45 (m, 2H), 7.42-7.34 (m, 5H), 6.89 (d, *J* = 8.8 Hz, 2H), 6.44 (t, *J* = 0.9 Hz, 1H), 5.83 (d, *J* = 3.7 Hz, 1H), 3.80 (s, 3H), 2.55 (d, *J* = 4.2 Hz, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ 159.3, 157.6, 141.4, 137.8, 128.9, 128.5, 127.2, 127.1, 127.0, 125.1, 114.6, 106.8, 70.5, 55.7; **HRMS (ESI+):** Calcd. for C₁₈H₁₆O₃ ([M+H]⁺): 281.1172, Found: 281.1175.

² H. W. Gschwend, H. R. Rodriguez, *Org. React.* **1979**, 26, 1.


V. Catalyst and reaction conditions optimization for the enantioselective oxa-Piancatelli rearrangement:

Scheme S1: Preliminary studies


■ Reaction with secondary 2-furyl carbinol (1a):



■ Reaction with tertiary 2-furyl carbinol (2a):



■ Reaction with tertiary 2-furyl carbinol (2a) in the presence of H₂O:



■ Reaction with secondary 2-furyl carbinol (1a) in the presence of H₂O:




Table S1: Optimization of solvent^a


entry	solvent	yield (%) ^b	er ^c
1	CH ₂ Cl ₂	44	86:14
2	CH ₃ CN	7	n.d.
3	Cyclohexane	18	89:11
4	THF	<5	n.d.
5	PhMe	(50)	89:11
6 ^d	PhMe	56	89:11
7	PhMe/CH ₂ Cl ₂ (1.5:1)	57	89.5:10.5
8	Acetone	<5	n.d.

^aReaction conditions: 0.05 mmol of **1a**, 0.2 mmol of H₂O, and catalyst **3a** (2 mol %) in 0.5 mL solvent.

^bYields were determined by ¹H-NMR spectroscopy with 1,3,5-trimethoxybenzene as internal standard.

Isolated yields are given in the parentheses. ^cThe enantiomeric ratio (er) was determined by HPLC analysis on a chiral stationary phase; n.d. = not determined. ^d10.0 equiv H₂O was used as an additive.


Table S2: Catalyst screening^a




^aReaction conditions: 0.05 mmol of **1a**, 0.2 mmol of H₂O, and catalyst **3** (10 mol %) in 0.5 mL PhMe. The diastereomeric ratio (dr) was determined by ¹H NMR and was >20:1 in all cases. ^bYields were determined by ¹H-NMR spectroscopy with 1,3,5-trimethoxybenzene as internal standard. Isolated yields are given in the parentheses. ^cThe enantiomeric ratio (er) was determined by HPLC analysis on a chiral stationary phase.

Scheme S2: Optimization of reaction conditions for the tertiary 2-furyl carbinol (**2a**)

■ Optimum reaction conditions obtained for **1a** were applied for the tertiary 2-furyl carbinol **2a**:




VI. General procedure for the preparation of racemic products (*rac*-4/5**):**



In a glass-vial, 2-furyl carbinols **1/2** (0.05 mmol, 1.0 equiv) and H_2O (1.8 μL , 0.10 mmol, 2.0 equiv) were taken in 0.5 mL of toluene. To this solution, diphenyl hydrogen phosphate (2.5 mg, 0.01 mmol, 20 mol%) was added and the resulting suspension was stirred at 25°C until TLC reveals the complete consumption of **1/2**. The crude mixture was purified by preparative TLC (ALUGRAM® Xtra SIL G/UV₂₅₄ pre-coated plates of 0.20 mm thickness) to obtain the racemic product (*rac*-**4/5**) samples for HPLC analysis.

VII. Typical procedure for the catalytic enantioselective oxa-Piancatelli rearrangement:






In a screw-cap vial, 2-furyl carbinols **1/2/6** (0.10 mmol, 1.0 equiv) and H_2O (3.6 μL , 0.20 mmol, 2.0 equiv) were taken with 0.5 mL of toluene/ CH_2Cl_2 (1.5:1) and stirred for 5 min. To this solution, catalyst **3g** (7.0 mg, 0.01 mmol, 10 mol%) was added along with 0.5 mL of toluene/ CH_2Cl_2 (1.5:1) and the resulting mixture was stirred at 25°C until TLC (20% EtOAc in hexane) revealed complete consumption of **1/2/6** (36 h). The reaction mixture was concentrated

under reduced pressure to obtain a reddish-brown oil. This residue was purified by preparative TLC (20-30% EtOAc in hexane) to obtain **4/5/7**. The enantiomeric excess was determined by HPLC on a chiral stationary phase. The diastereomeric ratio was determined via ¹H-NMR of the crude reaction mixture. Unless otherwise noted, the diastereomeric ratio was >20:1 in all cases.

Compound 4a: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (27.0 mg, 0.096 mmol, 96% yield); **FT-IR (Thin film):** 3436 (br), 1707 (s), 1604 (m), 1510 (s), 1258 (s), 1180 (m), 1030 (w), 831 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.75 (d, *J* = 8.9 Hz, 1H), 7.58 (d, *J* = 2.5 Hz, 1H), 7.36-7.33 (m, 2H), 7.31-7.29 (m, 1H), 7.17-7.14 (m, 1H), 6.93 (d, *J* = 8.9 Hz, 1H), 4.94 (t, *J* = 2.7 Hz, 1H), 3.83 (s, 3H), 3.59 (d, *J* = 2.8 Hz, 1H), 2.60 (br s, 1H); **¹³C-NMR (100 MHz, CDCl₃):** δ 203.7, 160.5, 152.8, 142.9, 137.3, 129.1, 129.0, 128.5, 127.5, 123.0, 114.1, 76.7, 63.8, 55.4; **HRMS (ESI+):** Calcd. for C₁₈H₁₆O₃ ([M+Na]⁺): 303.0992, Found: 303.0990; **Optical rotation:** [α]_D²⁴ +28.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 98:2 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiraldak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, τ_{major} = 29.6 min, τ_{minor} = 35.2 min). The absolute stereochemistry of the product **4a** was assigned in analogy with **4j**.

Compound 4b: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (24.0 mg, 0.082 mmol, 82% yield); **FT-IR (Thin film):** 3425 (br), 1709 (s), 1606 (m), 1510 (s), 1258 (s), 1258 (s), 1180 (m), 1032 (m), 833 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.76 (d, *J* = 8.9 Hz, 2H), 7.58 (d, *J* = 2.5 Hz, 1H), 7.16 (d, *J* = 7.8 Hz, 2H), 7.05 (d, *J* = 8.1 Hz, 2H), 6.93 (d, *J* = 8.8 Hz, 2H), 4.93 (t, *J* = 2.7 Hz, 1H), 3.83 (s, 3H), 3.56 (d, *J* = 2.9 Hz, 1H), 2.54 (br s, 1H), 2.34 (s, 3H); **¹³C-NMR (100 MHz, CDCl₃):** δ 203.8, 160.5, 152.7, 142.8, 137.2, 134.2, 129.7, 129.1, 128.4, 123.1, 114.1, 76.7, 63.5, 55.4, 21.2; **HRMS (ESI+):** Calcd. for C₁₉H₁₈O₃ ([M+Na]⁺): 317.1148, Found: 317.1145; **Optical rotation:** [α]_D²⁴ +24.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 97.5:2.5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiraldak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm, τ_{major} = 33.7 min, τ_{minor} = 39.7 min). The absolute stereochemistry of the product **4b** was assigned in analogy with **4j**.



Compound 4c: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (28.0 mg, 0.095 mmol, 95% yield); **FT-IR (Thin film):** 3435 (br), 2838 (w), 1708 (s), 1605 (m), 1510 (s), 1258 (s), 1180 (s), 1110 (m), 1032 (m), 833 (m), 753 (m); **¹H-NMR (300 MHz, CDCl₃):** δ 7.78 (d, *J* = 8.9 Hz, 2H), 7.61 (d, *J* = 2.5 Hz, 1H), 7.23-7.13 (m, 3H), 6.94 (d, *J* = 8.8 Hz, 2H), 4.98 (t, *J* = 2.6 Hz, 1H), 3.88 (d, *J* = 2.8 Hz, 1H), 3.84 (s, 3H), 2.35 (s, 3H), 2.22 (br s, 1H); **¹³C-NMR (75 MHz, CDCl₃):** δ 204.0, 160.6, 152.5, 143.1, 137.2, 136.1, 131.0, 129.2, 128.4, 127.6, 126.6, 123.1, 114.2, 76.7, 61.4, 55.5, 20.3; **HRMS (ESI+):** Calcd. for C₁₉H₁₈O₃



([M+H]⁺): 295.1329, Found: 295.1333; **Optical rotation:** $[\alpha]_D^{24} +22.0$ (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 97:3 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IC column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 232 nm, $\tau_{\text{minor}} = 24.6$ min, $\tau_{\text{major}} = 32.9$ min). The absolute stereochemistry of the product **4c** was assigned in analogy with **4j**.

Compound 4d: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (27.0 mg, 0.088 mmol, 88% yield); **FT-IR (Thin film):** 3415 (br), 3012 (w), 2917 (m), 2840 (m), 1766 (m), 1710 (s), 1605 (s), 1510 (s), 1442 (m), 1306 (m), 1257 (s), 1180 (s), 1112 (s), 1032 (s), 837 (s), 754 (s), 693 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.78 (d, *J* = 8.8 Hz, 2H), 7.61 (d, *J* = 2.5 Hz, 1H), 6.95-6.93 (m, 3H), 6.78 (s, 2H), 4.97 (t, *J* = 2.7 Hz, 1H), 3.84 (s, 3H), 3.54 (d, *J* = 2.8 Hz, 1H), 2.30 (s, 6H); **¹³C-NMR (75 MHz, CDCl₃):** δ 203.8, 160.6, 152.6, 143.0, 138.6, 137.2, 129.3, 129.2, 126.3, 123.1, 114.1, 76.9, 63.9, 55.5, 21.4; **HRMS (ESI⁺):** Calcd. for C₂₀H₂₀O₃ ([M+H]⁺): 309.1485, Found: 309.1490; **Optical rotation:** $[\alpha]_D^{24} +16.0$ (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 97:3 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 240 nm, $\tau_{\text{major}} = 22.0$ min, $\tau_{\text{minor}} = 39.6$ min). The absolute stereochemistry of the product **4d** was assigned in analogy with **4j**.

Compound 4e: Purified by preparative TLC (20% EtOAc in hexane); Brown thick oil (27.0 mg, 0.087 mmol, 87% yield); **FT-IR (Thin film):** 3437 (br), 2837 (w), 1709 (s), 1604 (s), 1510 (s), 1258 (s), 1035 (s), 924 (w); **¹H-NMR (400 MHz, CDCl₃):** δ 7.76 (d, *J* = 8.8 Hz, 2H), 7.60 (d, *J* = 2.5 Hz, 1H), 7.29-7.25 (m, 1H), 6.93 (d, *J* = 8.8 Hz, 2H), 6.85-6.82 (m, 1H), 6.75 (d, *J* = 7.6 Hz, 1H), 6.72-6.71 (m, 1H), 4.97 (t, *J* = 2.7 Hz, 1H), 3.83 (s, 3H), 3.79 (s, 3H), 3.59 (d, *J* = 2.8 Hz, 1H); **¹³C-NMR (100 MHz, CDCl₃):** δ 203.4, 160.5, 160.1, 152.8, 142.9, 138.8, 130.1, 129.1, 123.0, 120.8, 114.4, 114.1, 112.9, 76.6, 63.8, 55.4, 55.4; **HRMS (ESI⁺):** Calcd. For C₁₉H₁₈O₄ ([M+Na]⁺): 333.1097, Found: 333.1087; **Optical rotation:** $[\alpha]_D^{24} +24.0$ (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 97:3 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IC column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm, $\tau_{\text{minor}} = 25.7$ min, $\tau_{\text{major}} = 31.8$ min). The absolute stereochemistry of the product **4e** was assigned in analogy with **4j**.




Compound 4f: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (21.0 mg, 0.064 mmol, 64% yield); **FT-IR (Thin film):** 3435 (br), 2918 (w), 1707 (s), 1605 (m), 1510 (s), 1257 (s), 1180 (m), 1030 (m), 831 (m), 804 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.77 (d, *J* = 8.8 Hz, 2H), 7.61 (d, *J* = 2.5 Hz, 1H), 7.26 (d, *J* = 8.2 Hz, 2H), 7.11 (d, *J* = 8.3 Hz, 2H), 6.93 (d, *J* = 8.7 Hz, 2H), 4.97 (t, *J* = 2.8 Hz, 1H), 3.84 (s, 3H), 3.60 (d, *J* = 2.9 Hz, 1H), 2.48 (s, 3H), 2.31 (br s, 1H); **¹³C-NMR (75 MHz, CDCl₃):** δ 203.3, 160.6, 152.5, 143.0, 137.8, 134.1, 129.1, 129.0, 127.4, 123.0, 114.2, 76.7, 63.4, 55.5, 16.1; **HRMS (ESI+):** Calcd. for C₁₉H₁₈O₃S ([M+H]⁺): 327.1049, Found: 327.1054; **Optical rotation:** [α]_D²⁴ +30.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 98.5:1.5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IA column (70:30 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 254 nm, $\tau_{\text{major}} = 13.8$ min, $\tau_{\text{minor}} = 26.4$ min). The absolute stereochemistry of the product **4f** was assigned in analogy with **4j**.

Compound 4g: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (30.0 mg, 0.084 mmol, 84% yield); **FT-IR (Thin film):** 3452 (br), 1710 (s), 1606 (m), 1510 (s), 1490 (m), 1257 (s), 1180 (s), 1023 (m), 830 (s), 763 (s); **¹H-NMR (400 MHz, CDCl₃):** δ 7.79 (d, *J* = 8.9 Hz, 2H), 7.64 (d, *J* = 2.5 Hz, 1H), 7.60-7.57 (m, 4H), 7.46-7.42 (m, 2H), 7.37-7.33 (m, 1H), 7.28-7.26 (m, 2H), 6.95 (d, *J* = 8.9 Hz, 2H), 5.05 (t, *J* = 2.7 Hz, 1H), 3.84 (s, 3H), 3.70 (d, *J* = 2.9 Hz, 1H); **¹³C-NMR (100 MHz, CDCl₃):** δ 203.4, 160.6, 152.5, 143.0, 140.9, 140.6, 136.3, 129.2, 129.0, 128.9, 127.8, 127.5, 127.3, 123.0, 114.2, 76.8, 63.6, 55.5; **HRMS (ESI+):** Calcd. for C₂₄H₂₀O₃ ([M+Na]⁺): 379.1305, Found: 379.1307; **Optical rotation:** [α]_D²³ +32.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 97:3 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 248 nm, $\tau_{\text{major}} = 22.3$ min, $\tau_{\text{minor}} = 31.1$ min). The absolute stereochemistry of the product **4g** was assigned in analogy with **4j**.

Compound 4h: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (25.0 mg, 0.084 mmol, 84% yield); **FT-IR (Thin film):** 3438 (br), 1710 (s), 1606 (s), 1511 (s), 1257 (s), 1181 (m), 1032 (m), 927 (w); **¹H-NMR (300 MHz, CDCl₃):** δ 7.74 (d, *J* = 8.8 Hz, 1H), 7.58 (d, *J* = 2.5 Hz, 1H), 7.35-7.27 (m, 1H), 7.02-6.96 (m, 1H), 6.93 (d, *J* = 8.9 Hz, 2H), 6.90-6.86 (m, 1H), 4.93 (t, *J* = 2.7 Hz, 1H), 3.83 (s, 3H), 3.61 (d, *J* = 2.9 Hz, 1H), 2.50 (br s, 1H); **¹³C-NMR (75 MHz, CDCl₃):** δ 202.9, 163.1 (d, *J* = 246.6 Hz), 160.6, 152.7, 142.9, 139.5 (d, *J* = 7.5 Hz), 130.5 (d, *J* = 8.3 Hz), 129.1, 124.3 (d, *J* = 3.0 Hz), 122.8, 115.5 (d, *J* = 21.7 Hz), 114.5 (d, *J* = 21.0 Hz), 114.2, 76.4, 63.3 (d, *J* = 1.8 Hz), 55.4; **HRMS (ESI+):** Calcd. for C₁₈H₁₅FO₃ ([M+Na]⁺): 321.0897, Found: 321.0893; **Optical rotation:** [α]_D²⁴ +42.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel


Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, $\tau_{\text{major}} = 27.7$ min, $\tau_{\text{minor}} = 37.1$ min). The absolute stereochemistry of the product **4h** was assigned in analogy with **4j**.

Compound 4i: Purified by preparative TLC (20% EtOAc in hexane); Yellow solid (27.0 mg,




0.086 mmol, 86% yield); **m.p.** 103-105 °C; **FT-IR (Thin film):** 3437 (br), 1709 (s), 1605 (s), 1510 (s), 1258 (s), 1180 (m), 1015 (m), 831 (m); **¹H-NMR (300 MHz, CDCl₃):** δ 7.73 (d, *J* = 8.8 Hz, 2H), 7.57 (d, *J* = 2.5 Hz, 1H), 7.31 (d, *J* = 8.4 Hz, 2H), 7.09 (d, *J* = 8.4 Hz, 2H), 6.92 (d, *J* = 8.9 Hz, 2H), 4.89 (t, *J* = 2.7 Hz, 1H), 3.83 (s, 3H), 3.58 (d, *J* = 2.9 Hz, 1H), 2.64 (br s, 1H); **¹³C-NMR (75 MHz, CDCl₃):** δ 203.2, 160.6, 152.7, 142.8, 135.7, 133.5, 129.9, 129.2, 129.1, 122.8, 114.2, 76.5, 63.1, 55.5; **HRMS (ESI+):** Calcd. for C₁₈H₁₅ClO₃ ([M+Na]⁺): 337.0602, Found: 337.0595; **Optical rotation:** [α]_D²⁴ +36.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 97:3 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, $\tau_{\text{major}} = 33.5$ min, $\tau_{\text{minor}} = 44.2$ min). The absolute stereochemistry of the product **4i** was assigned in analogy with **4j**.

Compound 4j: Purified by preparative TLC (20% EtOAc in hexane); Pale-yellow solid (33.0 mg,



0.092 mmol, 92% yield); **m.p.** 130-132 °C; **FT-IR (Thin film):** 3435 (br), 1709 (s), 1605 (m), 1510 (s), 1257 (s), 1180 (m), 1111 (m), 831 (m); **¹H-NMR (300 MHz, CDCl₃):** δ 7.74 (d, *J* = 8.9 Hz, 2H), 7.59 (d, *J* = 2.5 Hz, 1H), 7.48 (d, *J* = 8.4 Hz, 2H), 7.05 (d, *J* = 8.4 Hz, 2H), 6.93 (d, *J* = 8.9 Hz, 2H), 4.92 (t, *J* = 2.7 Hz, 1H), 3.83 (s, 3H), 3.59 (d, *J* = 2.9 Hz, 1H), 2.46 (br s, 1H); **¹³C-NMR (75 MHz, CDCl₃):** δ 202.93, 160.7, 152.6, 142.9, 136.2, 132.1, 130.2, 129.1, 122.8, 121.6, 114.2, 76.5, 63.2, 55.5; **HRMS (ESI+):** Calcd. for C₁₈H₁₅BrO₃ ([M+H]⁺): 359.0277, Found: 359.0282; **Optical rotation:** [α]_D²⁴ +34.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 98:2 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm, $\tau_{\text{major}} = 34.8$ min, $\tau_{\text{minor}} = 45.9$ min). The relative and absolute stereochemistry of the product **4j** was determined by single crystal X-Ray diffraction analysis.

Compound 4k: Purified by preparative TLC (20% EtOAc in hexane); Yellow solid (30.0 mg,






0.084 mmol, 84% yield); **m.p.** 128-130 °C; **FT-IR (Thin film):** 3457 (br), 1708 (s), 1605 (m), 1510 (s), 1257 (s), 1180 (m), 1031 (m), 833 (m), 687 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.77 (d, *J* = 8.8 Hz, 2H), 7.62 (d, *J* = 2.5 Hz, 1H), 7.44 (ddd, *J* = 7.9, 2.0, 1.1 Hz, 1H), 7.35 (t, *J* = 1.8 Hz, 1H), 7.24 (t, *J* = 7.9 Hz, 1H), 7.13 (dt, *J* = 7.7, 1.5 Hz, 1H), 6.94 (d, *J* = 8.9 Hz, 2H), 4.98 (t, *J* = 2.7 Hz, 1H), 3.84 (s, 3H), 3.62 (d, *J* = 2.9 Hz, 1H); **¹³C-NMR (100 MHz, CDCl₃):** δ 202.6, 160.7, 152.4, 143.0, 139.5, 131.6, 130.7, 130.6, 129.2, 127.3, 123.1, 122.8, 114.2, 76.5, 63.3, 55.5; **HRMS (ESI+):** Calcd. for C₁₈H₁₅BrO₃ ([M+Na]⁺): 381.0097, Found:

381.0097; **Optical rotation:** $[\alpha]_D^{24} +40.0$ (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 98:2 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IA column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 240 nm, $\tau_{\text{major}} = 30.3$ min, $\tau_{\text{minor}} = 41.1$ min). The absolute stereochemistry of the product **4k** was assigned in analogy with **4j**.

Compound 4l: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (31.0 mg, 0.089 mmol, 89% yield); **FT-IR (Thin film):** 3442 (br), 1694 (s), 1604 (m), 1511 (s), 1329 (s), 1261 (m), 1125 (m), 1066 (m), 832 (m), 806 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.77-7.74 (m, 2H), 7.62-7.60 (m, 3H), 7.30 (d, *J* = 8.5 Hz, 2H), 6.94 (d, *J* = 8.9 Hz, 2H), 4.99-4.97 (m, 1H), 3.84 (s, 3H), 3.71-3.70 (m, 1H); **¹³C-NMR (100 MHz, CDCl₃):** δ 202.6, 160.7, 152.6, 143.0, 141.2 (d, *J* = 1.5 Hz), 129.9 (q, *J* = 32.6 Hz), 129.2, 129.0, 126.0 (q, *J* = 3.8 Hz), 124.2 (q, *J* = 272.1 Hz), 122.7, 114.2, 76.4, 63.5, 55.5; **HRMS (ESI+):** Calcd. for C₁₉H₁₅F₃O₃ ([M+Na]⁺): 371.0866, Found: 371.0866; **Optical rotation:** $[\alpha]_D^{23} +30.0$ (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 97:3 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 240 nm, $\tau_{\text{major}} = 27.9$ min, $\tau_{\text{minor}} = 33.7$ min). The absolute stereochemistry of the product **4l** was assigned in analogy with **4j**.

Compound 4m: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (25.0 mg, 0.082 mmol, 82% yield); **FT-IR (Thin film):** 3452 (br), 1710 (s), 1606 (s), 1510 (s), 1257 (s), 1180 (m), 1031 (m), 832 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.73 (d, *J* = 8.9 Hz, 2H), 7.62 (d, *J* = 2.5 Hz, 1H), 7.60 (d, *J* = 8.3 Hz, 2H), 7.30 (d, *J* = 8.3 Hz, 2H), 6.93 (d, *J* = 8.9 Hz, 2H), 4.98 (t, *J* = 2.8 Hz, 1H), 3.83 (s, 3H), 3.71 (d, *J* = 3.0 Hz, 1H); **¹³C-NMR (100 MHz, CDCl₃):** δ 202.2, 160.7, 152.8, 142.8, 132.7, 129.4, 129.1, 122.6, 118.8, 114.2, 111.3, 76.0, 63.6, 55.5; **HRMS (ESI+):** Calcd. for C₁₉H₁₅NO₃ ([M+H]⁺): 306.1125, Found: 306.1114; **Optical rotation:** $[\alpha]_D^{24} +46.0$ (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 96.5:3.5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, $\tau_{\text{minor}} = 28.2$ min, $\tau_{\text{major}} = 31.5$ min). The absolute stereochemistry of the product **4m** was assigned in analogy with **4j**.



Compound 4n: Purified by preparative TLC (20% EtOAc in hexane); Yellow solid (33.0 mg, 0.098 mmol, 98% yield); **m.p.** 179-181 °C; **FT-IR (Thin film):** 3477 (br), 2917 (w), 1699 (s), 1605 (m), 1511 (s), 1385 (m), 1287 (m), 1181 (m), 1107 (m), 1020 (m), 761 (m); **¹H-NMR (400 MHz, CD₂Cl₂):** δ 8.02 (d, *J* = 8.3 Hz, 2H), 7.76 (d, *J* = 8.9 Hz, 2H), 7.66 (d, *J* = 2.5 Hz, 1H), 7.29 (d, *J* = 8.3 Hz, 2H), 6.95 (d, *J* = 8.9 Hz, 2H), 5.03-5.02 (m, 1H), 3.89 (s, 3H), 3.83 (s, 3H), 3.71 (d, *J* = 3.0 Hz, 1H), 2.44 (br s, 1H); **¹³C-NMR (100 MHz, CD₂Cl₂):** δ




202.9, 167.0, 161.0, 153.4, 143.0, 130.3, 129.8, 129.4, 129.0, 123.3, 114.3, 76.6, 64.0, 55.7 52.4; **HRMS (ESI+)**: Calcd. for C₂₀H₁₈O₅ ([M+H]⁺): 339.1227, Found: 339.1217; **Optical rotation**: [α]_D²⁴ +30.0 (*c* 0.33, CHCl₃) for an enantiomerically enriched sample with 97:3 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (85:15 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 244 nm, $\tau_{\text{major}} = 32.9$ min, $\tau_{\text{minor}} = 39.0$ min). The absolute stereochemistry of the product **4n** was assigned in analogy with **4j**.

Compound 4o: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (32.0 mg, 0.097 mmol, 97% yield); **FT-IR (Thin film)**: 3437 (br), 3049 (w), 2923 (w), 1708 (s), 1605 (m), 1510 (s), 1258 (s), 1180 (m), 1119 (m), 1032 (m), 837 (m), 797 (m), 779 (m); **¹H-NMR (400 MHz, CDCl₃)**: δ 7.90-7.88 (m, 1H), 7.86 (d, *J* = 8.9 Hz, 2H), 7.82 (d, *J* = 8.4 Hz, 1H), 7.81-7.75 (m, 1H), 7.67 (d, *J* = 2.5 Hz, 1H), 7.52-7.47 (m, 2H), 7.46-7.42 (m, 1H), 7.28 (d, *J* = 1.2 Hz, 1H), 6.97 (d, *J* = 8.9 Hz, 2H), 5.14 (t, *J* = 2.7 Hz, 1H), 4.27 (d, *J* = 2.8 Hz, 1H), 3.86 (s, 3H); **¹³C-NMR (75 MHz, CDCl₃)**: δ 204.0, 160.7, 152.1, 143.2, 134.4, 134.0, 132.1, 129.3, 129.2, 128.4, 127.3, 126.7, 126.0, 125.7, 123.7, 123.1, 114.2, 76.6, 55.5; **HRMS (ESI+)**: Calcd. for C₂₂H₁₈O₃ ([M+Na]⁺): 353.1148, Found: 353.1137; **Optical rotation**: [α]_D²³ +62.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 96:4 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (80:20 *n*-Hexane/*i*-PrOH, 0.5 mL/min, 240 nm, $\tau_{\text{minor}} = 54.4$ min, $\tau_{\text{major}} = 59.8$ min). The absolute stereochemistry of the product **4o** was assigned in analogy with **4j**.

Compound 4p: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (22.0 mg, 0.067 mmol, 67% yield); **FT-IR (Thin film)**: 3490 (br), 1705 (s), 1605 (m), 1509 (s), 1257 (m), 1181 (m), 1108 (m), 815 (m); **¹H-NMR (400 MHz, CDCl₃)**: δ 7.82-7.76 (m, 5H), 7.66 (s, 1H), 7.59 (d, *J* = 2.5 Hz, 1H), 7.50-7.46 (m, 2H), 7.19 (d, *J* = 10.3 Hz, 1H), 6.94 (d, *J* = 8.9 Hz, 2H), 5.00 (t, *J* = 2.7 Hz, 1H), 3.83 (s, 3H), 3.74 (d, *J* = 2.9 Hz, 1H); **¹³C-NMR (100 MHz, CDCl₃)**: δ 203.7, 160.6, 152.8, 142.9, 134.7, 133.6, 132.8, 129.2, 128.9, 127.9, 127.8, 127.8, 126.5, 126.1, 126.0, 123.0, 114.2, 76.6, 64.0, 55.5; **HRMS (ESI+)**: Calcd. For C₂₂H₁₈O₃ ([M+H]⁺): 331.1329, Found: 331.1320; **Optical rotation**: [α]_D²⁴ +16.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 96:4 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm, $\tau_{\text{major}} = 20.9$ min, $\tau_{\text{minor}} = 26.2$ min). The absolute stereochemistry of the product **4p** was assigned in analogy with **4j**.




Compound 4q: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (31.0 mg, 0.078 mmol, 78% yield); **FT-IR (Thin film):** 3444 (br), 3009 (w),



2960 (m), 1710 (s), 1606 (m), 1510 (s), 1449 (m), 1305 (m), 1257 (s), 1180 (s), 1032 (m), 832 (m), 759 (s), 740 (s); **¹H-NMR (400 MHz, CDCl₃):** δ 7.70 (d, *J* = 8.8 Hz, 2H), 7.62-7.58 (m, 2H), 7.54 (d, *J* = 2.5 Hz, 1H), 7.34-7.32 (m, 1H), 7.26-7.20 (m, 2H), 7.15 (d, *J* = 1.6 Hz, 1H), 7.03 (dd, *J* = 7.8, 1.6 Hz, 1H), 6.85 (d, *J* = 8.8 Hz, 2H), 4.94 (t, *J* = 2.7 Hz, 1H), 3.74 (s, 3H), 3.62 (d, *J* = 2.8 Hz, 1H), 2.08 (br s, 1H), 1.38 (d, *J* = 2.5 Hz, 6H); **¹³C-NMR (75 MHz, CDCl₃):** δ 203.6, 160.6, 154.4, 153.8, 152.5, 143.0, 138.9, 138.7, 136.3, 129.2, 127.4, 127.3, 127.1, 123.1, 123.0, 122.7, 120.5, 120.1, 114.2, 77.0, 64.3, 55.5, 47.1, 27.3; **HRMS (ESI+):** Calcd. for C₂₇H₂₄O₃ ([M+H]⁺): 397.1798, Found: 397.1796; **Optical rotation:** [α]_D²³ +30.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 97:3 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 272 nm, τ_{major} = 13.5 min, τ_{minor} = 19.5 min). The absolute stereochemistry of the product 4q was assigned in analogy with 4j.


Compound 4r: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (16.0 mg, 0.056 mmol, 56% yield); **FT-IR (Thin film):** 3439 (br), 1709 (s), 1606 (m), 1510 (s), 1258 (s), 1180 (s), 1112 (m), 1032 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.75 (d, *J* = 8.9 Hz, 2H), 7.57 (d, *J* = 2.5 Hz, 1H), 7.35 (dd, *J* = 5.0, 2.9 Hz, 1H), 7.23-7.22 (m, 1H), 7.02 (dd, *J* = 5.0, 1.3 Hz, 1H), 6.93 (d, *J* = 8.9 Hz, 2H), 5.00 (t, *J* = 2.8 Hz, 1H), 3.83 (s, 3H), 3.77 (d, *J* = 3.0 Hz, 1H), 2.26 (br s, 1H); **¹³C-NMR (100 MHz, CDCl₃):** δ 202.6, 160.6, 152.1, 142.7, 136.6, 129.1, 127.1, 126.5, 123.0, 122.6, 114.2, 75.9, 58.9, 55.5; **HRMS (ESI+):** Calcd. For C₁₆H₁₄O₃S ([M+Na]⁺): 309.0556, Found: 309.0554; **Optical rotation:** [α]_D²⁴ +28.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 98:2 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, τ_{major} = 34.6 min, τ_{minor} = 39.7 min). The absolute stereochemistry of the product 4r was assigned in analogy with 4j.

Compound 4s: Purified by preparative TLC (20% EtOAc in hexane); Red thick oil (16.0 mg, 0.056 mmol, 56% yield); **FT-IR (Thin film):** 3449 (br), 2923 (m), 1711 (s), 1604 (m), 1510 (s), 1257 (s), 1180 (m), 1031 (m), 832 (m), 702 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.76 (d, *J* = 8.9 Hz, 2H), 7.58 (d, *J* = 2.5 Hz, 1H), 7.27 (dd, *J* = 4.8, 1.6 Hz, 1H), 7.05-7.02 (m, 2H), 6.94 (d, *J* = 8.9 Hz, 2H), 5.09 (t, *J* = 2.8 Hz, 1H), 3.94 (d, *J* = 3.1 Hz, 1H), 3.84 (s, 3H), 1.90 (br s, 1H); **¹³C-NMR (75 MHz, CDCl₃):** δ 201.2, 160.6, 151.7, 142.3, 138.1, 129.1, 127.3, 126.1, 125.0, 122.9, 114.2, 76.74, 58.7, 55.5; **HRMS (ESI+):** Calcd. for C₁₆H₁₄O₃S ([M+Na]⁺): 309.0556, Found: 309.0560; **Optical rotation:** [α]_D²⁴ +2.0 (*c* 1.0, CHCl₃) for an enantiomerically



enriched sample with 97:3 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IA column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, $\tau_{\text{major}} = 19.1$ min, $\tau_{\text{minor}} = 26.1$ min). The absolute stereochemistry of the product **4s** was assigned in analogy with **4j**.


Compound 4t: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (23.0 mg,



0.071 mmol, 71% yield); **FT-IR (Thin film):** 3437 (br), 2900 (w), 1709 (s), 1605 (m), 1509 (s), 1443 (m), 1248 (s), 1180 (m), 1037 (s), 803 (m); **¹H-NMR (300 MHz, CDCl₃):** δ 7.76 (d, *J* = 8.9 Hz, 2H), 7.59 (d, *J* = 2.5 Hz, 1H), 6.93 (d, *J* = 8.9 Hz, 2H), 6.80 (d, *J* = 7.9 Hz, 1H), 6.68-6.62 (m, 2H), 5.94 (q, *J* = 1.2 Hz, 2H), 4.93 (t, *J* = 2.7 Hz, 1H), 3.83 (s, 3H), 3.55 (d, *J* = 2.9 Hz, 1H), 2.17 (br s, 1H); **¹³C-NMR (100 MHz, CDCl₃):** δ 203.4, 160.6, 152.4, 148.3, 147.1, 142.9, 130.9, 129.1, 123.0, 122.0, 114.2, 108.8, 108.7, 101.3, 76.8, 63.6, 55.5; **HRMS (ESI+):** Calcd. for C₁₉H₁₆O₅ ([M+Na⁺]): 347.0890, Found: 347.0885; **Optical rotation:** $[\alpha]_D^{24}$ +24.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 97.5:2.5 er.


The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 284 nm, $\tau_{\text{major}} = 22.4$ min, $\tau_{\text{minor}} = 26.5$ min). The absolute stereochemistry of the product **4t** was assigned in analogy with **4j**.

Compound 4u: Purified by preparative TLC (20% EtOAc in hexane); White thick oil (15.0 mg,




0.065 mmol, 65% yield); **FT-IR (Thin film):** 3436 (br), 1686 (s), 1604 (s), 1512 (s), 1465 (m), 1258 (s), 1095 (s), 836 (s); **¹H-NMR (400 MHz, CDCl₃):** δ 7.70 (d, *J* = 8.8 Hz, 2H), 7.48 (d, *J* = 2.6 Hz, 1H), 6.91 (d, *J* = 8.8 Hz, 2H), 4.69 (t, *J* = 2.5 Hz, 1H), 3.82 (s, 3H), 2.39-2.35 (m, 1H), 2.06 (br s, 1H), 2.02-1.92 (m, 1H), 1.67-1.55 (m, 1H), 1.07 (t, *J* = 7.4 Hz, 3H); **¹³C-NMR (75 MHz, CDCl₃):** δ 206.1, 160.4, 152.9, 142.9, 129.0, 123.2, 114.1, 74.1, 58.4, 55.4, 22.0, 11.7; **HRMS (ESI+):** Calcd. For C₁₄H₁₆O₃ ([M+Na⁺]): 255.0992, Found: 255.0994; **Optical rotation:** $[\alpha]_D^{24}$ +64.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 97:3 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, $\tau_{\text{major}} = 14.5$ min, $\tau_{\text{minor}} = 18.0$ min). The absolute stereochemistry of the product **4u** was assigned in analogy with **4j**.

Compound 4v: Purified by preparative TLC (20% EtOAc in hexane); Off-white thick oil (20.0 mg, 0.066 mmol, 66% yield); **FT-IR (Thin film):** 3464 (br), 2926 (s), 1685 (s), 1603 (m), 1512 (s), 1256 (s), 1034 (s), 837 (s); **¹H-NMR (400 MHz, CDCl₃):** δ 7.70 (d, *J* = 8.8 Hz, 2H), 7.47 (d, *J* = 2.5 Hz, 1H), 6.90 (d, *J* = 8.9 Hz, 2H), 4.68 (t, *J* = 2.5 Hz, 1H), 3.82 (s, 3H), 2.42-2.38 (m, 1H), 2.10 (br s, 1H), 1.95-1.90 (m, 1H), 1.56-1.46 (m, 2H), 1.36-1.25 (m, 9H), 0.90-0.86 (m, 3H); **¹³C-NMR (100 MHz, CDCl₃):** δ 206.2, 160.4, 152.9, 142.8, 129.0, 123.3, 114.1, 74.6, 57.2, 55.4, 31.9, 29.8, 29.3, 29.2, 27.5, 22.8, 14.2;




HRMS (ESI+): Calcd. For $C_{19}H_{26}O_3$ ($[M+H]^+$): 303.1955, Found: 303.1948; **Optical rotation:** $[\alpha]_D^{24} +62.0$ (c 1.0, $CHCl_3$) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, $\tau_{\text{major}} = 11.7$ min, $\tau_{\text{minor}} = 14.8$ min). The absolute stereochemistry of the product **4v** was assigned in analogy with **4j**.


Compound 4w: Purified by preparative TLC (20% EtOAc in hexane); White thick oil (17.0 mg,

 0.069 mmol, 69% yield); **FT-IR (Thin film):** 3481 (br), 2959 (m), 1685 (s), 1511 (s), 1258 (s), 1186 (m), 1031 (m), 833 (m); **1H -NMR (400 MHz, CDCl₃):** δ 7.70 (d, $J = 8.8$ Hz, 2H), 7.49 (d, $J = 2.6$ Hz, 1H), 6.91 (d, $J = 8.8$ Hz, 2H), 4.81 (t, $J = 2.4$ Hz, 1H), 3.82 (s, 3H), 2.42-2.39 (m, 1H), 2.37-2.34 (m, 1H), 1.99 (br s, 1H), 1.15 (d, $J = 6.7$ Hz, 3H), 0.89 (d, $J = 6.6$ Hz, 3H); **^{13}C -NMR (100 MHz, CDCl₃):** δ 205.9, 160.4, 153.3, 143.4, 129.0, 123.3, 114.1, 70.7, 62.6, 55.4, 27.7, 20.9, 18.5; **HRMS (ESI+):** Calcd. For $C_{15}H_{18}O_3$ ($[M+Na]^+$): 269.1148, Found: 269.1149; **Optical rotation:** $[\alpha]_D^{24} +60.0$ (c 1.0, $CHCl_3$) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 240 nm, $\tau_{\text{major}} = 11.9$ min, $\tau_{\text{minor}} = 16.8$ min). The absolute stereochemistry of the product **4w** was assigned in analogy with **4j**.

Compound 4x: Purified by preparative TLC (20% EtOAc in hexane); White thick oil (20.0 mg,

 0.077 mmol, 77% yield); **FT-IR (Thin film):** 3465 (br), 2957 (m), 1603 (m), 1510 (s), 1254 (s), 1183 (m), 1254 (s), 840 (s); **1H -NMR (400 MHz, CDCl₃):** δ 7.68 (d, $J = 8.8$ Hz, 2H), 7.46 (d, $J = 2.6$ Hz, 1H), 6.90 (d, $J = 8.8$ Hz, 2H), 4.64 (t, $J = 2.5$ Hz, 1H), 3.81 (s, 3H), 2.50-2.45 (m, 1H), 2.11 (br s, 1H), 1.97-1.89 (m, 1H), 1.81-1.74 (m, 1H), 1.40-1.33 (m, 1H), 1.01-0.98 (m, 6H); **^{13}C -NMR (100 MHz, CDCl₃):** δ 206.6, 160.4, 152.8, 142.6, 129.0, 123.3, 114.1, 75.3, 55.4, 55.4, 38.8, 26.6, 23.6, 22.0; **HRMS (ESI+):** Calcd. For $C_{16}H_{20}O_3$ ($[M+Na]^+$): 283.1305, Found: 283.1305; **Optical rotation:** $[\alpha]_D^{24} +66.0$ (c 1.0, $CHCl_3$) for an enantiomerically enriched sample with 97.5:2.5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 290 nm, $\tau_{\text{major}} = 13.1$ min, $\tau_{\text{minor}} = 17.6$ min). The absolute stereochemistry of the product **4x** was assigned in analogy with **4j**.

Compound 4y: Purified by preparative TLC (20% EtOAc in hexane); Off-white thick oil (20.0




 mg, 0.077 mmol, 77% yield); **FT-IR (Thin film):** 3470 (br), 1685 (s), 1602 (m), 1510 (s), 1293 (s), 1254 (s), 1181 (s), 1100 (s); **1H -NMR (400 MHz, CDCl₃):** δ 7.69 (d, $J = 8.8$ Hz, 2H), 7.47 (d, $J = 2.6$ Hz, 1H), 6.91 (d, $J = 8.9$ Hz, 2H), 5.89 (ddt, $J = 16.9, 10.2, 6.6$ Hz, 1H), 5.11 (dq, $J = 17.1, 1.7$ Hz, 1H), 5.05-5.02 (m, 1H), 4.67 (t, $J = 2.6$ Hz, 1H), 3.82 (s, 3H), 2.42 (ddd, $J = 9.5, 4.6, 2.6$ Hz, 1H), 2.34-2.28 (m, 1H), 2.13 (br s, 1H), 2.10-2.04 (m, 1H), 1.66-1.56 (m, 1H); **^{13}C -**

NMR (100 MHz, CDCl₃): δ 205.8, 160.4, 152.8, 142.8, 138.5, 129.0, 123.2, 115.7, 114.1, 74.6, 56.7, 55.4, 31.9, 28.4; **HRMS (ESI+):** Calcd. For C₁₆H₁₈O₃ ([M+H]⁺): 259.1329, Found: 259.1334; **Optical rotation:** [α]_D²⁴ +64.0 (c 1.0, CHCl₃) for an enantiomerically enriched sample with 98:2 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, τ_{major} = 14.0 min, τ_{minor} = 17.8 min). The absolute stereochemistry of the product **4y** was assigned in analogy with **4j**.

Compound 4z: Purified by preparative TLC (20% EtOAc in hexane); Off-white thick oil (21.0 mg, 0.068 mmol, 68% yield); **FT-IR (Thin film):** 3436 (br), 1716 (s), 1603 (m), 1510 (s), 1258 (s), 1181 (m), 875 (w), 754 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.74 (d, J = 8.8 Hz, 2H), 7.49 (d, J = 2.6 Hz, 1H), 7.38-7.30 (m, 4H), 7.28-7.24 (m, 1H), 6.95 (d, J = 8.9 Hz, 2H), 4.69 (t, J = 2.5 Hz, 1H), 3.86 (s, 3H), 2.98-2.86 (m, 2H), 2.49-2.45 (m, 1H), 2.40-2.31 (m, 1H), 1.99 (br s, 1H), 1.94-1.85 (m, 1H); **¹³C-NMR (100 MHz, CDCl₃):** δ 205.7, 160.4, 152.8, 142.8, 141.6, 129.0, 128.7, 126.3, 123.2, 114.1, 74.9, 56.7, 55.4, 33.7, 30.8; **HRMS (ESI+):** Calcd. For C₂₀H₂₀O₃ ([M+Na]⁺): 331.1305, Found: 331.1301; **Optical rotation:** [α]_D²⁴ +30 .0 (c 1.0, CHCl₃) for an enantiomerically enriched sample with 98:2 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, τ_{major} = 23.1 min, τ_{minor} = 29.4 min). The absolute stereochemistry of the product **4z** was assigned in analogy with **4j**.

Compound 4aa: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (16.0 mg, 0.059 mmol, 59% yield); **FT-IR (Thin film):** 3481 (br), 2945 (s), 1684 (s), 1604 (s), 1511 (s), 1292 (s), 1256 (s), 838 (s); **¹H-NMR (400 MHz, CDCl₃):** δ 7.70 (d, J = 8.9 Hz, 2H), 7.48 (d, J = 2.6 Hz, 1H), 6.91 (d, J = 8.8 Hz, 2H), 4.74 (t, J = 2.5 Hz, 1H), 3.82 (s, 3H), 2.49 (dd, J = 6.5, 2.4 Hz, 1H), 2.37-2.26 (m, 1H), 2.03-1.97 (m, 1H), 1.92 (br s, 1H), 1.79-1.48 (m, 7H); **¹³C-NMR (100 MHz, CDCl₃):** δ 206.0, 160.4, 152.8, 143.2, 129.1, 123.3, 114.1, 72.6, 60.4, 55.4, 39.7, 30.8, 29.3, 25.5, 25.3; **HRMS (ESI+):** Calcd. For C₁₇H₂₀O₃ ([M+H]⁺): 273.1485, Found: 273.1484; **Optical rotation:** [α]_D²⁴ +52.0 (c 1.0, CHCl₃) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, τ_{major} = 13.9 min, τ_{minor} = 19.1 min). The absolute stereochemistry of the product **4aa** was assigned in analogy with **4j**.

Compound 4ab: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (19.0 mg, 0.066 mmol, 66% yield); **FT-IR (Thin film):** 3434 (br), 2925 (s), 1704 (s), 1606 (s), 1510 (s), 1255 (s), 1034 (s), 835 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.69 (d, J = 8.8 Hz, 2H), 7.48 (d, J = 2.6 Hz, 1H), 6.90 (d, J = 8.8 Hz, 2H), 4.83 (t, J = 2.6 Hz, 1H), 3.82 (s, 3H), 2.37 (dd, J = 4.4, 2.4






Hz, 1H), 2.06-2.00 (m, 1H), 2.03 (br s, 1H), 1.84-1.76 (m, 2H), 1.73-1.67 (m, 2H), 1.52-1.47 (m, 1H), 1.37-1.25 (m, 3H), 1.19-1.05 (m, 2H); **¹³C-NMR (100 MHz, CDCl₃)**: δ 206.1, 160.4, 153.3, 143.4, 129.0, 123.3, 114.1, 71.2, 62.4, 55.4, 37.9, 31.4, 28.9, 26.7, 26.4, 26.3; **HRMS (ESI+)**: Calcd. For C₁₈H₂₂O₃ ([M+Na]⁺): 309.1461, Found: 309.1471; **Optical rotation**: [α]_D²⁴ +54.0 (c 1.0, CHCl₃) for an enantiomerically enriched sample with 98:2 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, τ_{major} = 13.2 min, τ_{minor} = 19.3 min). The absolute stereochemistry of the product **4ab** was assigned in analogy with **4j**.

Compound 4ac: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (21.0 mg, 0.084 mmol, 84% yield); **FT-IR (Thin film)**: 3460 (br), 1698 (s), 1492 (m), 1448 (m), 1297 (s), 1111 (m), 1062 (s), 898 (w); **¹H-NMR (400 MHz, CDCl₃)**: δ 7.78-7.76 (m, 2H), 7.69 (d, *J* = 2.4 Hz, 1H), 7.44-7.40 (m, 3H), 7.36-7.34 (m, 2H), 7.32-7.28 (m, 1H), 7.19-7.16 (m, 2H), 4.98 (t, *J* = 2.7 Hz, 1H), 3.64 (d, *J* = 2.9 Hz, 1H), 2.40 (br s, 1H); **¹³C-NMR (100 MHz, CDCl₃)**: δ 203.2, 154.7, 143.7, 137.2, 130.5, 129.4, 129.1, 128.7, 128.5, 127.8, 127.6, 76.7, 63.8; **HRMS (ESI+)**: Calcd. For C₁₇H₁₄O₂ ([M+H]⁺): 251.1067, Found: 251.1068; **Optical rotation**: [α]_D²⁴ +8.0 (c 1.0, CHCl₃) for an enantiomerically enriched sample with 97:3 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 254 nm, τ_{major} = 22.2 min, τ_{minor} = 33.8 min). The absolute stereochemistry of the product **4ac** was assigned in analogy with **4j**.


Compound 4ad: Purified by preparative TLC (20% EtOAc in hexane); Brown thick oil (24.0 mg, 0.091 mmol, 91% yield); **FT-IR (Thin film)**: 3419 (br), 1709 (s), 1510 (m), 1303 (m), 1112 (m), 1038 (m), 932 (m), 817 (s); **¹H-NMR (400 MHz, CDCl₃)**: δ 7.68 (d, *J* = 8.2 Hz, 2H), 7.64 (d, *J* = 2.5 Hz, 1H), 7.37-7.28 (m, 3H), 7.22 (d, *J* = 7.9 Hz, 2H), 7.18-7.16 (m, 2H), 4.96 (t, *J* = 2.7 Hz, 1H), 3.61 (d, *J* = 2.9 Hz, 1H), 2.43 (br s, 1H), 2.38 (s, 3H); **¹³C-NMR (100 MHz, CDCl₃)**: δ 203.4, 153.9, 143.5, 139.5, 137.2, 129.4, 129.0, 128.5, 127.6, 127.5, 76.7, 63.8, 21.5; **HRMS (ESI+)**: Calcd. For C₁₈H₁₆O₂ ([M+Na]⁺): 287.1043, Found: 287.1047; **Optical rotation**: [α]_D²⁴ +18.0 (c 1.0, CHCl₃) for an enantiomerically enriched sample with 97:3 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 275 nm, τ_{major} = 10.0 min, τ_{minor} = 12.3 min). The absolute stereochemistry of the product **4ad** was assigned in analogy with **4j**.

Compound 4ae: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (23.0 mg, 0.087 mmol, 87% yield); **FT-IR (Thin film)**: 3421 (br), 3027 (w), 2924 (w), 1704 (s), 1496 (m), 1454 (m), 1313 (m), 1131 (m), 1038 (m), 749 (s), 699 (s); **¹H-NMR (400 MHz, CDCl₃)**: δ 7.48-7.46 (m, 1H), 7.39-7.35 (m, 2H), 7.32-



7.30 (m, 1H), 7.29-7.27 (m, 1H), 7.26-7.23 (m, 1H), 7.23-7.21 (m, 2H), 7.20-7.18 (m, 2H), 5.01 (dt, J = 3.5, 2.3 Hz, 1H), 3.63 (d, J = 2.7 Hz, 1H), 2.29 (br s, 1H), 2.28 (s, 3H); **$^{13}\text{C-NMR}$ (100 MHz, CDCl_3):** δ 203.0, 157.7, 157.6, 146.7, 146.7, 137.2, 136.6, 130.8, 130.6, 129.6, 129.1, 129.0, 128.5, 127.6, 125.9, 77.3, 62.7, 20.5; **HRMS (ESI+):** Calcd. for $\text{C}_{18}\text{H}_{17}\text{O}_2$ ($[\text{M}+\text{H}]^+$): 265.1223, Found: 265.1225; **Optical rotation:** $[\alpha]_D^{23} -12.0$ (c 1.0, CHCl_3) for an enantiomerically enriched sample with 96:4 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiraldak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm, $\tau_{\text{major}} = 19.8$ min, $\tau_{\text{minor}} = 28.0$ min). The absolute stereochemistry of the product **4ae** was assigned in analogy with **4j**.


Compound 4af: Purified by preparative TLC (20% EtOAc in hexane); Brown thick oil (24.0 mg,



0.089 mmol, 89% yield); **FT-IR (Thin film):** 3424 (br), 1709 (s), 1601 (s), 1508 (s), 1229 (s), 1161 (s), 932 (w), 834 (s); **$^1\text{H-NMR}$ (400 MHz, CDCl_3):** δ 7.55-7.49 (m, 2H), 7.39 (d, J = 2.5 Hz, 1H), 7.12-7.08 (m, 2H), 7.07-7.00 (m, 1H), 6.92-6.89 (m, 2H), 6.87-6.81 (m, 2H), 4.72 (t, J = 2.7 Hz, 1H), 3.37 (d, J = 2.9 Hz, 1H), 2.18 (br s, 1H); **$^{13}\text{C-NMR}$ (100 MHz, CDCl_3):** δ 203.2,

163.4 (d, J = 249.5 Hz), 154.4, 142.5, 137.0, 129.7 (d, J = 8.3 Hz), 129.1, 128.5, 127.7, 126.6 (d, J = 3.5 Hz), 115.8 (d, J = 21.6 Hz), 76.6, 63.8; **HRMS (ESI+):** Calcd. For $\text{C}_{17}\text{H}_{13}\text{FO}_2$ ($[\text{M}+\text{H}]^+$): 269.0972, Found: 269.0966; **Optical rotation:** $[\alpha]_D^{24} +4.0$ (c 1.0, CHCl_3) for an enantiomerically enriched sample with 97:3 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiraldak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm, $\tau_{\text{minor}} = 19.3$ min, $\tau_{\text{major}} = 21.4$ min). The absolute stereochemistry of the product **4af** was assigned in analogy with **4j**.

Compound 4ag: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (20.0 mg,



0.075 mmol, 75% yield); **FT-IR (Thin film):** 3422 (br), 3030 (w), 1712 (s), 1492 (s), 1452 (m), 1316 (m), 1124 (m), 936 (w), 753 (s), 699 (s); **$^1\text{H-NMR}$ (400 MHz, CDCl_3):** δ 7.92-7.88 (m, 2H), 7.38-7.33 (m, 3H), 7.33-7.28 (m, 1H), 7.21-7.17 (m, 3H), 7.15-7.12 (m, 1H), 5.06-5.03 (m, 1H), 3.63-3.62 (m, 1H), 2.28 (br s, 1H); **$^{13}\text{C-NMR}$ (100 MHz, CDCl_3):** δ 203.0, 160.8 (d, J = 250.9 Hz), 158.7 (d, J = 8.6 Hz), 138.0, 137.0, 130.7 (d, J = 8.7 Hz), 130.5 (d, J = 2.9 Hz), 129.1, 128.6, 127.7, 124.3 (d, J = 3.6 Hz), 118.6 (d, J = 12.7 Hz), 116.0 (d, J = 22.3 Hz), 77.1, 62.9;

HRMS (ESI+): Calcd. for $\text{C}_{17}\text{H}_{13}\text{FO}_2$ ($[\text{M}+\text{Na}]^+$): 291.0792, Found: 291.0804; **Optical rotation:** $[\alpha]_D^{23} -8.0$ (c 1.0, CHCl_3) for an enantiomerically enriched sample with 97:3 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiraldak IA column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 254 nm, $\tau_{\text{major}} = 40.4$ min, $\tau_{\text{minor}} = 51.2$ min). The absolute stereochemistry of the product **4ag** was assigned in analogy with **4j**.

Compound 4ah: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (25.0 mg, 0.083 mmol, 83% yield); **FT-IR (Thin film):** 3431 (br), 3060 (w), 1710 (s), 1497 (w), 1307 (w), 1139 (m), 803 (m), 780 (s), 748 (m), 698 (m); **¹H-NMR (300 MHz, CDCl₃):** δ 7.90-7.80 (m, 3H), 7.68 (d, *J* = 2.3 Hz, 1H), 7.53-7.49 (m, 2H), 7.48-7.45 (m, 2H), 7.43-7.37 (m, 2H), 7.35-7.30 (m, 1H), 7.27 (d, *J* = 1.7 Hz, 1H), 7.26-7.25 (m, 1H), 5.14 (t, *J* = 2.6 Hz, 1H), 3.77 (d, *J* = 2.8 Hz, 1H), 2.30 (br s, 1H); **¹³C-NMR (75 MHz, CDCl₃):** δ 203.2, 158.8, 145.2, 137.2, 133.8, 131.4, 129.4, 129.2, 128.7, 128.6, 128.5, 127.7, 127.5, 126.6, 126.2, 125.3, 125.0, 77.3, 62.9; **HRMS (ESI+):** Calcd. for C₂₁H₁₆O₂ ([M+H]⁺): 301.1223, Found: 301.1232; **Optical rotation:** [α]_D²³ -20.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 94:6 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm, τ_{major} = 19.1 min, τ_{minor} = 47.0 min). The absolute stereochemistry of the product **4ah** was assigned in analogy with **4j**.




Compound 4ai: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (22.0 mg, 0.086 mmol, 86% yield); **FT-IR (Thin film):** 3420 (br), 3028 (w), 2918 (w), 1704 (s), 1497 (m), 1109 (m), 1034 (m), 795 (s), 744 (m), 699 (s); **¹H-NMR (400 MHz, CDCl₃):** δ 8.18 (dd, *J* = 3.0, 1.3 Hz, 1H), 7.61 (d, *J* = 2.5 Hz, 1H), 7.43 (dd, *J* = 5.1, 1.3 Hz, 1H), 7.38-7.34 (m, 3H), 7.32-7.28 (m, 1H), 7.18-7.16 (m, 2H), 5.02 (t, *J* = 2.7 Hz, 1H), 3.61 (d, *J* = 2.8 Hz, 1H), 2.23 (br s, 1H); **¹³C-NMR (100 MHz, CDCl₃):** δ 203.2, 152.2, 138.7, 137.1, 131.0, 129.1, 128.5, 127.6, 126.2, 126.1, 126.0, 77.0, 63.5; **HRMS (ESI+):** Calcd. for C₁₅H₁₂O₂S ([M+H]⁺): 257.0631, Found: 257.0635; **Optical rotation:** [α]_D²³ +12.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 94:6 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 250 nm, τ_{major} = 21.5 min, τ_{minor} = 28.6 min). The absolute stereochemistry of the product **4ai** was assigned in analogy with **4j**.

Compound 5a: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (33.0 mg, 0.093 mmol, 93% yield); **FT-IR (Thin film):** 3465 (br), 1710 (s), 1606 (s), 1510 (s), 1444 (m), 1258 (s), 1180 (s), 835 (s); **¹H-NMR (400 MHz, CDCl₃):** δ 7.79 (d, *J* = 8.9 Hz, 2H), 7.73 (d, *J* = 2.8 Hz, 1H), 7.50-7.47 (m, 2H), 7.37-7.28 (m, 6H), 7.17-7.15 (m, 2H), 6.94 (d, *J* = 8.9 Hz, 2H), 5.55 (s, 1H), 3.84 (s, 3H); **¹³C-NMR (100 MHz, CDCl₃):** δ 203.9, 160.7, 152.7, 142.9, 140.8, 140.3, 129.9, 129.2, 128.7, 128.7, 128.6, 127.6, 127.4, 123.1, 114.2, 76.3, 67.2, 55.5; **HRMS (ESI+):** Calcd. For C₂₄H₂₀O₃ ([M+H]⁺): 357.1485, Found: 357.1477; **Optical rotation:** [α]_D²⁴ -344.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IE column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, τ_{major} = 35.6 min, τ_{minor} = 49.0 min). The absolute stereochemistry of the product **5a** was assigned in analogy with **4j**.

Compound 5b: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (37.0 mg, 0.096 mmol, 96% yield); **FT-IR (Thin film):** 3466 (br), 1709 (s), 1606 (m), 1510 (s), 1257 (s), 1180 (m), 1033 (m), 835 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.79 (d, *J* = 8.8 Hz, 2H), 7.71 (d, *J* = 2.8 Hz, 1H), 7.37 (d, *J* = 8.3 Hz, 2H), 7.16-7.11 (m, 4H), 7.03 (d, *J* = 8.3 Hz, 2H), 6.93 (d, *J* = 8.9 Hz, 2H), 5.51 (d, *J* = 2.8 Hz, 1H), 3.83 (s, 3H), 2.33 (d, *J* = 6.4 Hz, 6H); **¹³C-NMR (75 MHz, CDCl₃):** δ 204.3, 160.6, 152.7, 142.7, 137.9, 137.4, 137.3, 137.0, 129.8, 129.4, 129.2, 129.2, 128.5, 123.2, 114.1, 76.2, 66.6, 55.5, 21.1, 21.1; **HRMS (ESI+):** Calcd. For C₂₆H₂₄O₃ ([M+H]⁺): 385.1798, Found: 385.1803; **Optical rotation:** [α]_D²⁴ -294.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 98.5:1.5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, $\tau_{\text{major}} = 31.0$ min, $\tau_{\text{minor}} = 35.2$ min). The absolute stereochemistry of the product **5b** was assigned in analogy with **4j**.

Compound 5c: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (37.0 mg, 0.090 mmol, 90% yield); **FT-IR (Thin film):** 3476 (br), 3006 (w), 2915 (w), 1708 (s), 1604 (s), 1511 (s), 1257 (s), 1180 (m), 1119 (m), 1034 (m), 835 (m), 755 (s); **¹H-NMR (400 MHz, CDCl₃):** δ 7.80-7.78 (m, 2H), 7.73 (d, *J* = 2.8 Hz, 1H), 7.09 (s, 2H), 6.96-6.95 (m, 1H), 6.94-6.92 (m, 3H), 6.75 (s, 2H), 5.49 (d, *J* = 2.8 Hz, 1H), 3.84 (s, 3H), 2.30 (s, 6H), 2.26 (s, 6H), 1.64 (br s, 1H); **¹³C-NMR (100 MHz, CDCl₃):** δ 204.3, 160.6, 152.9, 142.8, 140.7, 140.1, 138.3, 137.9, 129.4, 129.2, 129.1, 127.5, 126.4, 123.4, 114.1, 76.4, 66.9, 55.5, 21.7; **HRMS (ESI+):** Calcd. for C₂₈H₂₈O₃ ([M+Na]⁺): 435.1931, Found: 435.1932; **Optical rotation:** [α]_D²⁴ -244.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 98:2 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 248 nm, $\tau_{\text{major}} = 14.3$ min, $\tau_{\text{minor}} = 17.1$ min). The absolute stereochemistry of the product **5c** was assigned in analogy with **4j**.

Compound 5d: Purified by preparative TLC (20% EtOAc in hexane); Colorless oil (36.0 mg, 0.086 mmol, 86% yield); **FT-IR (Thin film):** 3475 (br), 1708 (s), 1604 (s), 1580 (s), 1511 (s), 1488 (m), 1292 (m), 1256 (s); **¹H-NMR (400 MHz, CDCl₃):** δ 7.81 (d, *J* = 8.9 Hz, 2H), 7.76 (d, *J* = 2.8 Hz, 1H), 7.32-7.25 (m, 2H), 7.15-7.11 (m, 2H), 6.97 (d, *J* = 8.9 Hz, 2H), 6.88-6.84 (m, 2H), 6.78-6.76 (m, 2H), 5.54 (d, *J* = 2.8 Hz, 1H), 3.87 (s, 3H), 3.80 (s, 3H), 3.76 (s, 3H); **¹³C-NMR (75 MHz, CDCl₃):** δ 203.5, 160.6, 159.8, 159.7, 152.8, 142.9, 142.1, 141.6, 129.7, 129.4, 129.2, 123.1, 121.9, 121.0, 116.3, 114.9, 114.1, 112.7, 112.6, 76.5, 66.8, 55.4, 55.4, 55.3; **HRMS (ESI+):** Calcd. For C₂₆H₂₄O₅ ([M+Na]⁺): 439.1516, Found: 439.1521; **Optical rotation:** [α]_D²⁴ -266.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample






with 98:2 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, $\tau_{\text{minor}} = 32.3$ min, $\tau_{\text{major}} = 37.5$ min). The absolute stereochemistry of the product **5d** was assigned in analogy with **4j**.

Compound 5e: Purified by preparative TLC (20% EtOAc in hexane); Red thick oil (37.0 mg, 0.083 mmol, 83% yield); **FT-IR (Thin film):** 3453 (br), 2919 (w), 1710 (s), 1605 (m), 1510 (s), 1494 (s), 1256 (s), 1179 (m), 1095 (m), 834 (m), 812 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.76 (d, $J = 8.9$ Hz, 2H), 7.71 (d, $J = 2.8$ Hz, 1H), 7.38 (d, $J = 8.6$ Hz, 2H), 7.21 (d, $J = 8.6$ Hz, 2H), 7.17 (d, $J = 8.5$ Hz, 2H), 7.05 (d, $J = 8.6$ Hz, 2H), 6.93 (d, $J = 8.9$ Hz, 2H), 5.47 (d, $J = 2.8$ Hz, 1H), 3.83 (s, 3H), 2.46 (s, 3H), 2.45 (s, 3H), 1.74 (br s, 1H); **¹³C-NMR (100 MHz, CDCl₃):** δ 203.7, 160.7, 152.5, 142.8, 138.2, 137.9, 137.4, 136.8, 130.4, 129.2, 129.0, 126.5, 126.4, 123.0, 114.2, 76.1, 66.4, 55.5, 15.8, 15.6; **HRMS (ESI+):** Calcd. for C₂₆H₂₄O₃S₂ ([M+Na⁺]): 471.1059, Found: 471.1063; **Optical rotation:** $[\alpha]_D^{24} -268.0$ (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 98.5:1.5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (85:15 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 260 nm, $\tau_{\text{minor}} = 26.6$ min, $\tau_{\text{major}} = 31.8$ min). The absolute stereochemistry of the product **5e** was assigned in analogy with **4j**.


Compound 5f: Purified by preparative TLC (20% EtOAc in hexane); Orange thick oil (49.0 mg, 0.096 mmol, 96% yield); **FT-IR (Thin film):** 3446 (br), 3029 (w), 2837 (w), 1712 (s), 1605 (s), 1510 (s), 1487 (s), 1258 (s), 1180 (s), 1113 (m), 944 (m), 832 (s), 752 (s), 698 (s); **¹H-NMR (400 MHz, CDCl₃):** δ 7.83 (d, $J = 8.8$ Hz, 2H), 7.78 (d, $J = 2.8$ Hz, 1H), 7.62-7.59 (m, 6H), 7.59-7.57 (m, 2H), 7.57-7.56 (m, 2H), 7.46-7.42 (m, 4H), 7.37-7.33 (m, 2H), 7.28 (d, $J = 8.5$ Hz, 2H), 6.96 (d, $J = 8.9$ Hz, 2H), 5.63 (d, $J = 2.8$ Hz, 1H), 3.85 (s, 3H); **¹³C-NMR (100 MHz, CDCl₃):** δ 203.9, 160.7, 152.7, 142.9, 140.6, 140.5, 140.3, 139.8, 139.2, 130.4, 129.2, 129.1, 129.0, 128.9, 127.6, 127.6, 127.4, 127.3, 127.2, 123.1, 114.2, 76.4, 66.9, 55.5; **HRMS (ESI+):** Calcd. for C₃₆H₂₈O₃ ([M+H⁺]): 509.2111, Found: 509.2104; **Optical rotation:** $[\alpha]_D^{23} -244.0$ (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 256 nm, $\tau_{\text{major}} = 38.1$ min, $\tau_{\text{minor}} = 48.3$ min). The absolute stereochemistry of the product **5f** was assigned in analogy with **4j**.

Compound 5g: Purified by preparative TLC (20% EtOAc in hexane); Colorless oil (50.0 mg, 0.097 mmol, 97% yield); **FT-IR (Thin film):** 3465 (br), 1710 (s), 1606 (m), 1510 (s), 1257 (m), 1179 (m), 1010 (m), 831 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.75 (d, $J = 8.9$ Hz, 2H), 7.70 (d, $J = 2.8$ Hz, 1H), 7.48-7.42 (m, 4H), 7.30 (d, $J = 8.7$ Hz, 2H), 7.00 (d, $J = 8.6$ Hz, 2H), 6.93 (d, J



δ = 8.9 Hz, 2H), 5.46 (d, J = 2.8 Hz, 1H), 3.83 (s, 3H); **¹³C-NMR (75 MHz, CDCl₃)**: δ 203.1, 160.8, 152.2, 142.8, 139.5, 138.9, 131.8, 131.7, 130.2, 129.2, 122.6, 122.0, 121.9, 114.2, 76.0, 66.4, 55.5; **HRMS (ESI+)**: Calcd. For C₂₄H₁₈Br₂O₃ ([M+Na]⁺): 534.9515, Found: 534.9517; **Optical rotation**: $[\alpha]_D^{24}$ -248.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, $\tau_{\text{minor}} = 21.3$ min, $\tau_{\text{major}} = 26.2$ min). The absolute stereochemistry of the product **5g** was assigned in analogy with **4j**.


Compound 5h: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (51.0 mg,



0.099 mmol, 99% yield); **FT-IR (Thin film)**: 3465 (br), 3009 (w), 2837 (w), 1709 (s), 1606 (m), 1561 (m), 1510 (s), 1473 (m), 1257 (s), 1180 (m), 1117 (m), 834 (m), 758 (m); **¹H-NMR (400 MHz, CDCl₃)**: δ 7.76 (d, J = 8.9 Hz, 2H), 7.73 (d, J = 2.8 Hz, 1H), 7.60 (t, J = 1.9 Hz, 1H), 7.45-7.42 (m, 2H), 7.38-7.35 (m, 1H), 7.30 (t, J = 1.9 Hz, 1H), 7.21 (dt, J = 9.3, 8.0 Hz, 2H), 7.09-7.06 (m, 1H), 6.94 (d, J = 8.9 Hz, 2H), 5.47 (d, J = 2.8 Hz, 1H), 3.84 (s, 3H), 1.65 (br s, 1H); **¹³C-NMR (75 MHz, CDCl₃)**: δ 202.7, 160.9, 152.3, 142.8, 142.6, 142.0, 132.9, 131.3, 131.0, 130.9, 130.2, 130.2, 129.2, 128.6, 127.4, 122.9, 122.9, 122.6, 114.2, 76.1, 66.5, 55.5; **HRMS (ESI+)**: Calcd. for C₂₄H₁₈Br₂O₃ ([M+Na]⁺): 534.9515, Found: 534.9517;

Optical rotation: $[\alpha]_D^{23}$ -196.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IA column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 240 nm, $\tau_{\text{minor}} = 24.6$ min, $\tau_{\text{major}} = 50.3$ min). The absolute stereochemistry of the product **5h** was assigned in analogy with **4j**.

Compound 5i: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (40.0 mg,






0.094 mmol, 94% yield); **FT-IR (Thin film)**: 3466 (br), 1710 (s), 1606 (m), 1510 (s), 1494 (s), 1257 (s), 1013 (m), 817 (s); **¹H-NMR (300 MHz, CDCl₃)**: δ 7.75 (d, J = 8.8 Hz, 2H), 7.71 (d, J = 2.8 Hz, 1H), 7.39-7.27 (m, 6H), 7.07 (d, J = 8.6 Hz, 2H), 6.94 (d, J = 8.7 Hz, 2H), 5.47 (d, J = 2.8 Hz, 1H), 3.83 (s, 3H); **¹³C-NMR (75 MHz, CDCl₃)**: δ 203.2, 160.8, 152.3, 142.8, 139.0, 138.5, 133.8, 133.7, 131.3, 129.9, 129.2, 128.8, 122.7, 114.2, 76.1, 66.3, 55.5; **HRMS (ESI+)**: Calcd. For C₂₄H₁₈Cl₂O₃ ([M+Na]⁺): 447.0525, Found: 447.0521; **Optical rotation**:

$[\alpha]_D^{24}$ -280.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, $\tau_{\text{minor}} = 19.6$ min, $\tau_{\text{major}} = 24.7$ min). The absolute stereochemistry of the product **5i** was assigned in analogy with **4j**.

Compound 5j: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (38.0 mg, 0.097 mmol, 97% yield); **FT-IR (Thin film):** 3466 (br), 1709 (s), 1608 (s), 1586 (s), 1511 (s), 1257 (s), 1032 (m), 827 (s); **¹H-NMR (400 MHz, CDCl₃):** δ 7.80 (d, *J* = 8.8 Hz, 2H), 7.76 (d, *J* = 2.8 Hz, 1H), 7.39-7.24 (m, 4H), 7.06-6.93 (m, 5H), 6.92-6.90 (m, 1H), 5.52 (d, *J* = 2.8 Hz, 1H), 3.87 (s, 3H); **¹³C-NMR (100 MHz, CDCl₃):** 202.8, 162.9 (d, *J* = 246.2 Hz), 162.8 (d, *J* = 247.0 Hz), 160.8, 152.4, 142.9, 142.8 (d, *J* = 7.3 Hz), 142.2 (d, *J* = 7.0 Hz), 130.2 (d, *J* = 7.7 Hz), 130.1 (d, *J* = 7.9 Hz), 129.2, 125.4 (d, *J* = 3.0 Hz), 124.2 (d, *J* = 2.9 Hz), 122.7, 117.3 (d, *J* = 22.9 Hz), 115.9 (d, *J* = 23.1 Hz), 114.9 (d, *J* = 11.2 Hz), 114.7 (d, *J* = 11.3 Hz), 114.2, 76.4, 66.5, 55.5; **HRMS (ESI+):** Calcd. For C₂₄H₁₈F₂O₃ ([M+H]⁺): 393.1297, Found: 393.1298; **Optical rotation:** [α]_D²⁴ -280.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm, τ_{minor} = 17.5 min, τ_{major} = 19.2 min). The absolute stereochemistry of the product **5j** was assigned in analogy with **4j**.


Compound 5k: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (49.0 mg, 0.099 mmol, 99% yield); **FT-IR (Thin film):** 3467 (br), 2842 (w), 1713 (s), 1607 (m), 1512 (s), 1328 (s), 1259 (s), 1169 (s), 1121 (s), 1071 (s), 1018 (s), 831 (s), 760 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.77 (dd, *J* = 5.9, 3.0 Hz, 3H), 7.63-7.60 (m, 3H), 7.58-7.55 (m, 3H), 7.28 (d, *J* = 8.2 Hz, 2H), 6.95 (d, *J* = 8.9 Hz, 2H), 5.57 (d, *J* = 2.8 Hz, 1H), 3.84 (s, 3H), 1.66 (br s, 1H); **¹³C-NMR (100 MHz, CDCl₃):** δ 202.6, 161.0, 152.1, 144.3, 143.7, 142.9, 130.5, 130.0 (q, *J* = 32.8 Hz), 129.9 (q, *J* = 32.8 Hz), 129.2, 129.0, 125.7 (q, *J* = 3.9 Hz), 125.6 (q, *J* = 3.8 Hz), 124.1 (q, *J* = 272.0 Hz), 124.0 (q, *J* = 271.9 Hz), 122.4, 114.3, 76.2, 67.1, 55.5; **HRMS (ESI+):** Calcd. for C₂₆H₁₈F₆O₃ ([M+H]⁺): 493.1233, Found: 493.1226; **Optical rotation:** [α]_D²⁴ -212.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 98.5:1.5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 236 nm, τ_{minor} = 14.4 min, τ_{major} = 18.0 min). The absolute stereochemistry of the product **5k** was assigned in analogy with **4j**.

Compound 5l: Purified by preparative TLC (20% EtOAc in hexane); Off-white thick oil (43.0 mg, 0.094 mmol, 94% yield); **FT-IR (Thin film):** 3452 (br), 1708 (s), 1604 (s), 1510 (s), 1258 (s), 1180 (m), 1107 (m), 809 (s); **¹H-NMR (400 MHz, CDCl₃):** δ 7.99 (d, *J* = 1.9 Hz, 1H), 7.84-7.80 (m, 7H), 7.79-7.73 (m, 3H), 7.56 (dd, *J* = 8.7, 2.0 Hz, 1H), 7.51-7.44 (m, 4H), 7.26-7.24 (m, 1H), 6.96 (d, *J* = 8.8 Hz, 2H), 5.76 (d, *J* = 2.8 Hz, 1H), 3.84 (s, 3H); **¹³C-NMR (100 MHz, CDCl₃):** δ 203.8, 160.7, 152.5, 142.8, 138.2, 137.4, 133.2, 133.2, 132.6, 132.5, 129.3, 129.2, 128.4, 128.4, 128.3, 128.3, 127.8, 127.6, 127.6, 127.3, 126.9, 126.6,




126.5, 126.4, 126.4, 123.1, 114.2, 76.3, 67.4, 55.5; **HRMS (ESI+)**: Calcd. For $C_{32}H_{24}O_3$ ($[M+Na]^+$): 479.1618, Found: 479.1623; **Optical rotation**: $[\alpha]_D^{24} -332.0$ (c 1.0, $CHCl_3$) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IF column (75:25 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm, $\tau_{\text{major}} = 29.3$ min, $\tau_{\text{minor}} = 39.3$ min). The absolute stereochemistry of the product **5l** was assigned in analogy with **4j**.

Compound 5m: Purified by preparative TLC (20% EtOAc in hexane); Reddish-brown solid (48.0 mg, 0.082 mmol, 82% yield); **m.p.** 165-167 °C; **FT-IR (Thin film)**:



3465 (br), 3011 (w), 2959 (m), 1708 (s), 1606 (m), 1510 (s), 1448 (m), 1257 (m), 1180 (m), 836 (m), 758 (s), 740 (s); **1H -NMR (400 MHz, CDCl₃)**: δ 7.83-7.80 (m, 3H), 7.74-7.70 (m, 3H), 7.67 (d, $J = 7.9$ Hz, 1H), 7.59 (d, $J = 1.8$ Hz, 1H), 7.50 (dd, $J = 8.1, 1.8$ Hz, 1H), 7.43-7.39 (m, 2H), 7.34-7.31 (m, 4H), 7.23 (d, $J = 1.7$ Hz, 1H), 7.18 (dd, $J = 8.0, 1.8$ Hz, 1H), 6.97 (d, $J = 8.8$ Hz, 2H), 5.64 (d, $J = 2.8$ Hz, 1H), 3.85 (s, 3H), 1.69 (br s, 1H), 1.48 (s, 3H), 1.42 (d, $J = 3.2$ Hz, 6H), 1.35 (s, 3H); **^{13}C -NMR (100 MHz, CDCl₃)**: δ 204.0, 160.7, 154.1, 154.0, 154.0, 152.9, 143.3, 140.0, 139.4, 138.8, 138.8, 138.6, 138.5, 129.3, 128.6, 127.7, 127.5, 127.3, 127.2, 127.1, 124.6, 123.4, 123.3, 122.8, 120.3, 120.3, 120.1, 119.9, 114.2, 76.8, 67.8, 55.5, 47.1, 47.1, 27.2, 27.2, 27.1; **HRMS (ESI+)**: Calcd. for $C_{42}H_{36}O_3$ ($[M+H]^+$): 589.2737, Found: 589.2740; **Optical rotation**: $[\alpha]_D^{24} -206.0$ (c 1.0, $CHCl_3$) for an enantiomerically enriched sample with 98:2 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IC column (90:10 *n*-Hexane/EtOAc, 0.5 mL/min, 276 nm, $\tau_{\text{major}} = 21.2$ min, $\tau_{\text{minor}} = 24.4$ min). The absolute stereochemistry of the product **5m** was assigned in analogy with **4j**.

Compound 5n: Purified by preparative TLC (20% EtOAc in hexane); Blue thick oil (26.0 mg, 0.071 mmol, 71% yield); **FT-IR (Thin film)**:






3465 (br), 2930 (w), 1714 (s), 1605 (m), 1510 (s), 1257 (s), 1180 (m), 1030 (m), 831 (m), 813 (m), 703 (s); **1H -NMR (400 MHz, CDCl₃)**: δ 7.78 (d, $J = 8.9$ Hz, 2H), 7.65 (d, $J = 2.5$ Hz, 1H), 7.36-7.33 (m, 2H), 7.24 (dd, $J = 5.2, 1.2$ Hz, 1H), 7.06 (dd, $J = 5.2, 3.6$ Hz, 1H), 6.98-6.94 (m, 3H), 6.78 (dd, $J = 3.6, 1.2$ Hz, 1H), 5.46 (d, $J = 2.5$ Hz, 1H), 3.85 (s, 3H), 1.98 (br s, 1H); **^{13}C -NMR (100 MHz, CDCl₃)**: δ 199.9, 160.9, 152.5, 143.0, 142.6, 142.5, 129.2, 127.7, 127.3, 126.8, 126.6, 126.4, 126.0, 122.7, 114.3, 78.6, 62.6, 55.5; **HRMS (ESI+)**: Calcd. for $C_{20}H_{16}O_3S_2$ ($[M+H]^+$): 369.0614, Found: 369.0608; **Optical rotation**: $[\alpha]_D^{24} -16.0$ (c 0.25, $CHCl_3$) for an enantiomerically enriched sample with 98:2 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IA column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 290 nm, $\tau_{\text{minor}} = 22.7$ min, $\tau_{\text{major}} = 48.9$ min). The absolute stereochemistry of the product **5n** was assigned in analogy with **4j**.

Compound 5o: Purified by preparative TLC (20% EtOAc in hexane); Brown thick oil (37.0 mg, 0.083 mmol, 83% yield); **FT-IR (Thin film):** 3477 (br), 2898 (w), 1706 (m), 1605 (m), 1504 (s), 1487 (s), 1241 (s), 1038 (s), 932 (m), 807 (m), 756 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.77 (d, *J* = 8.9 Hz, 2H), 7.69 (d, *J* = 2.7 Hz, 1H), 7.00 (d, *J* = 2.0 Hz, 1H), 6.97-6.92 (m, 3H), 6.76 (dd, *J* = 9.4, 8.4 Hz, 2H), 6.64-6.61 (m, 2H), 5.95-5.94 (m, 4H), 5.41 (d, *J* = 2.7 Hz, 1H), 3.83 (s, 3H), 1.66 (br s, 1H); **¹³C-NMR (100 MHz, CDCl₃):** δ 203.7, 160.7, 152.5, 148.0, 148.0, 147.1, 146.9, 142.7, 134.6, 134.0, 129.2, 123.1, 121.5, 114.2, 110.6, 109.7, 108.3, 108.0, 101.4, 101.3, 76.5, 66.3, 55.5; **HRMS (ESI+):** Calcd. for C₂₆H₂₀O₇ ([M+H]⁺): 445.1282, Found: 445.1284; **Optical rotation:** [α]_D²⁴ -232.0 (*c* 0.25, CHCl₃) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 240 nm, $\tau_{\text{minor}} = 27.1$ min, $\tau_{\text{major}} = 33.4$ min). The absolute stereochemistry of the product **5o** was assigned in analogy with **4j**.


Compound 5p: Diastereoselectivity (dr) = 10:1 was determined by ¹H NMR analysis of the crude reaction mixture. Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (33.0 mg, 0.089 mmol, 89% yield); **FT-IR (Thin film):** 3477 (br), 3013 (w), 2838 (w), 1708 (s), 1605 (s), 1511 (s), 1257 (s), 1180 (s), 1033 (m), 835 (s), 757 (s), 702 (m); **¹H-NMR (300 MHz, CDCl₃):** major diastereomer δ 7.77 (d, *J* = 8.9 Hz, 2H), 7.69 (d, *J* = 2.8 Hz, 1H), 7.39-7.36 (m, 1H), 7.34-7.28 (m, 3H), 7.24-7.22 (m, 2H), 7.20-7.16 (m, 3H), 6.93 (d, *J* = 8.9 Hz, 2H), 5.34 (d, *J* = 2.8 Hz, 1H), 3.83 (s, 3H), 2.11 (s, 3H), 1.85 (br s, 1H); **¹³C-NMR (75 MHz, CDCl₃):** major diastereomer δ 204.1, 160.6, 151.5, 142.9, 139.3, 139.0, 138.6, 133.1, 129.5, 129.2, 128.7, 128.3, 127.6, 127.3, 126.0, 123.3, 114.1, 77.7, 68.0, 55.4, 22.6; **HRMS (ESI+):** Calcd. for C₂₅H₂₂O₃ ([M+H]⁺): 371.1642, Found: 371.1639; **Optical rotation:** [α]_D²⁴ -110.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 97:3 er for each of the diastereomers. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IA column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, for major diastereomer $\tau_{\text{minor}} = 9.8$ min, $\tau_{\text{major}} = 17.4$ min and for minor diastereomer $\tau_{\text{minor}} = 15.9$ min, $\tau_{\text{major}} = 17.4$ min). The relative stereochemistry was determined by 1D NOE.

Compound 5q: Diastereoselectivity (dr) = 1.6:1 was determined by ¹H NMR analysis of the crude reaction mixture. Purified (both diastereomers are separable) by preparative TLC (20% EtOAc in hexane); Yellow thick oil (37.0 mg, 0.096 mmol, 96% combined yield). **Major diastereomer:** Obtained as yellow thick oil (23.0 mg, 0.060 mmol, 60% yield); **FT-IR (Thin film):** 3482 (br), 3007 (w), 2838 (m), 1707 (s), 1605 (s), 1510 (s), 1489 (s), 1463 (m), 1306 (m), 1243 (s), 1179 (s), 1028 (s), 835 (s), 755 (s), 703 (m); **¹H-NMR (300 MHz, CDCl₃):** δ 7.82



(d, $J = 8.3$ Hz, 2H), 7.79 (dd, $J = 2.6, 0.7$ Hz, 1H), 7.68 (dd, $J = 7.9, 1.3$ Hz, 1H), 7.43-7.37 (m, 1H), 7.30-7.24 (m, 3H), 7.18-7.15 (m, 2H), 7.09-7.03 (m, 2H), 6.98 (d, $J = 8.3$ Hz, 2H), 5.27 (d, $J = 2.5$ Hz, 1H), 3.87 (s, 3H), 3.76 (s, 3H), 2.97 (br s, 1H); **$^{13}\text{C-NMR}$ (100 MHz, CDCl_3)**: δ 203.7, 160.5, 158.1, 153.4, 142.9, 137.6, 129.6, 129.5, 129.4, 129.1, 128.8, 127.9, 126.9, 123.5, 121.5, 114.1, 112.3, 79.7, 65.9, 56.0, 55.5; **HRMS (ESI+)**: Calcd. for $\text{C}_{25}\text{H}_{22}\text{O}_4$ ([M+Na]+): 409.1410, Found: 409.1401; **Optical rotation**: $[\alpha]_D^{24} +222.0$ (c 1.0, CHCl_3) for an enantiomerically enriched sample with 98:2 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IC column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, $\tau_{\text{minor}} = 34.5$ min, $\tau_{\text{major}} = 38.4$ min). The relative stereochemistry was determined by 1D NOE. **Minor diastereomer**: Obtained as yellow thick oil (14.0 mg, 0.036 mmol, 36% yield); **FT-IR (Thin film)**: 3510 (br), 3006 (w), 2934 (w), 2837 (w), 1712 (s), 1605 (s), 1511 (s), 1490 (s), 1462 (m), 1305 (m), 1246 (s), 1179 (s), 1028 (m), 835 (s), 754 (s), 701 (m); **$^1\text{H-NMR}$ (300 MHz, CDCl_3)**: δ 7.78 (d, $J = 8.8$ Hz, 2H), 7.65 (d, $J = 3.1$ Hz, 1H), 7.37-7.27 (m, 6H), 7.08-7.05 (m, 1H), 6.97 (d, $J = 7.8$ Hz, 2H), 6.93 (d, $J = 8.8$ Hz, 2H), 5.57 (d, $J = 3.1$ Hz, 1H), 3.83 (s, 3H), 3.62 (s, 3H); **$^{13}\text{C-NMR}$ (75 MHz, CDCl_3)**: δ 205.2, 160.4, 157.3, 151.1, 141.6, 140.6, 131.7, 130.1, 129.1, 129.0, 128.5, 128.1, 127.2, 123.8, 122.0, 114.1, 112.9, 77.7, 65.1, 56.1, 55.5; **HRMS (ESI+)**: Calcd. for $\text{C}_{25}\text{H}_{22}\text{O}_4$ ([M+Na]+): 409.1410, Found: 409.1394; **Optical rotation**: $[\alpha]_D^{24} -180.0$ (c 1.0, CHCl_3) for an enantiomerically enriched sample with >99.5:0.5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IC column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, $\tau_{\text{major}} = 37.1$ min, $\tau_{\text{minor}} = 42.0$ min).




Compound 5r: Diastereoselectivity (dr) > 20:1 was determined by ^1H NMR analysis of the crude reaction mixture. Purified by preparative TLC (20% EtOAc in hexane); Yellow solid (35.0 mg, 0.088 mmol, 88% yield); **m.p.** 173-175 °C; **FT-IR (Thin film)**: 3465 (br), 2918 (w), 1712 (m), 1686 (s), 1511 (s), 1385 (s), 1257 (s), 1180 (m), 1033 (m), 831 (m), 761 (m), 596 (s); **$^1\text{H-NMR}$ (400 MHz, CDCl_3)**: δ 7.79 (d, $J = 8.9$ Hz, 2H), 7.68 (d, $J = 2.8$ Hz, 1H), 7.44 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.39-7.35 (m, 2H), 7.33-7.31 (m, 2H), 7.29-7.26 (m, 1H), 7.23-7.16 (m, 3H), 6.96 (d, $J = 8.9$ Hz, 2H), 5.39 (d, $J = 2.8$ Hz, 1H), 3.86 (s, 3H), 3.01 (hept, $J = 6.7$ Hz, 1H), 2.01 (br s, 1H), 1.15 (d, $J = 6.7$ Hz, 3H), 0.90 (d, $J = 6.8$ Hz, 3H); **$^{13}\text{C-NMR}$ (100 MHz, CDCl_3)**: δ 203.7, 160.6, 151.0, 149.9, 142.9, 140.2, 137.8, 129.4, 129.1, 128.7, 128.5, 128.0, 128.0, 127.2, 125.7, 123.3, 114.1, 77.9, 68.1, 55.5, 30.3, 24.2, 24.0; **HRMS (ESI+)**: Calcd. for $\text{C}_{27}\text{H}_{26}\text{O}_3$ ([M+H]+): 399.1955, Found: 399.1952; **Optical rotation**: $[\alpha]_D^{24} -48.0$ (c 1.0, CHCl_3) for an enantiomerically enriched sample with 95:5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, $\tau_{\text{major}} = 18.9$ min, $\tau_{\text{minor}} = 23.9$ min). The relative stereochemistry was determined by 1D NOE.



Compound 5s: Diastereoselectivity ($\text{dr} = 11.4:1$) was determined by ^1H NMR analysis of the crude reaction mixture. Purified by preparative TLC (20% EtOAc in hexane); Blue thick oil (37.0 mg, 0.091 mmol, 91% yield); **FT-IR (Thin film):** 3476 (br), 2925 (w), 1705 (s), 1605 (m), 1510 (s), 1258 (s), 1180 (m), 836 (m), 778 (m), 754 (m), 701 (m); **$^1\text{H-NMR}$ (300 MHz, CDCl_3): major diastereomer** δ 7.94-7.90 (m, 1H), 7.89-7.86 (m, 1H), 7.85-7.78 (m, 3H), 7.69 (d, $J = 2.7$ Hz, 1H), 7.66 (dd, $J = 7.4, 1.2$ Hz, 1H), 7.45-7.40 (m, 2H), 7.32-7.27 (m, 1H), 7.26-7.22 (m, 3H), 7.18-7.13 (m, 2H), 6.94 (d, $J = 8.9$ Hz, 2H), 5.41 (d, $J = 2.8$ Hz, 1H), 3.84 (s, 3H); **$^{13}\text{C-NMR}$ (75 MHz, CDCl_3): major diastereomer** δ 204.3, 160.7, 152.6, 142.8, 139.3, 136.8, 135.3, 132.6, 129.7, 129.3, 129.2, 128.9, 128.6, 127.6, 127.2, 126.6, 125.7, 125.6, 125.3, 123.2, 114.2, 78.9, 67.7, 55.5; **HRMS (ESI+):** Calcd. for $\text{C}_{28}\text{H}_{22}\text{O}_3$ ($[\text{M}+\text{H}]^+$): 407.1642, Found: 407.1636; **Optical rotation:** $[\alpha]_D^{24} -40.0$ (c 0.25, CHCl_3) for an enantiomerically enriched sample with 98.5:1.5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IA column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm, for major diastereomer $\tau_{\text{minor}} = 12.2$ min, $\tau_{\text{major}} = 18.0$ min). The absolute stereochemistry of the product **5s** was assigned in analogy with **5p**.


Compound 5t: Purified by preparative TLC (20% EtOAc in hexane); Off-white thick oil (29.0 mg, 0.089 mmol, 89% yield); **FT-IR (Thin film):** 3485 (br), 1704 (s), 1494 (s), 1447 (m), 1119 (m), 1067 (s), 830 (w), 759 (s); **$^1\text{H-NMR}$ (400 MHz, CDCl_3):** δ 7.83 (d, $J = 2.7$ Hz, 1H), 7.81-7.78 (m, 2H), 7.51-7.48 (m, 2H), 7.45-7.40 (m, 3H), 7.38-7.29 (m, 6H), 7.18-7.15 (m, 2H), 5.58 (d, $J = 2.7$ Hz, 1H); **$^{13}\text{C-NMR}$ (100 MHz, CDCl_3):** δ 203.6, 154.7, 143.6, 140.7, 140.2, 130.6, 129.9, 129.5, 128.8, 128.7, 128.7, 128.6, 127.8, 127.7, 127.5, 76.3, 67.2; **HRMS (ESI+):** Calcd. For $\text{C}_{23}\text{H}_{18}\text{O}_2$ ($[\text{M}+\text{H}]^+$): 327.1380, Found: 327.1381; **Optical rotation:** $[\alpha]_D^{24} -390.0$ (c 1.0, CHCl_3) for an enantiomerically enriched sample with 98:2 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm, $\tau_{\text{major}} = 12.3$ min, $\tau_{\text{minor}} = 14.7$ min). The absolute stereochemistry of the product **5t** was assigned in analogy with **4j**.

Compound 5u: Purified by preparative TLC (20% EtOAc in hexane); White thick oil (33.0 mg, 0.097 mmol, 97% yield); **FT-IR (Thin film):** 3446 (br), 1711 (s), 1495 (m), 1444 (w), 1303 (w), 1116 (m), 822 (s), 756 (s); **$^1\text{H-NMR}$ (400 MHz, CDCl_3):** δ 7.78 (d, $J = 2.7$ Hz, 1H), 7.71 (d, $J = 8.2$ Hz, 2H), 7.51-7.48 (m, 2H), 7.38-7.29 (m, 6H), 7.23 (d, $J = 7.9$ Hz, 2H), 7.17-7.14 (m, 2H), 5.57 (d, $J = 2.7$ Hz, 1H), 2.39 (s, 3H); **$^{13}\text{C-NMR}$ (100 MHz, CDCl_3):** δ 203.7, 153.8, 143.4, 140.8, 140.3, 139.6, 129.9, 129.4, 128.7, 128.7, 128.6, 127.7, 127.7, 127.6, 127.4, 76.3, 67.2, 21.5; **HRMS (ESI+):** Calcd. For $\text{C}_{24}\text{H}_{20}\text{O}_2$ ($[\text{M}+\text{H}]^+$): 341.1536, Found: 341.1533; **Optical rotation:**




$[\alpha]_D^{24} -326.0$ (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IE column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm, $\tau_{\text{major}} = 36.9$ min, $\tau_{\text{minor}} = 50.9$ min). The absolute stereochemistry of the product **5u** was assigned in analogy with **4j**.

Compound 5v: Purified by preparative TLC (20% EtOAc in hexane); White thick oil (30.0 mg,




0.087 mmol, 87% yield); **FT-IR (Thin film):** 3648 (br), 1712 (s), 1601 (w), 1507 (s), 1224 (s), 1068 (s), 975 (w), 839 (s); **¹H-NMR (300 MHz, CDCl₃):** δ 7.84-7.77 (m, 3H), 7.50-7.46 (m, 2H), 7.39-7.27 (m, 6H), 7.17-7.07 (m, 4H), 5.56 (d, *J* = 2.7 Hz, 1H); **¹³C-NMR (75 MHz, CDCl₃):** δ 203.6, 163.5 (d, *J* = 249.7 Hz), 154.3 (d, *J* = 1.5 Hz), 142.4, 140.6, 140.1, 129.9, 129.7 (d, *J* = 8.2 Hz), 128.8, 128.6, 128.6, 127.6 (d, *J* = 12.4 Hz), 126.7, 126.7, 115.8 (d, *J* = 21.6 Hz), 76.2, 67.1; **HRMS (ESI+):** Calcd. For C₂₃H₁₇FO₂ ([M+Na]⁺): 367.1105, Found: 367.1100; **Optical rotation:** $[\alpha]_D^{24} -344.0$ (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IE column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, $\tau_{\text{major}} = 12.5$ min, $\tau_{\text{minor}} = 15.9$ min). The absolute stereochemistry of the product **5v** was assigned in analogy with **4j**.

Compound 5w: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (15.0 mg,



0.044 mmol, 44% yield); **FT-IR (Thin film):** 3453 (br), 3059 (w), 2922 (w), 1712 (s), 1495 (m), 1445 (m), 1131 (m), 755 (s), 700 (s); **¹H-NMR (300 MHz, CDCl₃):** δ 7.66 (d, *J* = 2.7 Hz, 1H), 7.49-7.46 (m, 2H), 7.41-7.38 (m, 1H), 7.36-7.35 (m, 2H), 7.34-7.32 (m, 2H), 7.31-7.27 (m, 2H), 7.24-7.21 (m, 5H), 5.58 (d, *J* = 2.7 Hz, 1H), 2.14 (s, 3H), 1.68 (br s, 1H); **¹³C-NMR (75 MHz, CDCl₃):** δ 203.2, 157.0, 146.5, 140.8, 139.8, 136.7, 130.6, 130.0, 129.6, 129.0, 128.8, 128.6, 127.7, 127.5, 125.9, 76.9, 66.4, 20.2; **HRMS (ESI+):** Calcd. for C₂₄H₂₀O₂ ([M+H]⁺): 341.1536, Found: 341.1528; **Optical rotation:** $[\alpha]_D^{23} -210.0$ (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 97.5:2.5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm, $\tau_{\text{major}} = 21.4$ min, $\tau_{\text{minor}} = 40.2$ min). The absolute stereochemistry of the product **5w** was assigned in analogy with **4j**.

Compound 5x: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (28.0 mg,





0.081 mmol, 81% yield); **FT-IR (Thin film):** 3647 (br), 3060 (w), 2924 (w), 1715 (s), 1492 (s), 1446 (m), 1316 (m), 1240 (m), 1125 (m), 1092 (m), 843 (m), 757 (s), 700 (s); **¹H-NMR (400 MHz, CDCl₃):** δ 8.01 (t, *J* = 2.4 Hz, 1H), 7.88 (td, *J* = 7.6, 1.8 Hz, 1H), 7.53-7.50 (m, 2H), 7.39-7.28 (m, 7H), 7.22-7.13 (m, 4H), 5.62 (d, *J* = 2.4 Hz, 1H), 1.69 (br s, 1H); **¹³C-NMR (100 MHz, CDCl₃):** δ 203.3, 160.8 Hz (d, *J* = 250.8 Hz), 158.8 (d, *J* = 8.1 Hz), 140.6, 140.0, 138.1 (d, *J* = 2.0 Hz), 130.8 (d, *J* = 8.7 Hz), 130.5 (d, *J* = 2.9 Hz), 129.9, 128.8, 128.7, 128.6, 127.7, 127.5, 124.3 (d, *J* = 3.6 Hz), 118.7 (d, *J* =

12.7 Hz), 116.0 (d, J = 22.2 Hz), 76.8, 66.3; **HRMS (ESI+)**: Calcd. for $C_{23}H_{17}FO_2$ ([M+H]+): 345.1285, Found: 345.1278; **Optical rotation**: $[\alpha]_D^{23} -336.0$ (c 1.0, CHCl₃) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IH column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm, $\tau_{\text{major}} = 14.3$ min, $\tau_{\text{minor}} = 17.8$ min). The absolute stereochemistry of the product **5x** was assigned in analogy with **4j**.

Compound 5y: Purified by preparative TLC (20% EtOAc in hexane); Yellow solid (31.0 mg, 0.093 mmol, 93% yield); **m.p.** 167-169 °C; **FT-IR (Thin film)**: 3481 (br), 3118 (m), 1704 (s), 1496 (m), 1303 (m), 1193 (m), 1070 (s), 805 (s), 762 (s), 700 (s); **¹H-NMR (400 MHz, CDCl₃)**: δ 8.23 (dd, J = 3.0, 1.2 Hz, 1H), 7.74 (d, J = 2.8 Hz, 1H), 7.49-7.46 (m, 2H), 7.45 (dd, J = 5.2, 1.3 Hz, 1H), 7.38-7.32 (m, 4H), 7.31-7.26 (m, 3H), 7.15-7.13 (m, 2H), 5.58 (d, J = 2.8 Hz, 1H), 1.67 (br s, 1H); **¹³C-NMR (75 MHz, CDCl₃)**: δ 203.8, 152.3, 140.7, 140.2, 138.5, 131.0, 129.9, 128.8, 128.6, 127.7, 127.5, 126.3, 126.1, 126.0, 76.6, 66.9; **HRMS (ESI+)**: Calcd. for $C_{21}H_{16}O_2S$ ([M+H]+): 333.0944, Found: 333.0944; **Optical rotation**: $[\alpha]_D^{24} -332.0$ (c 1.0, CHCl₃) for an enantiomerically enriched sample with 97.5:2.5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IA column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm, $\tau_{\text{minor}} = 25.7$ min, $\tau_{\text{major}} = 50.0$ min). The absolute stereochemistry of the product **5y** was assigned in analogy with **4j**.

Compound 5z: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (26.0 mg, 0.082 mmol, 82% yield); **FT-IR (Thin film)**: 3446 (br), 3022 (w), 2925 (w), 1714 (s), 1496 (m), 1445 (m), 1325 (m), 1123 (m), 1013 (m), 754 (s), 699 (s); **¹H-NMR (400 MHz, CDCl₃)**: δ 7.77 (d, J = 2.8 Hz, 1H), 7.50 (d, J = 1.8 Hz, 1H), 7.48-7.44 (m, 2H), 7.37-7.28 (m, 6H), 7.20 (d, J = 3.4 Hz, 1H), 7.14-7.12 (m, 2H), 6.49 (dd, J = 3.4, 1.8 Hz, 1H), 5.59 (d, J = 2.9 Hz, 1H), 1.57 (br s, 1H); **¹³C-NMR (100 MHz, CDCl₃)**: δ 201.8, 149.5, 145.8, 143.7, 140.5, 140.0, 134.5, 129.9, 128.8, 128.6, 128.6, 127.7, 127.5, 112.3, 111.9, 76.9, 66.9; **HRMS (ESI+)**: Calcd. for $C_{21}H_{16}O_3$ ([M+Na]+): 339.0992, Found: 339.0989; **Optical rotation**: $[\alpha]_D^{24} -330.0$ (c 1.0, CHCl₃) for an enantiomerically enriched sample with 96.5:3.5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IA column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 240 nm, $\tau_{\text{minor}} = 14.3$ min, $\tau_{\text{major}} = 23.4$ min). The absolute stereochemistry of the product **5z** was assigned in analogy with **4j**.


Compound 5aa: Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (29.0 mg, 0.088 mmol, 88% yield); **FT-IR (Thin film)**: 3446 (br), 1725 (s), 1597 (m), 1496 (m), 1445 (m), 1259 (m), 1061 (m), 679 (m); **¹H-NMR (400 MHz, CDCl₃)**: δ 7.84 (d, J = 2.8 Hz, 1H), 7.45-7.42 (m, 2H), 7.38-7.28 (m, 6H), 7.07-7.04 (m, 2H), 5.49 (d, J = 2.7 Hz, 1H); **¹³C-NMR (100 MHz, CDCl₃)**: δ 198.4, 159.1, 139.6, 139.0, 129.7, 128.9, 128.8, 128.5, 128.2, 128.0, 127.9, 77.5, 65.0; **HRMS (ESI+)**: Calcd. For



$C_{17}H_{13}BrO_2$ ($[M+Na]^+$): 350.9991, Found: 350.9997; **Optical rotation:** $[\alpha]_D^{24} -290.0$ (c 1.0, $CHCl_3$) for an enantiomerically enriched sample with 94:6 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IF column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, $\tau_{\text{major}} = 15.9$ min, $\tau_{\text{minor}} = 23.8$ min). The absolute stereochemistry of the product **5aa** was assigned in analogy with **4j**.


[Note: The dehalogenation of **5aa** under Pd-catalysis (*Tetrahedron Lett.* **2017**, *58*, 2830-2834) failed due to the harsh reaction conditions leading to dehydration and complex product formation.]

Compound 7a: Diastereoselectivity (dr) > 20:1 was determined by 1H NMR analysis of the crude



reaction mixture. Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (36.0 mg, 0.080 mmol, 80% yield); **FT-IR (Thin film):** 3407 (br), 2954 (s), 1712 (s), 1606 (m), 1510 (s), 1258 (s), 1180 (s), 924 (w); **1H -NMR (400 MHz, CDCl₃):** δ 7.75 (d, $J = 8.9$ Hz, 2H), 7.57 (d, $J = 2.5$ Hz, 1H), 7.32 (d, $J = 8.0$ Hz, 2H), 7.11 (d, $J = 8.1$ Hz, 2H), 6.93 (d, $J = 8.9$ Hz, 2H), 4.87 (t, $J = 2.7$ Hz, 1H), 4.63 (d, $J = 11.4$ Hz, 1H), 4.38 (d, $J = 11.4$ Hz, 1H), 3.83 (s, 3H), 3.50 (d, $J = 2.8$ Hz, 1H), 3.19 (td, $J = 10.6, 4.1$ Hz, 1H), 2.83 (br s, 1H), 2.32-2.24 (m, 1H), 2.20-2.16 (m, 1H), 1.68-1.61 (m, 2H), 1.40-1.35 (m, 1H), 1.32-1.26 (m, 1H), 1.03-0.96 (m, 1H), 0.94 (d, $J = 6.5$ Hz, 3H), 0.92-0.90 (m, 1H), 0.89 (d, $J = 7.0$ Hz, 3H), 0.85-0.81 (m, 1H), 0.73 (d, $J = 6.9$ Hz, 3H); **^{13}C -NMR (100 MHz, CDCl₃):** δ 203.7, 160.5, 152.9, 142.8, 138.3, 136.6, 129.1, 128.5, 123.1, 114.1, 79.2, 76.7, 70.3, 63.6, 55.4, 48.4, 40.5, 34.7, 31.7, 25.7, 23.4, 22.5, 21.2, 16.2; **HRMS (ESI+):** Calcd. For $C_{29}H_{36}O_4$ ($[M+Na]^+$): 471.2506, Found: 471.2509; **Optical rotation:** $[\alpha]_D^{24} -24.0$ (c 1.0, $CHCl_3$). The absolute stereochemistry of the product **7a** was assigned in analogy with **4j**.

Compound 7b: Diastereoselectivity (dr) > 20:1 was determined by 1H NMR analysis of the crude



reaction mixture. Purified by preparative TLC (20% EtOAc in hexane); Yellow oil (39.0 mg, 0.087 mmol, 87% yield); **FT-IR (Thin film):** 3410 (br), 2852 (m), 1712 (s), 1606 (m), 1510 (s), 1258 (s), 1180 (m), 929 (w), 831 (m); **1H -NMR (400 MHz, CDCl₃):** δ 7.76 (d, $J = 8.9$ Hz, 2H), 7.58 (d, $J = 2.5$ Hz, 1H), 7.32 (d, $J = 8.1$ Hz, 2H), 7.13 (d, $J = 8.1$ Hz, 2H), 6.93 (d, $J = 8.9$ Hz, 2H), 5.12-5.09 (m, 1H), 4.91 (t, $J = 2.7$ Hz, 1H), 4.48 (s, 2H), 3.83 (s, 3H), 3.55 (d, $J = 2.9$ Hz, 1H), 3.53-3.48 (m, 2H), 2.04-1.93 (m, 2H), 1.68 (s, 3H), 1.67-1.63 (m, 1H), 1.60 (s, 3H), 1.58-1.54 (m, 1H), 1.47-1.40 (m, 1H), 1.37-1.30 (m, 1H), 1.21-1.12 (m, 1H), 0.89 (d, $J = 6.6$ Hz, 3H); **^{13}C -NMR (100 MHz, CDCl₃):** δ 203.6, 160.5, 152.8, 142.9, 138.0, 136.6, 131.3, 129.1, 128.6, 128.3, 124.9, 123.1, 114.1, 76.7, 72.7, 69.1, 63.6, 55.4, 37.4, 36.8, 29.7, 25.9, 25.6, 19.7, 17.8; **HRMS (ESI+):** Calcd. For $C_{29}H_{36}O_4$ ($[M+Na]^+$): 471.2506, Found: 471.2507; **Optical rotation:** $[\alpha]_D^{24} +22.0$ (c 1.0, $CHCl_3$). The absolute stereochemistry of the product **7b** was assigned in analogy with **4j**.

Compound 7c: Purified by preparative TLC (20% EtOAc in hexane); Yellow oil (36.0 mg, 0.081 mmol, 81% yield); **FT-IR (Thin film):** 3410 (br), 1712 (s), 1606 (m), 1511 (s), 1306 (m), 1258 (s), 928 (w), 831 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.75 (d, *J* = 8.9 Hz, 2H), 7.57 (d, *J* = 2.5 Hz, 1H), 7.32 (d, *J* = 8.1 Hz, 2H), 7.12 (d, *J* = 8.1 Hz, 2H), 6.93 (d, *J* = 9.0 Hz, 2H),




5.41-5.37 (m, 1H), 5.12-5.08 (m, 1H), 4.87 (t, *J* = 2.7 Hz, 1H), 4.48 (s, 2H), 4.04 (d, *J* = 6.8 Hz, 2H), 3.83 (s, 3H), 3.51 (d, *J* = 2.9 Hz, 1H), 2.14-2.13 (m, 1H), 2.09-2.03 (m, 1H), 1.68 (s, 3H), 1.65 (s, 3H), 1.61 (s, 3H); **¹³C-NMR (75 MHz, CDCl₃):** δ 203.7, 160.5, 152.9, 142.8, 140.7, 137.8, 136.7, 131.8, 129.1, 128.6, 128.5, 124.1, 123.1, 120.8, 114.1, 76.7, 71.7, 66.8, 63.6, 55.4, 39.7, 26.5, 25.8, 17.8, 16.7; **HRMS (ESI+):** Calcd. For C₂₉H₃₄O₄ ([M+Na]⁺): 469.2349, Found: 469.2338; **Optical rotation:** [α]_D²⁴ +26.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 95:5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, τ_{major} = 30.1 min, τ_{minor} = 35.8 min). The absolute stereochemistry of the product **7c** was assigned in analogy with **4j**.

Compound 7d: Diastereoselectivity (dr) > 20:1 was determined by ¹H NMR analysis of the crude

reaction mixture. Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (43.0 mg, 0.096 mmol, 96% yield); **FT-IR (Thin film):** 3433 (br), 2951 (s), 1712 (s), 1606 (m), 1510 (s), 1258 (s), 1118 (m), 831 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.75 (d, *J* = 8.9 Hz, 2H), 7.57 (d, *J* = 2.5 Hz, 1H), 7.32 (d, *J* = 8.1 Hz, 2H), 7.11 (d, *J* = 8.1 Hz, 2H), 6.93 (d, *J* = 8.9 Hz, 2H), 4.90 (t, *J* = 2.7 Hz, 1H), 4.55 (d, *J* = 12.2 Hz, 1H), 4.43 (d, *J* = 12.2 Hz, 1H), 3.83 (s, 3H), 3.71 (ddd, *J* = 9.4, 3.3, 1.8 Hz, 1H), 3.54 (d, *J* = 2.8 Hz, 1H), 2.74 (br s, 1H), 2.17-2.05 (m, 2H), 1.76-1.69 (m, 1H), 1.65 (t, *J* = 4.6 Hz, 1H), 1.29-1.21 (m, 2H), 1.10 (dd, *J* = 13.0, 3.3 Hz, 1H), 0.91 (s, 3H), 0.86 (s, 3H), 0.84 (s, 3H); **¹³C-NMR (100 MHz, CDCl₃):** δ 203.8, 160.5, 152.9, 142.8, 138.8, 136.2, 129.1, 128.4, 127.9, 123.1, 114.1, 84.7, 76.7, 71.4, 63.6, 55.4, 49.5, 48.0, 45.2, 36.3, 28.4, 26.9, 19.9, 19.0, 14.2; **HRMS (ESI+):** Calcd. For C₂₉H₃₄O₄ ([M+H]⁺): 447.2530, Found: 447.2533; **Optical rotation:** [α]_D²⁴ -12.0 (*c* 1.0, CHCl₃). The absolute stereochemistry of the product **7d** was assigned in analogy with **4j**.

Compound 7e: Diastereoselectivity (dr) > 20:1 was determined by ¹H NMR analysis of the crude

reaction mixture. Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (41.0 mg, 0.092 mmol, 92% yield); **FT-IR (Thin film):** 3434 (br), 2954 (m), 1712 (s), 1606 (m), 1510 (s), 1258 (s), 1180 (m), 831 (m); **¹H-NMR (400 MHz, CDCl₃):** δ 7.76 (d, *J* = 8.9 Hz, 2H), 7.58 (d, *J* = 2.5 Hz, 1H), 7.34 (d, *J* = 8.2 Hz, 2H), 7.12 (d, *J* = 8.1 Hz, 2H), 6.93 (d, *J* = 8.9 Hz, 2H), 4.92 (t, *J* = 2.7 Hz,





1H), 4.59 (d, $J = 12.0$ Hz, 1H), 4.42 (d, $J = 12.1$ Hz, 1H), 3.83 (s, 3H), 3.58 (d, $J = 2.8$ Hz, 1H), 3.03 (d, $J = 1.8$ Hz, 1H), 1.84-1.77 (m, 1H), 1.73-1.68 (m, 1H), 1.65-1.64 (m, 1H), 1.47-1.36 (m, 2H), 1.10 (s, 3H), 1.10-1.06 (m, 1H), 1.04 (s, 3H), 1.03-1.00 (m, 1H), 0.98 (s, 3H); **$^{13}\text{C-NMR}$ (100 MHz, CDCl_3)**: δ 203.7, 160.5, 152.8, 142.8, 138.8, 136.2, 129.1, 128.3, 128.0, 123.1, 114.1, 92.8, 76.7, 73.2, 63.6, 55.4, 49.4, 48.9, 41.6, 39.7, 31.9, 26.3, 26.2, 20.9, 20.3; **HRMS (ESI+)**: Calcd. For $\text{C}_{29}\text{H}_{34}\text{O}_4$ ($[\text{M}+\text{H}]^+$): 447.2530, Found: 447.2535; **Optical rotation**: $[\alpha]_D^{24} +42.0$ (c 1.0, CHCl_3). The absolute stereochemistry of the product **7e** was assigned in analogy with **4j**.

Compound 7f: Diastereoselectivity (dr) > 20:1 was determined by ^1H NMR analysis of the crude reaction mixture. Purified by preparative TLC (30% EtOAc in hexane); Yellow thick oil (50.0 mg, 0.091 mmol, 91% yield); **FT-IR (Thin film)**: 3457 (br), 1712 (s), 1606 (s), 1511 (s), 1257 (s), 1069 (s), 920 (w), 757 (m); **$^1\text{H-NMR}$ (400 MHz, CDCl_3)**: δ 7.75 (d, $J = 8.9$ Hz, 2H), 7.60 (d, $J = 2.5$ Hz, 1H), 7.32 (d, $J = 8.0$ Hz, 2H), 7.11 (d, $J = 8.2$ Hz, 2H), 6.92 (d, $J = 8.9$ Hz, 2H), 5.54 (d, $J = 5.0$ Hz, 1H), 4.88 (t, $J = 2.7$ Hz, 1H), 4.61-4.58 (m, 2H), 4.52 (d, $J = 12.1$ Hz, 1H), 4.31 (dd, $J = 5.0, 2.4$ Hz, 1H), 4.25 (dd, $J = 7.9, 1.9$ Hz, 1H), 4.03-3.99 (m, 1H), 3.83 (s, 3H), 3.71-3.62 (m, 2H), 3.54 (d, $J = 2.9$ Hz, 1H), 1.53 (s, 3H), 1.44 (s, 3H), 1.33 (d, $J = 3.0$ Hz, 6H); **$^{13}\text{C-NMR}$ (100 MHz, CDCl_3)**: δ 203.7, 160.5, 153.0, 142.7, 137.5, 136.8, 129.1, 128.6, 128.5, 123.1, 114.1, 109.4, 108.7, 96.5, 76.6, 73.1, 71.3, 70.8, 70.7, 69.2, 67.1, 63.6, 55.4, 26.2, 26.1, 25.1, 24.6; **HRMS (ESI+)**: Calcd. For $\text{C}_{31}\text{H}_{36}\text{O}_9$ ($[\text{M}+\text{Na}]^+$): 575.2252, Found: 575.2256; **Optical rotation**: $[\alpha]_D^{24} -30.0$ (c 1.0, CHCl_3). The absolute stereochemistry of the product **7f** was assigned in analogy with **4j**.

Compound 7g: Diastereoselectivity (dr) > 20:1 was determined by ^1H NMR analysis of the crude reaction mixture. Purified by preparative TLC (30% EtOAc in hexane); Yellow thick oil (50.0 mg, 0.091 mmol, 91% yield); **FT-IR (Thin film)**: 3457 (br), 1712 (s), 1606 (s), 1511 (s), 1257 (s), 1069 (s), 920 (w), 757 (m); **$^1\text{H-NMR}$ (400 MHz, CDCl_3)**: δ 7.75 (d, $J = 8.9$ Hz, 2H), 7.60 (d, $J = 2.5$ Hz, 1H), 7.32 (d, $J = 8.0$ Hz, 2H), 7.11 (d, $J = 8.2$ Hz, 2H), 6.92 (d, $J = 8.9$ Hz, 2H), 5.54 (d, $J = 5.0$ Hz, 1H), 4.88 (t, $J = 2.7$ Hz, 1H), 4.61-4.58 (m, 2H), 4.52 (d, $J = 12.1$ Hz, 1H), 4.31 (dd, $J = 5.0, 2.4$ Hz, 1H), 4.25 (dd, $J = 7.9, 1.9$ Hz, 1H), 4.03-3.99 (m, 1H), 3.83 (s, 3H), 3.71-3.62 (m, 2H), 3.54 (d, $J = 2.9$ Hz, 1H), 1.53 (s, 3H), 1.44 (s, 3H), 1.33 (d, $J = 3.0$ Hz, 6H); **$^{13}\text{C-NMR}$ (100 MHz, CDCl_3)**: δ 203.7, 160.5, 153.0, 142.7, 137.5, 136.8, 129.1, 128.6, 128.5, 123.1, 114.1, 109.4, 108.7, 96.5, 76.6, 73.1, 71.3, 70.8, 70.7, 69.2, 67.1, 63.6, 55.4, 26.2, 26.1, 25.1, 24.6; **HRMS (ESI+)**: Calcd. For $\text{C}_{31}\text{H}_{36}\text{O}_9$ ($[\text{M}+\text{Na}]^+$): 575.2252, Found: 575.2256; **Optical rotation**: $[\alpha]_D^{24} -30.0$ (c 1.0, CHCl_3). The absolute stereochemistry of the product **7f** was assigned in analogy with **4j**.

Compound 7g: Diastereoselectivity (dr) > 20:1 was determined by ^1H NMR analysis of the crude reaction mixture. Purified by preparative TLC (20% EtOAc in hexane); Yellow thick oil (51.0 mg, 0.088 mmol, 88% yield); **FT-IR (Thin film)**: 3436 (br), 2931 (m), 1711 (s), 1607 (m), 1510 (s), 1256 (s), 1036 (s), 831 (m); **$^1\text{H-NMR}$ (400 MHz, CDCl_3)**: δ 7.77 (d, $J = 8.9$ Hz, 2H), 7.59 (d, $J = 2.5$ Hz, 1H), 7.34 (d, $J = 8.1$ Hz, 2H), 7.21 (d, $J = 8.7$ Hz, 1H), 7.14 (d, $J = 8.1$ Hz, 2H), 6.94 (d, $J = 8.9$ Hz, 2H), 6.72 (dd, $J = 8.6, 2.8$ Hz, 1H), 6.63 (d, $J = 2.8$ Hz, 1H), 4.92 (t, $J = 2.7$ Hz, 1H), 4.56 (s, 2H), 3.84 (s, 3H), 3.78 (s, 3H), 3.56 (d, $J = 2.8$ Hz, 1H), 3.51 (t, $J = 8.3$ Hz, 1H), 2.88-2.83 (m, 2H), 2.31-2.27 (m, 1H), 2.21-2.15 (m, 1H), 2.11-2.00 (m, 2H), 1.90-1.85 (m, 1H), 1.72-1.58 (m, 2H), 1.53-1.47 (m, 1H), 1.43-1.29 (m, 4H), 1.23-1.16 (m, 1H), 0.87 (s, 3H); **$^{13}\text{C-NMR}$ (100 MHz, CDCl_3)**: δ 203.7, 160.5, 157.5, 152.8, 142.8, 138.6, 138.1, 136.4, 132.9, 129.1, 128.5, 128.0, 126.5, 123.1, 114.1, 113.9, 111.6, 88.5, 76.7, 71.5, 63.6, 55.4, 55.3, 50.4, 44.1, 43.6, 38.8, 38.1, 30.0, 28.1, 27.4, 26.6, 23.3, 12.0; **HRMS**




(ESI+): Calcd. For $C_{38}H_{42}O_5$ ($[M+H]^+$): 579.3105, Found: 579.3102; **Optical rotation:** $[\alpha]_D^{24} +40.0$ (c 1.0, $CHCl_3$) The absolute stereochemistry of the product **7g** was assigned in analogy with **4j**.


Compound 7h: Diastereoselectivity (dr) $> 20:1$ was determined by 1H NMR analysis of the crude reaction mixture.

Purified by preparative TLC (30% EtOAc in hexane); Yellow thick oil (55.0 mg, 0.081 mmol, 81% yield); **FT-IR (Thin film):** 3465 (br), 2952 (s), 1710 (s), 1511 (s), 1258 (s), 1180 (m), 1024 (m), 834 (w); **1H -NMR (400 MHz, CDCl₃):** δ 7.76 (d, $J = 8.9$ Hz, 2H), 7.57 (d, $J = 2.5$ Hz, 1H), 7.32 (d, $J = 8.1$ Hz, 2H), 7.11 (d, $J = 8.1$ Hz, 2H), 6.93 (d, $J = 8.9$ Hz, 2H), 5.35 (d, $J = 5.5$ Hz, 1H), 4.87 (t, $J = 2.8$ Hz, 1H), 4.54 (s, 2H), 3.83 (s, 3H), 3.51 (d, $J = 2.9$ Hz, 1H), 3.32-3.24 (m, 1H), 2.73 (br s, 1H), 2.44-2.39 (m, 1H), 2.31-2.24 (m, 1H), 2.03-1.93 (m, 3H), 1.88-1.79 (m, 2H), 1.61-1.43 (m, 8H), 1.41-1.20 (m, 5H), 1.20-1.05 (m, 7H), 1.04-0.99 (m, 1H), 1.01 (s, 3H), 0.92 (d, $J = 6.5$ Hz, 3H), 0.87 (d, $J = 8.4$ Hz, 6H), 0.68 (s, 3H); **^{13}C -NMR (100 MHz, CDCl₃):** δ 203.7, 160.5, 152.9, 142.8, 141.0, 138.3, 136.6, 129.1, 128.6, 128.3, 123.1, 121.8, 114.1, 78.8, 76.7, 69.7, 63.6, 56.9, 56.3, 55.4, 50.3, 42.5, 39.9, 39.7, 39.3, 37.4, 37.0, 36.3, 35.9, 32.1, 32.0, 28.6, 28.4, 28.2, 24.4, 24.0, 23.0, 22.7, 21.2, 19.5, 18.9, 12.0; **HRMS (ESI+):** Calcd. For $C_{46}H_{62}O_4$ ($[M+Na]^+$): 701.4540, Found: 701.4543; **Optical rotation:** $[\alpha]_D^{24} +2.0$ (c 1.0, $CHCl_3$). The absolute stereochemistry of the product **7h** was assigned in analogy with **4j**.

VIII. Unsuccessful substrates for enantioselective oxa-Piancatelli rearrangement:




IX. Large scale synthesis of **4a**:



In an oven and vacuum-dried 100 mL reaction tube, 2-furyl carbinol **1a** (561.0 mg, 2.00 mmol, 1.0 equiv) and H_2O (72.0 μL , 4.00 mmol, 2.0 equiv) were taken with 10.0 mL of toluene/ CH_2Cl_2 (1.5:1) and stirred for 5 min. To this solution, catalyst **3g** (140.0 mg, 0.20 mmol, 10 mol%) was added along with 10.0 mL of toluene/ CH_2Cl_2 (1.5:1) and the resulting mixture was stirred at 25°C until TLC (20% EtOAc in hexane) revealed complete consumption of **1a** (36 h). The reaction mixture was concentrated under reduced pressure to obtain a reddish-brown oil. This residue was purified by silica-gel flash column chromatography (13% EtOAc in hexane) to obtain **4a** as yellow thick oil (527.0 mg, 1.88 mmol, 94% yield) with 98:2 er.

X. Procedure for the γ -hydroxy protection of **4a**:




In an oven dried 10 mL round-bottom flask, **4a** (204.0 mg, 0.73 mmol, 1.0 equiv), TBSCl (330.0 mg, 2.19 mmol, 3.0 equiv), and DMAP (9.8 mg, 0.08 mmol, 0.11 equiv) were taken, degassed, purged with nitrogen, and dissolved in 3.5 mL dry CH_2Cl_2 . Then, the reaction mixture was cooled to 0°C and Et_3N (0.16 mL, 1.17 mmol, 1.6 equiv) was added dropwise. The reaction mixture was then slowly warmed to 25°C and stirred for 24 h under nitrogen. The reaction was quenched with H_2O (10 mL) and the organic layer was separated from the aqueous layer. The aqueous layer was extracted with EtOAc (3×10.0 mL). Combined organic layer was washed with brine (10.0 mL), dried over anh. Na_2SO_4 and concentrated under reduced pressure to obtain crude product. The crude product was purified by silica-gel column chromatography (2% EtOAc in hexane) to obtain **8** as a colorless oil, essentially as a single diastereomer (254.0 mg, 0.644 mmol, 88% yield); **FT-IR (Thin film)**: 2954 (m), 1715 (s), 1606 (m), 1510 (s), 1258 (s), 1180 (m), 906 (w), 779 (m); **$^1\text{H-NMR (300 MHz, CDCl}_3$** : δ 7.77 (d, $J = 8.9$ Hz, 2H), 7.52 (d, $J = 2.5$ Hz, 1H), 7.38-7.27 (m, 3H), 7.16-7.13 (m, 2H), 6.93 (d, $J = 9.0$ Hz, 2H), 4.93 (t, $J = 2.6$ Hz, 1H), 3.83 (s,

3H), 3.62 (d, J = 2.8 Hz, 1H), 0.89 (s, 9H), -0.01 (s, 3H), -0.05 (s, 3H); **$^{13}\text{C-NMR}$ (75 MHz, CDCl_3):** δ 203.8, 160.4, 153.8, 142.3, 137.7, 129.1, 128.9, 128.7, 127.4, 123.3, 114.1, 76.7, 64.6, 55.4, 25.9, 18.2, -4.5, -4.7; **HRMS (ESI+):** Calcd. For $\text{C}_{24}\text{H}_{30}\text{O}_3\text{Si}$ ($[\text{M}+\text{H}]^+$): 395.2037, Found: 395.2037; **Optical rotation:** $[\alpha]_D^{24} -6.0$ (c 1.0, CHCl_3) for an enantiomerically enriched sample with 97.5:2.5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IE column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm, $\tau_{\text{minor}} = 18.4$ min, $\tau_{\text{major}} = 19.5$ min). The absolute stereochemistry of the product **8** was assigned in analogy with **4j**.


[Note: This compound is sensitive to silica-gel and rapid chromatographic purification is necessary.]

XI. Procedure for selective reduction of the carbonyl group of **8**:



In an oven dried 10 mL 2-necked round-bottom flask, **8** (30.0 mg, 0.075 mmol, 1.0 equiv.) and $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ (56.0 mg, 0.15 mmol, 2.0 equiv.) were taken in 0.75 mL of dry methanol under nitrogen and the resulting solution was cooled to 0 °C. To this solution, LiBH_4 (10.0 mg, 0.45 mmol, 6.0 equiv.) was added portionwise and the resulting mixture was stirred at 0 °C. After 2 h, the reaction mixture was quenched with 2 mL of sat. NH_4Cl solution and diluted with 5 mL EtOAc . The organic layer was separated from the aqueous layer and the aqueous layer was extracted with EtOAc (3×5.0 mL). The combined organic layer was washed with brine (5.0 mL), dried over anh. Na_2SO_4 and concentrated under reduced pressure. The crude product was purified by preparative TLC (10% EtOAc in hexane) to obtain **9** as a yellow oil, essentially as a single diastereomer (19.0 mg, 0.048 mmol, 64% yield); **FT-IR (Thin film):** 3472 (br), 2929 (m), 1603 (s), 1512 (s), 1255 (s), 1179 (s), 1033 (m), 835 (s); **$^1\text{H-NMR}$ (400 MHz, CDCl_3):** δ 7.55 (d, J = 9.0 Hz, 2H), 7.41-7.35 (m, 4H), 7.32-7.29 (m, 1H), 6.89 (d, J = 8.9 Hz, 2H), 6.25 (d, J = 1.8 Hz, 1H), 5.34 (dt, J = 6.3, 1.7 Hz, 1H), 5.15 (d, J = 5.4 Hz, 1H), 3.82 (s, 3H), 3.36 (t, J = 6.2 Hz, 1H), 0.81 (s, 9H), -0.06 (s, 3H), -0.16 (s, 3H); **$^{13}\text{C-NMR}$ (100 MHz, CDCl_3):** δ 159.7, 143.5, 137.6, 131.4, 129.9, 128.6, 127.9, 127.3, 127.2, 114.1, 81.5, 76.8, 61.0, 55.4, 25.9, 18.2, -4.6, -4.6; **HRMS (EI):** Calcd. for $\text{C}_{24}\text{H}_{32}\text{O}_3\text{Si}$ (M^+): 396.2115, Found: 396.2128; **Optical rotation:** $[\alpha]_D^{24} -76.0$ (c 1.0, CHCl_3) for an enantiomerically enriched sample with 97.5:2.5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IA column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 260 nm, $\tau_{\text{major}} = 25.5$ min, $\tau_{\text{minor}} = 38.2$ min). The relative stereochemistry was determined by 1D NOE experiment.

XII. Procedure for vinyl Grignard addition on the carbonyl group of **8:**



In an oven dried 10 mL 2-necked round-bottom flask, **8** (30.0 mg, 0.075 mmol, 1.0 equiv.) was taken in 1.0 mL of dry Et_2O under nitrogen and the resulting solution was cooled to 0 °C. To this solution, vinyl magnesium bromide (1 M in THF) (0.2 mL, 0.19 mmol, 2.5 equiv.) was added dropwise and the resulting mixture was stirred at 0 °C. After 2 h, the reaction mixture was quenched with 2 mL H_2O and diluted with 5 mL EtOAc . The organic layer was separated from the aqueous layer and the aqueous layer was extracted with EtOAc (3×5.0 mL). The combined organic layer was washed with brine (5.0 mL), dried over anh. Na_2SO_4 and concentrated under reduced pressure. The crude product (with 1.2:1 dr, as obtained from $^1\text{H-NMR}$) was purified by preparative TLC (10% EtOAc in hexane) to obtain **10** (both diastereomers are separable) as a yellow thick oil (20.0 mg, 0.047 mmol, 63% combined yield).

Compound 10 (major diastereomer): Purified by preparative TLC (10% EtOAc in hexane);

Yellow thick oil (12.0 mg, 0.028 mmol, 38% yield); **FT-IR (Thin film):** 3491 (br), 2855 (s), 1606 (s), 1513 (s), 1473 (s), 1253 (s), 1034 (s), 884 (m); **$^1\text{H-NMR}$ (400 MHz, CD_2Cl_2):** δ 7.53 (d, $J = 8.8$ Hz, 2H), 7.39-7.35 (m, 2H), 7.33-7.29 (m, 3H), 6.83 (d, $J = 8.9$ Hz, 2H), 6.21 (d, $J = 1.9$ Hz, 1H), 6.04 (dd, $J = 17.3, 10.8$ Hz, 1H), 5.29 (dd, $J = 6.1, 1.9$ Hz, 1H), 5.10 (dd, $J = 10.8, 1.2$ Hz, 1H), 5.05 (dd, $J = 17.3, 1.2$ Hz, 1H), 3.79 (s, 3H), 3.27 (d, $J = 6.1$ Hz, 1H), 1.70 (s, 1H), 0.81 (s, 9H), -0.03 (s, 3H), -0.18 (s, 3H); **$^{13}\text{C-NMR}$ (100 MHz, CD_2Cl_2):** δ 159.8, 145.6, 143.6, 136.6, 133.2, 130.6, 129.2, 128.7, 127.8, 127.6, 113.8, 113.7, 85.3, 80.0, 66.5, 55.6, 25.9, 18.3, -4.6; **HRMS (ESI+):** Calcd. For $\text{C}_{26}\text{H}_{34}\text{O}_3\text{Si}$ ($[\text{M}+\text{Na}]^+$): 445.2169, Found: 445.2180; **Optical rotation:** $[\alpha]_D^{24} -24.0$ (c 1.0, CHCl_3) for an enantiomerically enriched sample with 97:3 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IB column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 264 nm, $\tau_{\text{minor}} = 5.8$ min, $\tau_{\text{major}} = 7.2$ min). The relative stereochemistry was determined by 1D NOE experiment.


Compound 10 (minor diastereomer): Purified by preparative TLC (10% EtOAc in hexane);

Yellow thick oil (8.0 mg, 0.029 mmol, 25% yield); **FT-IR (Thin film):** 3445 (br), 2955 (m), 1606 (m), 1512 (s), 1255 (s), 1180 (m), 992 (s), 837 (s); **$^1\text{H-NMR}$ (400 MHz, CD_2Cl_2):** δ 7.59 (d, $J = 8.9$ Hz, 2H), 7.33-7.23 (m, 5H), 6.84 (d, $J = 8.9$ Hz, 2H), 6.21 (d, $J = 1.9$ Hz, 1H), 5.57 (dd, $J = 17.3, 10.7$ Hz, 1H), 5.10 (dd, $J = 17.4, 1.5$ Hz, 1H), 5.03-4.98 (m, 2H), 3.79 (s, 3H), 3.37 (d,

J = 7.0 Hz, 1H), 2.30 (s, 1H), 0.81 (s, 9H), 0.02 (s, 3H), -0.15 (s, 3H); **¹³C-NMR (75 MHz, CDCl₃)**: δ 159.9, 146.0, 140.8, 137.6, 130.5, 130.2, 129.1, 128.2, 127.2, 126.9, 114.6, 113.9, 86.6, 76.9, 70.4, 55.6, 25.9, 18.3, -4.5, -4.6; **HRMS (EI)**: Calcd. for C₂₆H₃₄O₃Si (M⁺): 422.2272, Found: 422.2283; **Optical rotation**: [α]_D²⁴ -108.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 97.5:2.5 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiraldpak IA column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 265 nm, $\tau_{\text{minor}} = 12.0$ min, $\tau_{\text{major}} = 14.1$ min).

[*Note*: This compound **10** is sensitive to temperature, pH, and rotary evaporation at 25 °C is necessary.]


XIII. Procedure for the γ -hydroxy protection of 5a:



In an oven dried 10 mL round-bottom flask, **5a** (120.0 mg, 0.34 mmol, 1.0 equiv) was taken, degassed, purged with nitrogen, and dissolved in 6.0 mL dry CH₂Cl₂. Then, the solution was cooled to 0 °C and 2,6-lutidine (0.32 mL, 2.70 mmol, 8.0 equiv) was added dropwise. The resulting solution was stirred for 5 min and TBSOTf (0.30 mL, 1.34 mmol, 4.0 equiv) was added and stirred for 2 h at 0 °C under nitrogen. The reaction was quenched with 5 mL of sat. NaHCO₃ solution and the organic layer was separated from the aqueous layer. The aqueous layer was extracted with CH₂Cl₂ (3 × 5.0 mL). The combined organic layer was washed with brine (5.0 mL), dried over anh. Na₂SO₄ and concentrated under reduced pressure to obtain crude product. The crude product was purified by silica-gel column chromatography (2% EtOAc in hexane) to obtain **11** as a colorless oil (156.0 mg, 0.331 mmol, 97% yield); **FT-IR (Thin film)**: 2855 (m), 1715 (s), 1606 (m), 1510 (s), 1258 (s), 1121 (s), 1034 (m), 834 (s); **¹H-NMR (400 MHz, CDCl₃)**: δ 7.72 (d, *J* = 8.9 Hz, 2H), 7.61 (d, *J* = 2.7 Hz, 1H), 7.41-7.38 (m, 2H), 7.35-7.30 (m, 2H), 7.29-7.27 (m, 1H), 7.25-7.15 (m, 5H), 6.91 (d, *J* = 8.9 Hz, 2H), 5.40 (d, *J* = 2.7 Hz, 1H), 3.82 (s, 3H), 0.73 (s, 9H), 0.08 (s, 3H), -0.15 (s, 3H); **¹³C-NMR (100 MHz, CDCl₃)**: δ 204.2, 160.5, 152.8, 141.8, 141.6, 140.6, 130.9, 129.1, 128.9, 128.4, 127.5, 127.2, 126.5, 123.6, 114.1, 77.9, 68.4, 55.5, 25.7, 18.0, -4.1, -4.9; **HRMS (ESI+)**: Calcd. For C₃₀H₃₄O₃Si ([M+H]⁺): 471.2350, Found: 471.2354; **Optical rotation**: [α]_D²⁴ -140.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IE column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 254 nm, τ_{minor} = 12.8 min, τ_{major} = 13.6 min). The absolute stereochemistry of the product **11** was assigned in analogy with **4j**.

[Note: This compound is sensitive to silica-gel and rapid chromatographic purification is necessary.]


XIV. Procedure for selective reduction of the conjugated double bond of 11:



In an oven dried 10 mL 2-necked round-bottom flask, **11** (35 mg, 0.075 mmol, 1.0 equiv.) and 10% Pd-C (8 mg, 0.008 mmol, 0.1 equiv.) was taken in 2.0 mL of dry EtOAc. The resulting mixture was degassed and stirred under H₂ balloon pressure for 5 h at 25 °C. The reaction mixture was filtered over Celite® and washed with EtOAc. The filtrate was concentrated under reduced pressure to obtain crude. The crude product was purified by preparative TLC (5% EtOAc in hexane) to obtain **12** as a colorless oil, essentially as a single diastereomer (27.0 mg, 0.057 mmol, 76% yield); **FT-IR (Thin film)**: 2954 (m), 1742 (s), 1513 (s), 1252 (s), 1079 (m), 1034 (m), 835 (s), 777 (s); **¹H-NMR (400 MHz, CDCl₃)**: δ 7.36-7.27 (m, 7H), 7.24-7.20 (m, 3H), 7.08 (d, *J* = 8.8 Hz, 2H), 6.82 (d, *J* = 8.9 Hz, 2H), 4.90 (dd, *J* = 6.8, 5.3 Hz, 1H), 3.78 (s, 3H), 3.58-3.53 (m, 1H), 2.82 (ddd, *J* = 13.2, 10.0, 5.3 Hz, 1H), 2.39 (ddd, *J* = 13.2, 8.6, 6.7 Hz, 1H), 0.82 (s, 9H), -0.10 (s, 3H), -0.27 (s, 3H); **¹³C-NMR (100 MHz, CDCl₃)**: δ 214.4, 158.7, 141.5, 138.7, 131.6, 130.9, 129.8, 128.8, 128.5, 127.6, 127.3, 126.9, 114.1, 68.1, 55.4, 52.1, 37.0, 25.9, 18.2, -4.8, -5.4; **HRMS (ESI+)**: Calcd. For C₃₀H₃₆O₃Si ([M+Na]⁺): 495.2326, Found: 495.2327; **Optical rotation**: [α]_D²⁴ -50.0 (*c* 1.0, CHCl₃) for an enantiomerically enriched sample with 99:1 er. The enantiomeric ratio was determined by HPLC analysis using Daicel Chiralpak IE column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm, τ_{major} = 9.7 min, τ_{minor} = 15.0 min). The relative stereochemistry was determined by 1D NOE experiment.

XV. Control experiments:


A) Reaction with tertiary 2-furyl carbinol **2'**:



In a screw-cap vial, 2-furyl carbinol **2'** (25.0 mg, 0.10 mmol, 1.0 equiv) and H₂O (3.6 μL, 0.20 mmol, 2.0 equiv) were taken with 0.5 mL of toluene/CH₂Cl₂ (1.5:1) and stirred for 5 min. To this solution, catalyst **3g** (7.0 mg, 0.01 mmol, 10 mol%) was added along with 0.5 mL of toluene/CH₂Cl₂ (1.5:1) and the resulting mixture was stirred at 25 °C until TLC (20% EtOAc in hexane) revealed complete consumption of **2'** (36 h). The reaction mixture was concentrated under reduced pressure to obtain a reddish-brown oil. This residue was purified by preparative TLC (20% EtOAc in hexane) to obtain **5'** as a yellow oil (4.0 mg, 0.016 mmol, 16% yield) and benzophenone as colorless oil (2.0 mg, 0.011 mmol, 11% yield). The spectroscopic data is in agreement with the literature.³

Compound 5': ¹H-NMR (400 MHz, CDCl₃): δ 8.01 (dd, *J* = 5.9, 2.4 Hz, 1H), 7.71-7.68 (m, 2H), 7.63-7.52 (m, 6H), 7.39-7.36 (m, 2H), 6.69 (dd, *J* = 5.9, 1.3 Hz, 1H), 5.81 (dd, *J* = 2.5, 1.3 Hz, 1H), 1.86 (br s, 1H).


B) Reaction with secondary 2-furyl carbinol **1a'**:







In a screw-cap vial, 2-furyl carbinol **1a'** (28.0 mg, 0.10 mmol, 1.0 equiv) and H₂O (3.6 μL, 0.20 mmol, 2.0 equiv) were taken with 0.5 mL of toluene/CH₂Cl₂ (1.5:1) and stirred for 5 min. To this solution, catalyst **3g** (7.0 mg, 0.01 mmol, 10 mol%) was added along with 0.5 mL of toluene/CH₂Cl₂ (1.5:1) and the resulting mixture was stirred at 25 °C for 36 h. After 36 h, the reaction only leads to the decomposition of alcohol **1a'** as observed by TLC (20% EtOAc in hexane).

³ D. Fisher, L. I. Palmer, J. E. Cook, J. E. Davis, J. Read de Alaniz, *Tetrahedron* **2014**, *70*, 4105.


XVI. NMR-Spectra and HPLC-Chromatograms









¹³C-NMR
(100 MHz, CD₂Cl₂)







¹H-NMR
(400 MHz, CD₂Cl₂)




1d









¹³C-NMR
(100 MHz, CD₂Cl₂)




1d












¹H-NMR
(400 MHz, CD₂Cl₂)




¹³C-NMR
(100 MHz, CD₂Cl₂)














¹H-NMR
(400 MHz, CD₂Cl₂)




¹³C-NMR
(100 MHz, CD₂Cl₂)








¹H-NMR
(400 MHz, CD₂Cl₂)





¹³C-NMR
(100 MHz, CD₂Cl₂)




¹H-NMR
(400 MHz, CDCl₃)




¹³C-NMR
(100 MHz, CDCl₃)






¹H-NMR
(300 MHz, CD₂Cl₂)




1n






¹³C-NMR

(75 MHz, CD₂Cl₂)





1n









¹H-NMR
 (300 MHz, CD₂Cl₂)




¹³C-NMR
 (75 MHz, CD₂Cl₂)







¹H-NMR
(400 MHz, CD₂Cl₂)




¹³C-NMR
(75 MHz, CD₂Cl₂)




¹H-NMR
(400 MHz, CD₂Cl₂)




¹³C-NMR
(100 MHz, CD₂Cl₂)









¹³C-NMR
(75 MHz, CD₂Cl₂)





¹H-NMR
(400 MHz, CD₂Cl₂)





¹³C-NMR
(100 MHz, CD₂Cl₂)





¹H-NMR
(300 MHz, CD₂Cl₂)





¹³C-NMR
(75 MHz, CD₂Cl₂)





¹H-NMR
(400 MHz, CD₂Cl₂)





¹³C-NMR
(100 MHz, CD₂Cl₂)





¹H-NMR
(400 MHz, CD₂Cl₂)





¹³C-NMR
75 MHz, CD₂Cl₂)







¹H-NMR
(300 MHz, CD₂Cl₂)





¹³C-NMR
(75 MHz, CD₂Cl₂)









7.41
7.40
7.38
7.36
6.95
6.93
6.50
6.49
5.32
5.32
4.47
4.45
3.82
2.58
2.52
2.50
2.48
2.48
1.97
1.94
1.93
1.89
1.63
1.62
1.62
1.61
1.61
1.60
1.59
1.59
1.59
1.58
1.58
1.57
1.57
1.56
1.56
1.56
1.53
1.53
1.52
1.52
1.51
1.51
1.51
1.50
1.50
1.49
1.49
1.49
1.49
1.48
1.48
1.47
1.47
1.46
1.46
1.45
1.44
1.44
1.44
1.02
1.01
0.97
0.95

¹H-NMR
(400 MHz, CD₂Cl₂)




¹³C-NMR
(100 MHz, CD₂Cl₂)








¹H-NMR
(400 MHz, CD₂Cl₂)




¹³C-NMR
(100 MHz, CD₂Cl₂)









¹H-NMR
(400 MHz, CDCl₃)





¹³C-NMR
(100 MHz, CDCl₃)












1ae





1ae












1ah





¹³C-NMR
(75 MHz, CD₂Cl₂)






1ah








¹³C-NMR
 (100 MHz, CD₂Cl₂)








2a









2c








¹³C-NMR
(100 MHz, CD₂Cl₂)




2c









2e





¹³C-NMR
(75 MHz, CD₂Cl₂)





2e










¹H-NMR
(400 MHz, CD₂Cl₂)




¹³C-NMR
(100 MHz, CD₂Cl₂)












¹³C-NMR
(100 MHz, CD₂Cl₂)







2j







¹H-NMR
(400 MHz, CD₂Cl₂)




¹³C-NMR
(100 MHz, CD₂Cl₂)







¹H-NMR
00 MHz, CD₂Cl₂)




2m








¹³C-NMR
(100 MHz, CD₂Cl₂)




2m












¹H-NMR
(300 MHz, CD₂Cl₂)





¹³C-NMR
(75 MHz, CD₂Cl₂)









¹H-NMR
(300 MHz, CD₂Cl₂)





¹³C-NMR
(75 MHz, CD₂Cl₂)



8.11
8.11
8.10
8.10
8.09
8.08
8.08
8.08
8.08
7.82
7.80
7.80
7.80
7.80
7.78
7.78
7.78


¹H-NMR
(400 MHz, CD₂Cl₂)




¹³C-NMR
(100 MHz, CD₂Cl₂)











¹³C-NMR
(100 MHz, CD₂Cl₂)










7.49
 7.49
 7.34
 7.33
 7.32
 7.28
 7.28
 7.27
 7.27
 7.27
 7.26
 7.26
 7.21
 7.21
 7.21
 7.20
 7.20



¹H-NMR
(400 MHz, CD₂Cl₂)





~161.13
 ~158.69
 ~153.18
 145.00
 141.51
 132.15
 132.12
 129.29
 129.21
 128.37
 128.13
 127.94
 127.75
 127.48
 123.87
 123.83
 115.46
 115.24
 114.50
 114.49
 54.38
 54.11
 53.84
 53.57
 53.30


¹³C-NMR
(100 MHz, CD₂Cl₂)









¹³C-NMR
(100 MHz, CD₂Cl₂)





¹H-NMR
(400 MHz, CD₂Cl₂)





¹³C-NMR
(100 MHz, CD₂Cl₂)










¹H-NMR
(400 MHz, CD₂Cl₂)




¹³C-NMR
(100 MHz, CD₂Cl₂)














¹H-NMR
(400 MHz, CD₂Cl₂)





¹³C-NMR
(100 MHz, CD₂Cl₂)









¹H-NMR



(400 MHz, CD₂Cl₂)




¹³C-NMR
(100 MHz, CD₂Cl₂)











¹H-NMR
 (400 MHz, CD₂Cl₂)




¹³C-NMR
 (100 MHz, CD₂Cl₂)









Daicel Chiraldpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)




¹H-NMR
(400 MHz, CDCl₃)




¹³C-NMR
(100 MHz, CDCl₃)







#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	33,717	3324523	43990	50,292	51,771	N/A	5330	2,851	2,116	
2	Unknown	10	39,150	3285983	40980	49,708	48,229	N/A	6289	N/A	1,944	

Daicel Chiraldex IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)




#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	33,723	2657286	35284	97,619	97,489	N/A	5404	3,172	2,070	
2	Unknown	10	39,693	64817	909	2,381	2,511	N/A	6706	N/A	1,233	






#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	24,093	5821895	125410	50,031	60,931	N/A	6548	6,152	1,415	
2	Unknown	11	33,097	5814681	80414	49,969	39,069	N/A	5764	N/A	2,399	

Daicel Chiralpak IC column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 232 nm)





#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	24,597	716462	15955	2,882	4,400	N/A	6703	5,802	1,208	
2	Unknown	11	32,947	24144232	346672	97,118	95,600	N/A	6121	N/A	2,529	

¹H-NMR
(400 MHz, CDCl₃)




¹³C-NMR
(75 MHz, CDCl₃)






Daicel Chiraldex IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 240 nm)








¹H-NMR
(400 MHz, CDCl₃)




4e




4e









Daicel Chiralpak IC column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)




¹H-NMR
(400 MHz, CDCl₃)




¹³C-NMR
(75 MHz, CDCl₃)







Daicel Chiraldak IA column (70:30 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 254 nm)





7.80
7.78
7.65
7.64
7.60
7.59
7.59
7.58
7.58
7.57
7.57
7.57
7.46
7.46
7.44
7.44
7.37
7.37
7.36
7.35
7.35
7.34
7.33
7.28
7.26
7.26
6.96
6.93


¹H-NMR
(400 MHz, CDCl₃)




— 203.40
— 152.51
— 143.04
— 140.90
— 140.61
— 136.28
— 129.17
— 128.97
— 128.93
— 127.84
— 127.48
— 127.26
— 123.04
— 114.19


¹³C-NMR
(100 MHz, CDCl₃)






Daicel Chiraldex IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 248 nm)








¹H-NMR
(300 MHz, CDCl₃)




4h






4h






Daicel Chiraldpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)









#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	33,803	4673481	66308	49,916	53,904	N/A	6041	5,201	2,216	
2	Unknown	11	43,643	4689244	56702	50,084	46,096	N/A	7221	N/A	1,950	

Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)





#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	33,533	5672678	80353	97,279	97,378	N/A	5954	5,753	2,298	
2	Unknown	11	44,187	158698	2164	2,721	2,622	N/A	8009	N/A	1,164	

¹H-NMR
(300 MHz, CDCl₃)




¹³C-NMR
(75 MHz, CDCl₃)






#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	34,930	3277185	42004	49,912	54,109	N/A	5355	4,946	2,075	
2	Unknown	10	45,230	3288782	35624	50,088	45,891	N/A	6368	N/A	1,874	

Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)




#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	34,810	4864935	61430	97,820	97,969	N/A	5270	5,316	2,229	
2	Unknown	10	45,960	108416	1273	2,180	2,031	N/A	6457	N/A	1,309	




#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	34,123	24399918	294025	99,985	99,979	N/A	4572	5,833	2,945	
2	Unknown	10	45,970	3641	63	0,015	0,021	N/A	8012	N/A	1,056	


Daicel Chiraldex IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)

¹H-NMR
(400 MHz, CDCl₃)




¹³C-NMR
(100 MHz, CDCl₃)









#	Peak Name	CH	tR [min]	Area [μV·sec]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	30,297	11562645	195228	49,858	56,104	N/A	6810	5,933	2,112	
2	Unknown	11	40,250	11628628	152748	50,142	43,896	N/A	7214	N/A	2,099	

Daicel Chiralpak IA column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 240 nm)




#	Peak Name	CH	tR [min]	Area [μV·sec]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	30,320	7996717	135438	97,859	98,024	N/A	6957	6,752	1,999	
2	Unknown	11	41,123	174948	2730	2,141	1,976	N/A	8789	N/A	1,102	








#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	28,073	4836209	81226	49,931	51,340	N/A	5862	3,440	2,120	
2	Unknown	11	33,263	4849592	76986	50,069	48,660	N/A	7289	N/A	1,844	

Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 240 nm)




#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	27,930	6743554	112513	96,846	96,600	N/A	5711	3,892	2,252	
2	Unknown	11	33,713	219621	3960	3,154	3,400	N/A	8065	N/A	1,207	







#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	13	27,973	1423986	19928	50,788	54,888	N/A	4022	2,162	1,774	
2	Unknown	13	32,100	1379781	16379	49,212	45,112	N/A	3876	N/A	1,882	

Daicel Chiralpak IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)




#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	28,163	256615	3775	3,478	4,184	N/A	3919	1,782	1,393	
2	Unknown	11	31,537	7122180	86452	96,522	95,816	N/A	3992	N/A	2,318	







#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	32,623	5766086	63739	50,166	54,151	N/A	3299	1,851	2,257	
2	Unknown	11	37,113	5727893	53966	49,834	45,849	N/A	3279	N/A	2,818	

Daicel Chiralpak IB column (85:15 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 244 nm)






#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	32,933	3172676	32969	96,818	96,952	N/A	3157	2,382	2,231	
2	Unknown	11	39,000	104274	1036	3,182	3,048	N/A	3186	N/A	1,401	

¹H-NMR
(400 MHz, CDCl₃)




¹³C-NMR
(75 MHz, CDCl₃)





#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	13	53,393	24467029	191044	50,736	59,049	N/A	4765	2,016	2,552	
2	Unknown	13	60,750	23757308	132489	49,264	40,951	N/A	3310	N/A	3,617	

Daicel Chiralpak IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 240 nm)






#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	54,467	1046395	8107	3,609	4,965	N/A	4005	1,406	1,495	
2	Unknown	11	59,783	27944356	155181	96,391	95,035	N/A	3334	N/A	3,859	




¹H-NMR
(400 MHz, CDCl₃)




4p




4p









#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	20,867	8219243	179995	49,779	54,780	N/A	5543	4,065	1,724	
2	Unknown	10	25,923	8292141	148586	50,221	45,220	N/A	5701	N/A	1,720	

Daicel Chiralpak IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)




#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	20,850	10470710	228281	96,184	96,617	N/A	5580	4,299	1,797	
2	Unknown	10	26,240	415409	7992	3,816	3,383	N/A	5638	N/A	1,200	







Daicel Chiraldpak IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 272 nm)




¹H-NMR
(400 MHz, CDCl₃)




¹³C-NMR
(100 MHz, CDCl₃)






#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	15	34.300	2949869	42494	49.316	52,749	N/A	6406	2,497	1,969	
2	Unknown	15	38.873	3031745	38066	50,684	47,251	N/A	6306	N/A	1,994	

Daicel Chiraldex IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)




#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	34,597	3171485	45372	97,881	97,731	N/A	6553	2,912	2,015	
2	Unknown	11	39,677	68671	1054	2,119	2,269	N/A	7876	N/A	1,201	












#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	19.023	2339537	69983	50.257	56.264	N/A	8273	6.963	1.387	
2	Unknown	11	25.723	2315576	54400	49.743	43.736	N/A	8863	N/A	1.209	

Daicel Chiralpak IA column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)




#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	19.073	11843172	345514	96.834	97.306	N/A	7924	7.298	1.551	
2	Unknown	11	26.183	387245	9567	3.166	2.694	N/A	9122	N/A	1.121	





#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	22,407	4400193	84655	50,117	53,049	N/A	4860	2,624	2,099	
2	Unknown	11	25,980	4379596	74925	49,883	46,951	N/A	5171	N/A	2,116	


Daicel Chiralpak IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 284 nm)




#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	22,373	3618474	68328	97,612	97,601	N/A	4831	3,045	2,107	
2	Unknown	11	26,480	88520	1680	2,388	2,399	N/A	5585	N/A	1,300	



¹H-NMR
(400 MHz, CDCl₃)




4u





77.58
77.16
76.74
74.08

¹³C-NMR
(75 MHz, CDCl₃)




4u






#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	14,533	1152974	44503	50,007	53,163	N/A	8306	4.981	1,632	
2	Unknown	11	17,943	1152648	39208	49,993	46,837	N/A	9533	N/A	1,464	

Daicel Chiraldpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)





#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	14,490	1639537	63574	96,949	97,102	N/A	8285	5,221	1,691	
2	Unknown	11	18,047	51591	1897	3,051	2,898	N/A	9797	N/A	1,148	

¹H-NMR
(400 MHz, CDCl₃)




¹³C-NMR
(100 MHz, CDCl₃)






#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	11.743	1906373	80173	49.902	54.266	N/A	6162	4.599	1.646	
2	Unknown	11	14.747	1913875	67569	50.098	45.734	N/A	6881	N/A	1.593	


Daicel Chiraldex IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)




#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	11.673	7711627	322750	98.894	98.921	N/A	5992	4.987	1.815	
2	Unknown	11	14.813	86269	3519	1.106	1.079	N/A	8073	N/A	1.140	



¹H-NMR
(400 MHz, CDCl₃)





— 205.94



4w


¹³C-NMR
(100 MHz, CDCl₃)






#	Peak Name	CH	tR [min]	Area [$\mu\text{V}\cdot\text{sec}$]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	13	11,907	822865	39952	50,218	56,322	N/A	8785	8,168	1,466	
2	Unknown	13	16,673	815717	30983	49,782	43,678	N/A	10144	N/A	1,355	

Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 240 nm)




#	Peak Name	CH	tR [min]	Area [$\mu\text{V}\cdot\text{sec}$]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	11,907	1505736	74297	98,918	99,046	N/A	8938	8,682	1,495	
2	Unknown	11	16,797	16470	716	1,082	0,954	N/A	11528	N/A	1,046	


¹H-NMR
(400 MHz, CDCl₃)




4x




¹³C-NMR
(100 MHz, CDCl₃)




4x








#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	13	13,287	1704563	67652	49,971	52,536	N/A	7175	6,474	1,704	
2	Unknown	13	17,577	1706512	61120	50,029	47,464	N/A	10045	N/A	1,565	

Daicel Chiraldex IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 290 nm)




#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	13,103	6284555	286294	97,565	98,209	N/A	9545	6,658	1,953	
2	Unknown	11	17,570	156847	5221	2,435	1,791	N/A	7550	N/A	1,235	






#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	12	14,183	1548975	65359	50,004	53,662	N/A	9234	5,515	1,557	
2	Unknown	12	17,713	1548722	56438	49,996	46,338	N/A	10451	N/A	1,420	


Daicel Chiraldex IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)




#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	12	14,043	6701033	280383	98,257	98,350	N/A	8962	5,911	1,816	
2	Unknown	12	17,787	118870	4703	1,743	1,650	N/A	11058	N/A	1,142	




¹H-NMR
(400 MHz, CDCl₃)




4z




¹³C-NMR
(100 MHz, CDCl₃)




4z








#	Peak Name	CH	tR [min]	Area [μV·sec]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	23,580	1338460	31239	49,974	53,465	N/A	7835	4,901	1,657	
2	Unknown	11	29,217	1339864	27189	50,026	46,535	N/A	8870	N/A	1,555	

Daicel Chiraldex IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)




#	Peak Name	CH	tR [min]	Area [μV·sec]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	23,130	10033040	228857	98,243	98,259	N/A	7271	5,504	2,200	
2	Unknown	11	29,373	179476	4055	1,757	1,741	N/A	9757	N/A	1,150	








#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	14.037	1440596	59647	50,086	55,179	N/A	8752	7,419	1,549	
2	Unknown	11	19.030	1435643	48450	49,914	44,821	N/A	10314	N/A	1,400	

Daicel Chiraldpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)




#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	13,860	10558610	425149	99,036	99,097	N/A	8091	7,958	1,973	
2	Unknown	11	19,147	102747	3876	0,964	0,903	N/A	11446	N/A	1,134	







#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	13,377	1395065	61050	49,799	57,184	N/A	8704	8,505	1,496	
2	Unknown	11	19,107	1406301	45710	50,201	42,816	N/A	9661	N/A	1,428	


Daicel Chiraldex IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)




#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	13,243	9156803	393869	98,256	98,549	N/A	8247	9,049	1,847	
2	Unknown	11	19,300	162511	5800	1,744	1,451	N/A	10347	N/A	1,110	




4ac





Daicel Chiraldex IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 254 nm)




7.69
7.67
7.64
7.64
7.37
7.35
7.34
7.34
7.32
7.31
7.31


4.97
4.96
4.95

2.43
2.38

¹H-NMR
(400 MHz, CDCl₃)



4ad



— 203.40

— 153.85

— 143.48

— 139.51

— 137.24

— 129.42

— 129.04

— 128.54

— 127.64

— 127.55

— 77.48

— 77.16


— 76.84

— 76.72


— 63.82


— 21.51

¹³C-NMR
(100 MHz, CDCl₃)




4ad







Daicel Chiraldex IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 275 nm)




¹H-NMR
 (400 MHz, CDCl₃)






¹³C-NMR
 (100 MHz, CDCl₃)







Daicel Chiraldak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)






4af







#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	19,047	2970622	90341	49,970	51,992	N/A	8617	2,770	1,667	
2	Unknown	10	21,413	2974173	83419	50,030	48,008	N/A	9214	N/A	1,559	

Daicel Chiraldex IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)






#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	19,263	68972	2179	3,207	3,621	N/A	8528	2,514	1,225	
2	Unknown	10	21,427	2081635	57995	96,793	96,379	N/A	9246	N/A	1,533	






Daicel Chiraldex IA column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 254 nm)












#	Peak Name	CH	tR [min]	Area [μV·sec]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	19.213	24685409	515088	49.669	70.272	N/A	4091	13.392	1.954	
2	Unknown	10	46.930	25013924	217907	50.331	29.728	N/A	4053	N/A	1.951	



Daicel Chiraldex IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)




#	Peak Name	CH	tR [min]	Area [μV·sec]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	19.070	15302512	334528	93.972	96.772	N/A	4439	15.923	1.853	
2	Unknown	10	47.047	981593	11159	6.028	3.228	N/A	6260	N/A	1.284	




4ai






Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 250 nm)






¹H-NMR
(300 MHz, CDCl₃)




5a





- 203.92

¹³C-NMR
(100 MHz, CDCl₃)




5a







#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	35.853	2780245	47061	50.382	63.129	N/A	8867	5.932	1.434	
2	Unknown	11	47.863	2738056	27487	49.618	36.871	N/A	5696	N/A	2.063	

Daicel Chiraldpak IE column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)






#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	35.597	7456056	124689	99.143	99.316	N/A	8708	7.420	1.686	
2	Unknown	11	49.013	64474	859	0.857	0.684	N/A	8716	N/A	0.969	

¹H-NMR
(400 MHz, CDCl₃)




¹³C-NMR
(75 MHz, CDCl₃)








#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	30,500	4107163	53212	50,260	57,387	N/A	4147	2,147	2,180	
2	Unknown	11	35,180	4064728	39513	49,740	42,613	N/A	3228	N/A	2,332	

Daicel Chiraldak IB column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)




#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	31,023	47306	718	1,322	2,110	N/A	4964	1,942	1,212	
2	Unknown	11	35,163	3531144	33311	98,678	97,890	N/A	3133	N/A	2,370	







#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	14,377	2266607	57032	49,815	51,299	N/A	3492	2,492	2,110	
2	Unknown	11	16,863	2283466	54145	50,185	48,701	N/A	4308	N/A	2,013	

Daicel Chiraldak IB column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 248 nm)






#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	14,320	3475499	86311	98,219	98,049	N/A	3476	2,868	2,292	
2	Unknown	11	17,137	63015	1717	1,781	1,951	N/A	4719	N/A	1,275	

¹H-NMR
(400 MHz, CDCl₃)




¹³C-NMR
(75 MHz, CDCl₃)










#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	31,417	3306768	37146	50,202	56,712	N/A	3372	2,317	2,272	
2	Unknown	11	37,147	3280094	28353	49,798	43,288	N/A	2824	N/A	2,482	

Daicel Chiraldak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)





#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	32,347	46122	570	1,801	2,668	N/A	3424	2,014	1,295	
2	Unknown	11	37,473	2515092	20811	98,199	97,332	N/A	2683	N/A	2,453	







Daicel Chiraldpak IB column (85:15 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 260 nm)








¹³C-NMR
(100 MHz, CDCl₃)








Daicel Chiraldex IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 256 nm)







¹³C-NMR
(75 MHz, CDCl₃)







Daicel Chiraldex IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)






¹³C-NMR
 (75 MHz, CDCl₃)






#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	12	24,430	682324	15702	50,052	66,708	N/A	7973	15,535	1,159	
2	Unknown	12	50,090	680914	7836	49,948	33,292	N/A	8160	N/A	1,119	

Daicel Chiraldak IA column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 240 nm)




#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	24,580	297420	7647	1,128	2,527	N/A	8702	15,522	1,076	
2	Unknown	11	50,260	26076925	294989	98,872	97,473	N/A	7888	N/A	1,212	


¹H-NMR
(300 MHz, CDCl₃)




5i




¹³C-NMR
(75 MHz, CDCl₃)




5i







#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	19,497	1032673	27118	50,087	58,811	N/A	6915	4,737	1,491	
2	Unknown	11	24,827	1029088	18992	49,913	41,189	N/A	5671	N/A	1,650	

Daicel Chiraldex IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)






#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	19,570	36830	1023	1,005	1,455	N/A	6729	4,578	1,187	
2	Unknown	11	24,650	3627222	69261	98,995	98,545	N/A	6018	N/A	1,779	

¹H-NMR
(400 MHz, CDCl₃)




¹³C-NMR
(100 MHz, CDCl₃)








#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	17,383	3327539	111600	50,114	56,527	N/A	8434	2,053	1,505	
2	Unknown	10	19,130	3312385	85829	49,886	43,473	N/A	6505	N/A	1,783	

Daicel Chiraldpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)




#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	17,540	21176	732	0,974	1,345	N/A	8149	1,871	1,079	
2	Unknown	10	19,167	2153345	53696	99,026	98,655	N/A	6297	N/A	1,747	






Daicel Chiraldak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 236 nm)






¹H-NMR
(400 MHz, CDCl₃)




5





¹³C-NMR

(100 MHz, CDCl₃)




51








#	Peak Name	CH	tR [min]	Area [$\mu\text{V}\cdot\text{sec}$]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	29,420	20540620	327411	50,650	77,960	N/A	5459	2,804	1,584	
2	Unknown	10	38,957	20013552	92561	49,350	22,040	N/A	889	N/A	1,998	

Daicel Chiraldex IF column (75:25 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)




#	Peak Name	CH	tR [min]	Area [$\mu\text{V}\cdot\text{sec}$]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	29,277	29788254	468183	98,781	99,571	N/A	5326	3,089	1,674	
2	Unknown	10	39,280	367498	2018	1,219	0,429	N/A	1033	N/A	1,360	





#	Peak Name	CH	tR [min]	Area [$\mu\text{V}\cdot\text{sec}$]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	21.067	87351278	1580457	49.810	52.122	N/A	3774	2.267	1.774	
2	Unknown	11	24.337	88015984	1451751	50.190	47.878	N/A	4099	N/A	1.698	

Daicel Chiraldex IC column (90:10 *n*-Hexane/EtOAc, 0.5 mL/min, 276 nm)





#	Peak Name	CH	tR [min]	Area [$\mu\text{V}\cdot\text{sec}$]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	21.177	24091192	404286	97.903	97.280	N/A	3297	2.358	1.748	
2	Unknown	11	24.358	515922	11305	2.097	2.720	N/A	6271	N/A	1.371	

7.80
7.77
7.65
7.64
7.36
7.35
7.35
7.34
7.33
7.33
7.25
7.25
7.24
7.24
7.06
7.07
7.06
7.05
6.98
6.97
6.96
6.96
6.95
6.94
6.79
6.78
6.78
5.47
5.46

— 3.85
— 1.98

¹H-NMR
(400 MHz, CDCl₃)




— 199.89


— 160.87
— 152.52
— 142.95
— 142.57
— 142.47
— 129.23
— 127.71
— 127.25
— 126.76
— 126.57
— 126.35
— 125.97
— 122.74
— 114.29


— 3.00
— 0.88

¹³C-NMR
(100 MHz, CDCl₃)




5n







#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	22.573	1230816	31870	50.446	68.835	N/A	8774	16.842	1.296	
2	Unknown	11	48.793	1209058	14429	49.554	31.165	N/A	8179	N/A	1.145	

Daicel Chiraldak IA column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 290 nm)




#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	22.690	232499	6452	1.790	4.114	N/A	9021	16.646	1.207	
2	Unknown	11	48.903	12758724	150390	98.210	95.886	N/A	7889	N/A	1.155	





#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	26,887	4528536	62315	49,879	60,445	N/A	3774	3,177	1,950	
2	Unknown	11	33,863	4550586	40778	50,121	39,555	N/A	2606	N/A	2,088	



Daicel Chiraldex IB column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 240 nm)





#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	27,143	114628	1766	1,112	1,864	N/A	3764	2,908	1,316	
2	Unknown	11	33,437	10195302	93023	98,888	98,136	N/A	2709	N/A	2,349	

7.78
 7.75
 7.69
 7.68
 7.39
 7.38
 7.36
 7.34
 7.33
 7.31
 7.31
 7.31
 7.30
 7.29
 7.28
 7.26
 7.24
 7.23
 7.22
 7.22
 7.19
 7.18
 7.17
 7.16
 7.16
 6.95
 6.92
 5.35
 5.34


¹H-NMR
 (300 MHz, CDCl₃)




¹³C-NMR
 (75 MHz, CDCl₃)







1D NOE of $3b_{16}$:







Daicel Chiraldpak IA column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)






1D NOE of $3b_{17}$:







#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	34.080	2441185	29293	50.064	54.221	N/A	4154	1.983	1.717	
2	Unknown	11	38.600	2434956	24732	49.936	45.779	N/A	3951	N/A	1.726	

Daicel Chiralpak IC column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)






#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	34.520	61313	756	1.869	2.298	N/A	3839	1.662	1.203	
2	Unknown	11	38.403	3218689	32162	98.131	97.702	N/A	3907	N/A	1.760	

¹H-NMR
(300 MHz, CDCl₃)




¹³C-NMR
(75 MHz, CDCl₃)





#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	37.030	2786682	30755	50.646	54.976	N/A	4233	1.877	1.622	
2	Unknown	11	41.713	2715647	25188	49.354	45.024	N/A	3743	N/A	1.701	



Daicel Chiraldpak IC column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)



#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	37.117	1643985	17557	99.692	99.412	N/A	4040	2.602	1.602	
2	Unknown	11	42.007	5082	104	0.308	0.588	N/A	13764	N/A	1.176	





¹H-NMR
(400 MHz, CDCl₃)




— 203.67
 — 160.57
 — 150.98
 — 149.88
 — 142.93
 — 140.20
 — 137.77
 — 129.40
 — 129.14
 — 128.70
 — 128.48
 — 128.04
 — 127.97
 — 127.20
 — 125.74
 — 123.28
 — 114.14


— 3.86
 — 3.06
 — 3.05
 — 3.03
 — 3.01
 — 3.00
 — 2.98
 — 2.96
 — 2.01
 — 1.03
 — 1.03
 — 3.01
 — 3.00

¹³C-NMR
(100 MHz, CDCl₃)







1D NOE of 3b₁₉:







Daicel Chiraldak IB column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)









Daicel Chiraldex IA column (80:20 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)




¹H-NMR
(400 MHz, CDCl₃)






¹³C-NMR
(100 MHz, CDCl₃)






Daicel Chiralpak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)











#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	36,733	7731663	105075	50,281	65,593	N/A	6413	4,337	2,144	
2	Unknown	10	48,213	7645173	55118	49,719	34,407	N/A	3084	N/A	3,017	

Daicel Chiralpak IE column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)





#	Peak Name	CH	tR [min]	Area [µV·sec]	Height [µV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	36,873	5780033	79690	99,001	99,268	N/A	6669	6,031	2,066	
2	Unknown	10	50,887	58336	588	0,999	0,732	N/A	5088	N/A	1,207	







Daicel Chiraldex IE column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)






¹³C-NMR
 (75 MHz, CDCl₃)








#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	21,813	13742445	297744	49,980	63,998	N/A	6354	10,855	2,522	
2	Unknown	10	38,947	13753646	167498	50,020	36,002	N/A	5660	N/A	3,265	

Daicel Chiraldpak IB column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)






#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	21,417	20879897	421262	97,545	97,984	N/A	4831	13,125	2,385	
2	Unknown	10	40,163	525519	8668	2,455	2,016	N/A	9693	N/A	1,407	







Daicel Chiralpak IH column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)







5y




5y








#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	25.760	4943447	120691	50.124	65.800	N/A	9701	16.580	1.306	
2	Unknown	10	51.193	4918910	62730	49.876	34.200	N/A	10175	N/A	1.377	

Daicel Chiraldpak IA column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)




#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	10	25.680	218591	5706	2.486	4.926	N/A	10412	16.209	1.117	
2	Unknown	10	49.993	8573847	110119	97.514	95.074	N/A	9984	N/A	1.492	








Daicel Chiraldpak IA column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 240 nm)




¹H-NMR
(400 MHz, CDCl₃)





#	Peak Name	CH	tR [min]	Area [$\mu\text{V}\cdot\text{sec}$]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	12	15,890	1380455	58034	50,217	61,927	N/A	10938	9,546		1,393
2	Unknown	12	23,423	1368538	35679	49,783	38,073	N/A	9239	N/A		1,624



Daicel Chiraldex IF column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)





#	Peak Name	CH	tR [min]	Area [$\mu\text{V}\cdot\text{sec}$]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	12	15,970	864694	36059	93,981	96,024	N/A	10927	9,845		1,372
2	Unknown	12	23,773	55376	1493	6,019	3,976	N/A	9449	N/A		1,174




¹H-NMR
(400 MHz, CDCl₃)




¹³C-NMR
(100 MHz, CDCl₃)





¹H-NMR
(400 MHz, CDCl₃)





¹³C-NMR
(100 MHz, CDCl₃)






¹H-NMR
(0 MHz, CDCl₃)







#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	30.993	2145788	28454	49.951	52.093	N/A	4265	2.488	1.820	
2	Unknown	11	35.923	2149989	26167	50.049	47.907	N/A	4795	N/A	1.678	

Daicel Chiraldak IB column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)







#	Peak Name	CH	tR [min]	Area [μ V·sec]	Height [μ V]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	30.067	20643434	263673	95.020	94.884	N/A	3744	2.873	2.185	
2	Unknown	11	35.763	1081821	14216	4.980	5.116	N/A	5064	N/A	1.474	



¹H-NMR
(400 MHz, CDCl₃)







¹³C-NMR
(100 MHz, CDCl₃)


















8



8


¹³C-NMR
(75 MHz, CDCl₃)







#	Peak Name	CH	tR [min]	Area [μV·sec]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	18.277	17433075	621495	49.936	51.466	N/A	9877	1.933	1.462	
2	Unknown	11	19.740	17477921	586100	50.064	48.534	N/A	10174	N/A	1.462	

Daicel Chiraldex IE column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 245 nm)





#	Peak Name	CH	tR [min]	Area [μV·sec]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	13	18.393	758922	31449	2.551	3.296	N/A	12312	1.551	1.041	
2	Unknown	13	19.540	28990974	922806	97.449	96.704	N/A	9090	N/A	1.683	


¹H-NMR
(400 MHz, CDCl₃)




¹³C-NMR
(100 MHz, CDCl₃)




1D NOE of 5:






#	Peak Name	CH	tR [min]	Area [μV·sec]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	12	25.470	1861228	48910	49.959	60.217	N/A	10631	10.199	1.092	
2	Unknown	12	38.130	1864280	32313	50.041	39.783	N/A	10323	N/A	1.099	


Daicel Chiraldex IA column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 260 nm)




#	Peak Name	CH	tR [min]	Area [μV·sec]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	11	25.473	734636	19090	97.495	98.185	N/A	10419	10.692	1.085	
2	Unknown	11	38.237	18877	353	2.505	1.815	N/A	12010	N/A	1.073	



¹H-NMR
(400 MHz, CD₂Cl₂)



10
(major diastereomer)




¹³C-NMR
(100 MHz, CD₂Cl₂)




— 159.7


~ 145.6
~ 143.6
~ 136.6
~ 133.2
~ 130.5

10
(major diastereomer)




1D NOE of 6:






#	Peak Name	CH	tR [min]	Area [μV·sec]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	13	5.783	1272494	121512	50.112	66.357	N/A	7525	3.585	1.378	
2	Unknown	13	7.187	1266807	61607	49.888	33.643	N/A	3075	N/A	1.309	

Daicel Chiraldex IB column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 264 nm)




#	Peak Name	CH	tR [min]	Area [μV·sec]	Height [μV]	Area%	Height%	Quantity	NTP	Resolution	Symmetry Factor	Warning
1	Unknown	13	5.780	169198	17669	2.791	5.763	N/A	8276	3.592	1.251	
2	Unknown	13	7.147	5892972	288948	97.209	94.237	N/A	3157	N/A	1.366	




¹H-NMR

(400 MHz, CD₂Cl₂)




10
(minor diastereomer)





¹³C-NMR

(75 MHz, CD₂Cl₂)




10
(minor diastereomer)







Daicel Chiraldpak IA column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 265 nm)




¹H-NMR
(400 MHz, CDCl₃)




11




¹³C-NMR
(100 MHz, CDCl₃)






11







Daicel Chiraldak IE column (95:5 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 254 nm)







1D NOE of 8:






Daicel Chiraldpak IE column (90:10 *n*-Hexane/*i*-PrOH, 1.0 mL/min, 230 nm)





XVII. Single crystal X-ray diffraction analysis of **4j**:

The crystal was prepared by liquid/liquid diffusion of a solution of **4j** in *n*-Hexane/CH₂Cl₂ (3:1) at 25 °C. A single crystal of **4j** was mounted and the diffraction data were collected on a Gemini diffractometer (Rigaku Oxford Diffraction) using Mo-K α radiation ($\lambda = 71.073$ pm) and ω -scan rotation. The structure was solved with SHELXT-2018 (dual-space method). Anisotropic refinement of all non-hydrogen atoms with SHELXL-2018. All hydrogen atoms were calculated on idealized positions. Structure was drawn using Olex-2 and ORTEP-3.



ORTEP representation of the X-ray structure of enantiopure **4j** (thermal ellipsoids at 30% probability)

The crystallographic refinement parameters are given below:

Table S3. Crystal data and structure refinement for **4j**

Identification code	4j		
CCDC	2295678		
Empirical formula	$C_{18}H_{15}BrO_3$		
Formula weight	359.21		
Temperature/K	130(2) K		
Crystal system	monoclinic		
Space group	P 21		
Unit cell dimensions	$a = 720.04(3)$ pm	$\alpha = 90^\circ$	
	$b = 686.61(3)$ pm	$\beta = 100.880(4)^\circ$	
	$c = 1600.22(6)$ pm	$\gamma = 90^\circ$	
Volume	$0.77691(6)$ nm ³		
Z	2		
Density (calculated)	1.536 Mg/m ³		
Absorption coefficient	2.655 mm ⁻¹		
F(000)	364		
Crystal size	0.43 x 0.08 x 0.01 mm ³		
Radiation	MoK α ($\lambda = 71.073$ pm)		
Theta range for data collection	2.592 to 28.229°		
Index ranges	$-9 \leq h \leq 9, -9 \leq k \leq 8, -20 \leq l \leq 20$		
Reflections collected	6895		
Independent reflections	3263 [R(int) = 0.0358]		
Completeness to theta = 25.350°	99.9 %		
Absorption correction	Analytical		
Max. and min. transmission	0.973 and 0.621		
Refinement method	Full-matrix least-squares on F ²		
Data/restraints/parameters	3263/1/201		
Goodness-of-fit on F ²	1.046		
Final R indexes [I>=2σ (I)]	$R_1 = 0.0409, wR_2 = 0.0727$		
Final R indexes [all data]	$R_1 = 0.0528, wR_2 = 0.0792$		
Largest diff. peak and hole	0.721 and -0.470 e.Å ⁻³		
Flack parameter	-0.025(8)		

Comments: Structure solution with SHELXT-2018 (dual-space method). Anisotropic refinement of all non-hydrogen atoms with SHELXL-2018. All hydrogen atoms were calculated on idealized positions. With intermolecular OH-O hydrogen donor acceptor bonds (Table 6) chains along [010] are formed.

Table S4. Atomic coordinates ($x \times 10^4$) and equivalent isotropic displacement parameters ($\text{pm}^2 \times 10^{-1}$) for **4j**. $U(\text{eq})$ is defined as one third of the trace of the orthogonalized U^{ij} tensor.

	x	y	z	$U(\text{eq})$
Br(1)	-283(1)	7524(1)	590(1)	33(1)
O(1)	2693(4)	7662(6)	4988(2)	20(1)
O(2)	1216(6)	1099(5)	4299(3)	24(1)
O(3)	5462(5)	7334(8)	9127(2)	28(1)
C(1)	1515(8)	4563(7)	4309(4)	14(1)
C(2)	2517(7)	5908(7)	5021(3)	17(1)
C(3)	3274(7)	4638(7)	5760(3)	16(1)
C(4)	3285(6)	2791(9)	5466(3)	20(1)
C(5)	2541(6)	2637(10)	4529(3)	16(1)
C(6)	1217(7)	5322(7)	3409(3)	17(1)
C(7)	1867(7)	4339(8)	2758(3)	23(1)
C(8)	1436(8)	4979(8)	1923(3)	25(1)
C(9)	348(7)	6653(7)	1735(3)	20(1)
C(10)	-304(6)	7654(11)	2365(3)	21(1)
C(11)	119(7)	6994(6)	3191(3)	20(1)
C(12)	3863(7)	5379(7)	6629(3)	17(1)
C(13)	3003(7)	7017(7)	6901(3)	23(1)
C(14)	3463(6)	7691(11)	7726(3)	22(1)
C(15)	4842(7)	6752(7)	8307(4)	22(1)
C(16)	5735(7)	5101(7)	8054(4)	23(1)
C(17)	5254(7)	4436(8)	7226(3)	21(1)
C(18)	4550(10)	8931(9)	9435(4)	38(2)

Table S5. Bond lengths [pm] and angles [$^{\circ}$] for **4j**.

Br(1)-C(9)	189.9(5)
O(1)-C(2)	121.3(7)
O(2)-C(5)	142.4(7)
O(2)-H(1O)	84.00
O(3)-C(15)	136.4(6)
O(3)-C(18)	141.3(8)
C(1)-C(6)	150.8(8)
C(1)-C(5)	152.3(8)
C(1)-C(2)	153.7(7)
C(1)-H(1)	100.00
C(2)-C(3)	148.7(7)
C(3)-C(4)	135.3(8)
C(3)-C(12)	146.7(7)
C(4)-C(5)	149.8(6)
C(4)-H(4)	95.00
C(5)-H(5)	100.00
C(6)-C(7)	139.4(7)
C(6)-C(11)	140.0(7)
C(7)-C(8)	138.5(7)
C(7)-H(7)	95.00
C(8)-C(9)	139.1(7)
C(8)-H(8)	95.00
C(9)-C(10)	137.4(7)
C(10)-C(11)	137.6(7)
C(10)-H(10)	95.00
C(11)-H(11)	95.00
C(12)-C(13)	139.2(7)
C(12)-C(17)	140.5(7)
C(13)-C(14)	138.0(7)
C(13)-H(13)	95.00
C(14)-C(15)	138.5(7)
C(14)-H(14)	95.00
C(15)-C(16)	140.0(7)
C(16)-C(17)	138.1(7)

C(16)-H(16)	95.00
C(17)-H(17)	95.00
C(18)-H(18A)	98.00
C(18)-H(18B)	98.00
C(18)-H(18C)	98.00
C(5)-O(2)-H(1O)	109.5
C(15)-O(3)-C(18)	118.3(4)
C(6)-C(1)-C(5)	119.8(4)
C(6)-C(1)-C(2)	117.6(4)
C(5)-C(1)-C(2)	102.2(4)
C(6)-C(1)-H(1)	105.3
C(5)-C(1)-H(1)	105.3
C(2)-C(1)-H(1)	105.3
O(1)-C(2)-C(3)	126.2(5)
O(1)-C(2)-C(1)	127.1(5)
C(3)-C(2)-C(1)	106.7(4)
C(4)-C(3)-C(12)	129.4(5)
C(4)-C(3)-C(2)	107.4(5)
C(12)-C(3)-C(2)	123.2(4)
C(3)-C(4)-C(5)	112.9(6)
C(3)-C(4)-H(4)	123.6
C(5)-C(4)-H(4)	123.6
O(2)-C(5)-C(4)	114.0(5)
O(2)-C(5)-C(1)	108.2(4)
C(4)-C(5)-C(1)	103.7(5)
O(2)-C(5)-H(5)	110.2
C(4)-C(5)-H(5)	110.2
C(1)-C(5)-H(5)	110.2
C(7)-C(6)-C(11)	117.7(5)
C(7)-C(6)-C(1)	122.6(4)
C(11)-C(6)-C(1)	119.5(4)
C(8)-C(7)-C(6)	121.4(5)
C(8)-C(7)-H(7)	119.3
C(6)-C(7)-H(7)	119.3
C(7)-C(8)-C(9)	119.0(5)
C(7)-C(8)-H(8)	120.5

C(9)-C(8)-H(8)	120.5
C(10)-C(9)-C(8)	120.7(5)
C(10)-C(9)-Br(1)	119.8(4)
C(8)-C(9)-Br(1)	119.4(4)
C(9)-C(10)-C(11)	119.7(6)
C(9)-C(10)-H(10)	120.2
C(11)-C(10)-H(10)	120.2
C(10)-C(11)-C(6)	121.5(5)
C(10)-C(11)-H(11)	119.3
C(6)-C(11)-H(11)	119.3
C(13)-C(12)-C(17)	117.5(5)
C(13)-C(12)-C(3)	120.7(5)
C(17)-C(12)-C(3)	121.8(5)
C(14)-C(13)-C(12)	121.9(5)
C(14)-C(13)-H(13)	119.0
C(12)-C(13)-H(13)	119.0
C(13)-C(14)-C(15)	119.9(6)
C(13)-C(14)-H(14)	120.1
C(15)-C(14)-H(14)	120.1
O(3)-C(15)-C(14)	124.9(5)
O(3)-C(15)-C(16)	115.5(5)
C(14)-C(15)-C(16)	119.5(5)
C(17)-C(16)-C(15)	120.0(5)
C(17)-C(16)-H(16)	120.0
C(15)-C(16)-H(16)	120.0
C(16)-C(17)-C(12)	121.1(5)
C(16)-C(17)-H(17)	119.4
C(12)-C(17)-H(17)	119.4
O(3)-C(18)-H(18A)	109.5
O(3)-C(18)-H(18B)	109.5
H(18A)-C(18)-H(18B)	109.5
O(3)-C(18)-H(18C)	109.5
H(18A)-C(18)-H(18C)	109.5
H(18B)-C(18)-H(18C)	109.5

Symmetry transformations used to generate equivalent atoms:

Table S6. Anisotropic displacement parameters ($\text{pm}^2 \times 10^{-1}$) for **4j**. The anisotropic displacement factor exponent takes the form: $-2\pi^2 [h^2 a^*{}^2 U_{11} + \dots + 2 h k a^* b^* U_{12}]$

	U ₁₁	U ₂₂	U ₃₃	U ₂₃	U ₁₃	U ₁₂
Br(1)	37(1)	40(1)	20(1)	6(1)	2(1)	0(1)
O(1)	20(2)	15(2)	24(2)	0(2)	2(1)	-2(2)
O(2)	24(2)	15(2)	32(3)	3(2)	1(2)	1(2)
O(3)	33(2)	31(2)	18(2)	-3(2)	1(1)	2(2)
C(1)	12(3)	15(3)	16(3)	0(2)	2(2)	2(2)
C(2)	12(2)	20(3)	19(3)	0(2)	5(2)	2(2)
C(3)	12(2)	18(3)	20(3)	3(2)	6(2)	1(2)
C(4)	15(2)	23(3)	22(2)	1(3)	4(2)	3(3)
C(5)	14(2)	13(2)	22(2)	3(3)	3(2)	0(3)
C(6)	13(2)	18(3)	18(3)	-2(2)	2(2)	-6(2)
C(7)	26(3)	22(3)	21(3)	4(2)	4(2)	7(2)
C(8)	25(3)	29(3)	23(3)	-3(2)	9(2)	0(3)
C(9)	18(3)	26(3)	16(3)	5(2)	0(2)	-3(2)
C(10)	21(2)	19(2)	24(2)	2(3)	1(2)	-2(3)
C(11)	18(2)	21(3)	22(3)	0(2)	4(2)	1(2)
C(12)	15(3)	16(2)	22(3)	2(2)	6(2)	-2(2)
C(13)	19(2)	27(4)	24(3)	5(2)	4(2)	4(2)
C(14)	21(2)	21(3)	24(2)	-4(3)	6(2)	5(3)
C(15)	20(3)	24(3)	23(3)	1(2)	4(2)	-3(2)
C(16)	19(3)	19(3)	29(3)	4(2)	2(2)	4(2)
C(17)	23(3)	21(3)	17(3)	0(2)	2(2)	4(2)
C(18)	48(4)	42(4)	23(4)	-10(3)	6(3)	9(3)

Table S7. Hydrogen coordinates ($\times 10^4$) and isotropic displacement parameters ($\text{pm}^2 \times 10^{-1}$) for **4j**.

	x	y	z	U(eq)
H(1O)	1766	23	4405	36
H(1)	217	4361	4430	17
H(4)	3718	1705	5818	24
H(5)	3610	2508	4215	20
H(7)	2621	3205	2890	28
H(8)	1877	4285	1485	30
H(10)	-1044	8797	2231	26
H(11)	-345	7687	3622	24
H(13)	2072	7689	6506	28
H(14)	2835	8798	7896	26
H(16)	6670	4439	8451	27
H(17)	5875	3322	7058	25
H(18A)	4661	10081	9085	56
H(18B)	5147	9197	10026	56
H(18C)	3211	8622	9406	56

Table S8. Hydrogen bonds for **4j** [pm and °].

D-H...A	d(D-H)	d(H...A)	d(D...A)	<(DHA)
O(2)-H(1O)...O(1)#1	84	193	273.4(6)	160.8

Symmetry transformations used to generate equivalent atoms:

#1 x, y-1, z